WO2015040533A1 - Methods for enhancing muscle protein synthesis during energy deficit - Google Patents
Methods for enhancing muscle protein synthesis during energy deficit Download PDFInfo
- Publication number
- WO2015040533A1 WO2015040533A1 PCT/IB2014/064478 IB2014064478W WO2015040533A1 WO 2015040533 A1 WO2015040533 A1 WO 2015040533A1 IB 2014064478 W IB2014064478 W IB 2014064478W WO 2015040533 A1 WO2015040533 A1 WO 2015040533A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- protein
- exercise
- vitamin
- protein synthesis
- combinations
- Prior art date
Links
- 230000014616 translation Effects 0.000 title claims abstract description 90
- 238000001243 protein synthesis Methods 0.000 title claims abstract description 89
- 238000000034 method Methods 0.000 title claims abstract description 74
- 230000006735 deficit Effects 0.000 title claims abstract description 73
- 102000008934 Muscle Proteins Human genes 0.000 title claims abstract description 65
- 108010074084 Muscle Proteins Proteins 0.000 title claims abstract description 65
- 230000002708 enhancing effect Effects 0.000 title claims abstract description 29
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 160
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 159
- 239000000203 mixture Substances 0.000 claims abstract description 56
- 235000018102 proteins Nutrition 0.000 claims description 155
- 210000002027 skeletal muscle Anatomy 0.000 claims description 45
- 229940024606 amino acid Drugs 0.000 claims description 39
- 235000001014 amino acid Nutrition 0.000 claims description 39
- 150000001413 amino acids Chemical class 0.000 claims description 39
- 235000016709 nutrition Nutrition 0.000 claims description 31
- -1 lactowolfberry Natural products 0.000 claims description 28
- 230000011664 signaling Effects 0.000 claims description 20
- 230000014509 gene expression Effects 0.000 claims description 19
- 235000013861 fat-free Nutrition 0.000 claims description 18
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 16
- 108010046377 Whey Proteins Proteins 0.000 claims description 16
- 230000035764 nutrition Effects 0.000 claims description 16
- 102000007544 Whey Proteins Human genes 0.000 claims description 15
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 15
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 14
- 235000021119 whey protein Nutrition 0.000 claims description 13
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 12
- 244000005700 microbiome Species 0.000 claims description 11
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 9
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims description 9
- 239000006041 probiotic Substances 0.000 claims description 9
- 235000018291 probiotics Nutrition 0.000 claims description 9
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims description 9
- 229930003427 Vitamin E Natural products 0.000 claims description 8
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 8
- 230000014621 translational initiation Effects 0.000 claims description 8
- 235000019165 vitamin E Nutrition 0.000 claims description 8
- 239000011709 vitamin E Substances 0.000 claims description 8
- 229940046009 vitamin E Drugs 0.000 claims description 8
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 7
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 7
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 7
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 7
- 229930003268 Vitamin C Natural products 0.000 claims description 7
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 7
- 229910052711 selenium Inorganic materials 0.000 claims description 7
- 239000011669 selenium Substances 0.000 claims description 7
- 235000011649 selenium Nutrition 0.000 claims description 7
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 claims description 7
- 235000019155 vitamin A Nutrition 0.000 claims description 7
- 239000011719 vitamin A Substances 0.000 claims description 7
- 235000019154 vitamin C Nutrition 0.000 claims description 7
- 239000011718 vitamin C Substances 0.000 claims description 7
- 229940045997 vitamin a Drugs 0.000 claims description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 6
- 241000222120 Candida <Saccharomycetales> Species 0.000 claims description 6
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 6
- 229920002907 Guar gum Polymers 0.000 claims description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 6
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 6
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 6
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 claims description 6
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 claims description 6
- 235000021466 carotenoid Nutrition 0.000 claims description 6
- 150000001747 carotenoids Chemical class 0.000 claims description 6
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims description 6
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 claims description 6
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims description 6
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims description 6
- 235000019152 folic acid Nutrition 0.000 claims description 6
- 239000011724 folic acid Substances 0.000 claims description 6
- 229960000304 folic acid Drugs 0.000 claims description 6
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 6
- 239000000665 guar gum Substances 0.000 claims description 6
- 235000010417 guar gum Nutrition 0.000 claims description 6
- 229960002154 guar gum Drugs 0.000 claims description 6
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 6
- 239000011707 mineral Substances 0.000 claims description 6
- 229960003512 nicotinic acid Drugs 0.000 claims description 6
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinic acid amide Natural products NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 6
- 235000013406 prebiotics Nutrition 0.000 claims description 6
- NHZMQXZHNVQTQA-UHFFFAOYSA-N pyridoxamine Chemical compound CC1=NC=C(CO)C(CN)=C1O NHZMQXZHNVQTQA-UHFFFAOYSA-N 0.000 claims description 6
- 230000003362 replicative effect Effects 0.000 claims description 6
- 229960002477 riboflavin Drugs 0.000 claims description 6
- 229940088594 vitamin Drugs 0.000 claims description 6
- 229930003231 vitamin Natural products 0.000 claims description 6
- 235000013343 vitamin Nutrition 0.000 claims description 6
- 239000011782 vitamin Substances 0.000 claims description 6
- 229940011671 vitamin b6 Drugs 0.000 claims description 6
- 239000003963 antioxidant agent Substances 0.000 claims description 5
- 235000006708 antioxidants Nutrition 0.000 claims description 5
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 claims description 5
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims description 5
- 150000008442 polyphenolic compounds Chemical class 0.000 claims description 5
- 229920002477 rna polymer Polymers 0.000 claims description 5
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 5
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 claims description 4
- 241000186000 Bifidobacterium Species 0.000 claims description 4
- 241000186660 Lactobacillus Species 0.000 claims description 4
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 claims description 4
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 claims description 4
- 235000013793 astaxanthin Nutrition 0.000 claims description 4
- 239000001168 astaxanthin Substances 0.000 claims description 4
- 229940022405 astaxanthin Drugs 0.000 claims description 4
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 claims description 4
- 229930003935 flavonoid Natural products 0.000 claims description 4
- 150000002215 flavonoids Chemical class 0.000 claims description 4
- 235000017173 flavonoids Nutrition 0.000 claims description 4
- 229930013686 lignan Natural products 0.000 claims description 4
- 235000009408 lignans Nutrition 0.000 claims description 4
- 150000005692 lignans Chemical class 0.000 claims description 4
- 235000012680 lutein Nutrition 0.000 claims description 4
- 229960005375 lutein Drugs 0.000 claims description 4
- 239000001656 lutein Substances 0.000 claims description 4
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 claims description 4
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 claims description 4
- 229960004999 lycopene Drugs 0.000 claims description 4
- 235000012661 lycopene Nutrition 0.000 claims description 4
- 239000001751 lycopene Substances 0.000 claims description 4
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 claims description 4
- 235000013336 milk Nutrition 0.000 claims description 4
- 239000008267 milk Substances 0.000 claims description 4
- 210000004080 milk Anatomy 0.000 claims description 4
- 229940012843 omega-3 fatty acid Drugs 0.000 claims description 4
- 239000006014 omega-3 oil Substances 0.000 claims description 4
- 229910052698 phosphorus Inorganic materials 0.000 claims description 4
- 235000013824 polyphenols Nutrition 0.000 claims description 4
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 claims description 4
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 claims description 4
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 claims description 3
- FVVCFHXLWDDRHG-UPLOTWCNSA-N (2s,3r,4s,5r,6r)-2-[(2r,3s,4r,5r,6r)-6-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](CO)O1 FVVCFHXLWDDRHG-UPLOTWCNSA-N 0.000 claims description 3
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 claims description 3
- JKQXZKUSFCKOGQ-JLGXGRJMSA-N (3R,3'R)-beta,beta-carotene-3,3'-diol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-JLGXGRJMSA-N 0.000 claims description 3
- OIZGSVFYNBZVIK-FHHHURIISA-N 3'-sialyllactose Chemical compound O1[C@@H]([C@H](O)[C@H](O)CO)[C@H](NC(=O)C)[C@@H](O)C[C@@]1(C(O)=O)O[C@@H]1[C@@H](O)[C@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)O[C@H](CO)[C@@H]1O OIZGSVFYNBZVIK-FHHHURIISA-N 0.000 claims description 3
- 241000193798 Aerococcus Species 0.000 claims description 3
- 229920000310 Alpha glucan Polymers 0.000 claims description 3
- 229920000189 Arabinogalactan Polymers 0.000 claims description 3
- 241000228212 Aspergillus Species 0.000 claims description 3
- 241000606125 Bacteroides Species 0.000 claims description 3
- 229920002498 Beta-glucan Polymers 0.000 claims description 3
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 claims description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 3
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 claims description 3
- 241000193403 Clostridium Species 0.000 claims description 3
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 claims description 3
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 3
- 229920002307 Dextran Polymers 0.000 claims description 3
- 241000194033 Enterococcus Species 0.000 claims description 3
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 3
- RTVRUWIBAVHRQX-PMEZUWKYSA-N Fucosyllactose Chemical compound C([C@H]1O[C@@H]([C@H]([C@@H](O[C@@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@@H]1O)O)OC)O[C@H]1OC[C@@H](O)[C@H](O)[C@@H]1O RTVRUWIBAVHRQX-PMEZUWKYSA-N 0.000 claims description 3
- 241000605909 Fusobacterium Species 0.000 claims description 3
- 229920000926 Galactomannan Polymers 0.000 claims description 3
- 108010024636 Glutathione Proteins 0.000 claims description 3
- 229920000084 Gum arabic Polymers 0.000 claims description 3
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 claims description 3
- 229920001202 Inulin Polymers 0.000 claims description 3
- 241000194036 Lactococcus Species 0.000 claims description 3
- 241000192132 Leuconostoc Species 0.000 claims description 3
- 244000241838 Lycium barbarum Species 0.000 claims description 3
- 235000015459 Lycium barbarum Nutrition 0.000 claims description 3
- 235000015468 Lycium chinense Nutrition 0.000 claims description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 3
- 229920002774 Maltodextrin Polymers 0.000 claims description 3
- 241001468189 Melissococcus Species 0.000 claims description 3
- 241000192041 Micrococcus Species 0.000 claims description 3
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 claims description 3
- 241000235395 Mucor Species 0.000 claims description 3
- 241000202223 Oenococcus Species 0.000 claims description 3
- 241000192001 Pediococcus Species 0.000 claims description 3
- 241000228143 Penicillium Species 0.000 claims description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 3
- 241000235648 Pichia Species 0.000 claims description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 3
- 241000186429 Propionibacterium Species 0.000 claims description 3
- 108010009736 Protein Hydrolysates Proteins 0.000 claims description 3
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 claims description 3
- 229920000294 Resistant starch Polymers 0.000 claims description 3
- 241000235527 Rhizopus Species 0.000 claims description 3
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 claims description 3
- 241000235070 Saccharomyces Species 0.000 claims description 3
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 claims description 3
- 241000191940 Staphylococcus Species 0.000 claims description 3
- 229920002472 Starch Polymers 0.000 claims description 3
- 241000194017 Streptococcus Species 0.000 claims description 3
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 claims description 3
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 claims description 3
- 229930003779 Vitamin B12 Natural products 0.000 claims description 3
- 229930003471 Vitamin B2 Natural products 0.000 claims description 3
- 229930003537 Vitamin B3 Natural products 0.000 claims description 3
- 229930003761 Vitamin B9 Natural products 0.000 claims description 3
- 229930003316 Vitamin D Natural products 0.000 claims description 3
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 3
- 229930003448 Vitamin K Natural products 0.000 claims description 3
- 241000202221 Weissella Species 0.000 claims description 3
- JKQXZKUSFCKOGQ-LQFQNGICSA-N Z-zeaxanthin Natural products C([C@H](O)CC=1C)C(C)(C)C=1C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-LQFQNGICSA-N 0.000 claims description 3
- QOPRSMDTRDMBNK-RNUUUQFGSA-N Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCC(O)C1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C QOPRSMDTRDMBNK-RNUUUQFGSA-N 0.000 claims description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 3
- 239000000205 acacia gum Substances 0.000 claims description 3
- 235000010489 acacia gum Nutrition 0.000 claims description 3
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims description 3
- JKQXZKUSFCKOGQ-LOFNIBRQSA-N all-trans-Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C JKQXZKUSFCKOGQ-LOFNIBRQSA-N 0.000 claims description 3
- 230000003078 antioxidant effect Effects 0.000 claims description 3
- 235000019312 arabinogalactan Nutrition 0.000 claims description 3
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 claims description 3
- 229960002685 biotin Drugs 0.000 claims description 3
- 235000020958 biotin Nutrition 0.000 claims description 3
- 239000011616 biotin Substances 0.000 claims description 3
- 229910052796 boron Inorganic materials 0.000 claims description 3
- 229910052791 calcium Inorganic materials 0.000 claims description 3
- 239000011575 calcium Substances 0.000 claims description 3
- 229910052804 chromium Inorganic materials 0.000 claims description 3
- 239000011651 chromium Substances 0.000 claims description 3
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 claims description 3
- 229940010007 cobalamins Drugs 0.000 claims description 3
- 150000001867 cobalamins Chemical class 0.000 claims description 3
- 235000017471 coenzyme Q10 Nutrition 0.000 claims description 3
- 229940110767 coenzyme Q10 Drugs 0.000 claims description 3
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims description 3
- 229910052802 copper Inorganic materials 0.000 claims description 3
- 239000010949 copper Substances 0.000 claims description 3
- 235000012754 curcumin Nutrition 0.000 claims description 3
- 239000004148 curcumin Substances 0.000 claims description 3
- 229940109262 curcumin Drugs 0.000 claims description 3
- 235000000639 cyanocobalamin Nutrition 0.000 claims description 3
- 239000011666 cyanocobalamin Substances 0.000 claims description 3
- 229960002104 cyanocobalamin Drugs 0.000 claims description 3
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 claims description 3
- 229940090949 docosahexaenoic acid Drugs 0.000 claims description 3
- 229960005135 eicosapentaenoic acid Drugs 0.000 claims description 3
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims description 3
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims description 3
- 150000003271 galactooligosaccharides Chemical class 0.000 claims description 3
- 229960003180 glutathione Drugs 0.000 claims description 3
- 229940025878 hesperidin Drugs 0.000 claims description 3
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 claims description 3
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 claims description 3
- 229940029339 inulin Drugs 0.000 claims description 3
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims description 3
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims description 3
- 229910052742 iron Inorganic materials 0.000 claims description 3
- 229940039696 lactobacillus Drugs 0.000 claims description 3
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 claims description 3
- 229960000511 lactulose Drugs 0.000 claims description 3
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 claims description 3
- AIHDCSAXVMAMJH-GFBKWZILSA-N levan Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@@H]1[C@@H](O)[C@H](O)[C@](CO)(CO[C@@H]2[C@H]([C@H](O)[C@@](O)(CO)O2)O)O1 AIHDCSAXVMAMJH-GFBKWZILSA-N 0.000 claims description 3
- 229910052749 magnesium Inorganic materials 0.000 claims description 3
- 239000011777 magnesium Substances 0.000 claims description 3
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 claims description 3
- 239000011676 menaquinone-4 Substances 0.000 claims description 3
- 239000011700 menaquinone-7 Substances 0.000 claims description 3
- 229910052750 molybdenum Inorganic materials 0.000 claims description 3
- 239000011733 molybdenum Substances 0.000 claims description 3
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 claims description 3
- 229910052759 nickel Inorganic materials 0.000 claims description 3
- 229960003966 nicotinamide Drugs 0.000 claims description 3
- 235000005152 nicotinamide Nutrition 0.000 claims description 3
- 239000011570 nicotinamide Substances 0.000 claims description 3
- 235000001968 nicotinic acid Nutrition 0.000 claims description 3
- 239000011664 nicotinic acid Substances 0.000 claims description 3
- 229920001542 oligosaccharide Polymers 0.000 claims description 3
- 150000002482 oligosaccharides Chemical class 0.000 claims description 3
- 239000011574 phosphorus Substances 0.000 claims description 3
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 claims description 3
- 239000011591 potassium Substances 0.000 claims description 3
- 229910052700 potassium Inorganic materials 0.000 claims description 3
- 230000000529 probiotic effect Effects 0.000 claims description 3
- 229960003581 pyridoxal Drugs 0.000 claims description 3
- 235000008164 pyridoxal Nutrition 0.000 claims description 3
- 239000011674 pyridoxal Substances 0.000 claims description 3
- 235000008151 pyridoxamine Nutrition 0.000 claims description 3
- 239000011699 pyridoxamine Substances 0.000 claims description 3
- 235000008160 pyridoxine Nutrition 0.000 claims description 3
- 239000011677 pyridoxine Substances 0.000 claims description 3
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 claims description 3
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 claims description 3
- 239000011764 pyridoxine hydrochloride Substances 0.000 claims description 3
- 229960004172 pyridoxine hydrochloride Drugs 0.000 claims description 3
- 235000005875 quercetin Nutrition 0.000 claims description 3
- 229960001285 quercetin Drugs 0.000 claims description 3
- 235000021254 resistant starch Nutrition 0.000 claims description 3
- 239000002151 riboflavin Substances 0.000 claims description 3
- 235000019192 riboflavin Nutrition 0.000 claims description 3
- 229940091258 selenium supplement Drugs 0.000 claims description 3
- 229910052710 silicon Inorganic materials 0.000 claims description 3
- 239000010703 silicon Substances 0.000 claims description 3
- 235000019698 starch Nutrition 0.000 claims description 3
- 239000008107 starch Substances 0.000 claims description 3
- 150000005846 sugar alcohols Chemical class 0.000 claims description 3
- 235000019157 thiamine Nutrition 0.000 claims description 3
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 claims description 3
- 229960003495 thiamine Drugs 0.000 claims description 3
- 239000011721 thiamine Substances 0.000 claims description 3
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims description 3
- 229910052718 tin Inorganic materials 0.000 claims description 3
- 239000011135 tin Substances 0.000 claims description 3
- 229910052720 vanadium Inorganic materials 0.000 claims description 3
- 235000019163 vitamin B12 Nutrition 0.000 claims description 3
- 239000011715 vitamin B12 Substances 0.000 claims description 3
- 235000019164 vitamin B2 Nutrition 0.000 claims description 3
- 239000011716 vitamin B2 Substances 0.000 claims description 3
- 235000019160 vitamin B3 Nutrition 0.000 claims description 3
- 239000011708 vitamin B3 Substances 0.000 claims description 3
- 235000021470 vitamin B5 (pantothenic acid) Nutrition 0.000 claims description 3
- 235000019158 vitamin B6 Nutrition 0.000 claims description 3
- 239000011726 vitamin B6 Substances 0.000 claims description 3
- 235000021467 vitamin B7(Biotin) Nutrition 0.000 claims description 3
- 235000019159 vitamin B9 Nutrition 0.000 claims description 3
- 239000011727 vitamin B9 Substances 0.000 claims description 3
- 235000019166 vitamin D Nutrition 0.000 claims description 3
- 239000011710 vitamin D Substances 0.000 claims description 3
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 3
- 235000019168 vitamin K Nutrition 0.000 claims description 3
- 239000011712 vitamin K Substances 0.000 claims description 3
- 150000003721 vitamin K derivatives Chemical class 0.000 claims description 3
- 229940046008 vitamin d Drugs 0.000 claims description 3
- 229940046010 vitamin k Drugs 0.000 claims description 3
- 235000019195 vitamin supplement Nutrition 0.000 claims description 3
- 235000010930 zeaxanthin Nutrition 0.000 claims description 3
- 239000001775 zeaxanthin Substances 0.000 claims description 3
- 229940043269 zeaxanthin Drugs 0.000 claims description 3
- 229910052725 zinc Inorganic materials 0.000 claims description 3
- 239000011701 zinc Substances 0.000 claims description 3
- DTOSIQBPPRVQHS-UHFFFAOYSA-N α-Linolenic acid Chemical compound CCC=CCC=CCC=CCCCCCCCC(O)=O DTOSIQBPPRVQHS-UHFFFAOYSA-N 0.000 claims description 3
- VHLJDTBGULNCGF-UHFFFAOYSA-N Limonin Natural products CC1(C)OC2CC(=O)OCC23C4CCC5(C)C(CC(=O)C6OC56C4(C)C(=O)CC13)c7cocc7 VHLJDTBGULNCGF-UHFFFAOYSA-N 0.000 claims description 2
- 208000002720 Malnutrition Diseases 0.000 claims description 2
- 235000019621 digestibility Nutrition 0.000 claims description 2
- KBDSLGBFQAGHBE-MSGMIQHVSA-N limonin Chemical compound C=1([C@H]2[C@]3(C)CC[C@H]4[C@@]([C@@]53O[C@@H]5C(=O)O2)(C)C(=O)C[C@@H]2[C@]34COC(=O)C[C@@H]3OC2(C)C)C=COC=1 KBDSLGBFQAGHBE-MSGMIQHVSA-N 0.000 claims description 2
- 230000001071 malnutrition Effects 0.000 claims description 2
- 235000000824 malnutrition Nutrition 0.000 claims description 2
- 208000015380 nutritional deficiency disease Diseases 0.000 claims description 2
- 235000002378 plant sterols Nutrition 0.000 claims description 2
- 230000037221 weight management Effects 0.000 claims description 2
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims 1
- LEONUFNNVUYDNQ-UHFFFAOYSA-N vanadium atom Chemical compound [V] LEONUFNNVUYDNQ-UHFFFAOYSA-N 0.000 claims 1
- 230000037406 food intake Effects 0.000 description 50
- 230000000284 resting effect Effects 0.000 description 45
- 230000000694 effects Effects 0.000 description 30
- 230000001965 increasing effect Effects 0.000 description 27
- 210000003205 muscle Anatomy 0.000 description 26
- 239000000902 placebo Substances 0.000 description 25
- 229940068196 placebo Drugs 0.000 description 25
- 238000011282 treatment Methods 0.000 description 24
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 22
- 230000026731 phosphorylation Effects 0.000 description 21
- 238000006366 phosphorylation reaction Methods 0.000 description 21
- 230000001195 anabolic effect Effects 0.000 description 20
- 235000005911 diet Nutrition 0.000 description 20
- 235000020776 essential amino acid Nutrition 0.000 description 20
- 239000003797 essential amino acid Substances 0.000 description 20
- 235000021075 protein intake Nutrition 0.000 description 19
- 230000004044 response Effects 0.000 description 18
- 241001465754 Metazoa Species 0.000 description 17
- 241000282414 Homo sapiens Species 0.000 description 16
- 238000011084 recovery Methods 0.000 description 16
- 208000016261 weight loss Diseases 0.000 description 14
- 230000001154 acute effect Effects 0.000 description 12
- 230000008901 benefit Effects 0.000 description 12
- 108090000765 processed proteins & peptides Proteins 0.000 description 12
- 230000002035 prolonged effect Effects 0.000 description 12
- 230000004580 weight loss Effects 0.000 description 12
- 102000004877 Insulin Human genes 0.000 description 11
- 108090001061 Insulin Proteins 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 239000003925 fat Substances 0.000 description 11
- 235000019197 fats Nutrition 0.000 description 11
- 229940125396 insulin Drugs 0.000 description 11
- 102000034263 Amino acid transporters Human genes 0.000 description 10
- 108050005273 Amino acid transporters Proteins 0.000 description 10
- 241000282412 Homo Species 0.000 description 10
- 230000037213 diet Effects 0.000 description 10
- 230000000378 dietary effect Effects 0.000 description 10
- 102000004196 processed proteins & peptides Human genes 0.000 description 10
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 9
- 241000124008 Mammalia Species 0.000 description 9
- 238000000540 analysis of variance Methods 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 229920001184 polypeptide Polymers 0.000 description 9
- 230000009467 reduction Effects 0.000 description 9
- 102100025014 E3 ubiquitin-protein ligase TRIM63 Human genes 0.000 description 8
- 101710164910 E3 ubiquitin-protein ligase TRIM63 Proteins 0.000 description 8
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 8
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 8
- 238000003639 Student–Newman–Keuls (SNK) method Methods 0.000 description 8
- 235000013305 food Nutrition 0.000 description 8
- 210000002414 leg Anatomy 0.000 description 8
- 238000001964 muscle biopsy Methods 0.000 description 8
- 239000002773 nucleotide Substances 0.000 description 8
- 125000003729 nucleotide group Chemical group 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 7
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 150000005693 branched-chain amino acids Chemical class 0.000 description 7
- 230000015556 catabolic process Effects 0.000 description 7
- 238000009826 distribution Methods 0.000 description 7
- 230000036541 health Effects 0.000 description 7
- 238000001802 infusion Methods 0.000 description 7
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 238000012549 training Methods 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 231100000673 dose–response relationship Toxicity 0.000 description 6
- 230000004060 metabolic process Effects 0.000 description 6
- 238000013105 post hoc analysis Methods 0.000 description 6
- 239000000700 radioactive tracer Substances 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 5
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 5
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 5
- 239000004472 Lysine Substances 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 235000019577 caloric intake Nutrition 0.000 description 5
- 239000012141 concentrate Substances 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 238000012423 maintenance Methods 0.000 description 5
- 229930182817 methionine Natural products 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 4
- RQFCJASXJCIDSX-UHFFFAOYSA-N 14C-Guanosin-5'-monophosphat Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(COP(O)(O)=O)C(O)C1O RQFCJASXJCIDSX-UHFFFAOYSA-N 0.000 description 4
- 108010088751 Albumins Proteins 0.000 description 4
- 102000009027 Albumins Human genes 0.000 description 4
- 108010078791 Carrier Proteins Proteins 0.000 description 4
- 102100040669 F-box only protein 32 Human genes 0.000 description 4
- 101710191029 F-box only protein 32 Proteins 0.000 description 4
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 4
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 4
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 4
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 4
- 102000052922 Large Neutral Amino Acid-Transporter 1 Human genes 0.000 description 4
- 108010064851 Plant Proteins Proteins 0.000 description 4
- 108091006232 SLC7A5 Proteins 0.000 description 4
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 4
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 4
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 4
- 239000004473 Threonine Substances 0.000 description 4
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 4
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 4
- 230000037147 athletic performance Effects 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 238000001574 biopsy Methods 0.000 description 4
- 230000005754 cellular signaling Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 4
- 235000018417 cysteine Nutrition 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 238000005755 formation reaction Methods 0.000 description 4
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000002503 metabolic effect Effects 0.000 description 4
- 230000037323 metabolic rate Effects 0.000 description 4
- 235000017807 phytochemicals Nutrition 0.000 description 4
- 229930000223 plant secondary metabolite Natural products 0.000 description 4
- 230000004844 protein turnover Effects 0.000 description 4
- 230000002797 proteolythic effect Effects 0.000 description 4
- 238000003753 real-time PCR Methods 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 4
- 230000002103 transcriptional effect Effects 0.000 description 4
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 4
- 239000004474 valine Substances 0.000 description 4
- YCCILVSKPBXVIP-UHFFFAOYSA-N 2-(4-hydroxyphenyl)ethanol Chemical class OCCC1=CC=C(O)C=C1 YCCILVSKPBXVIP-UHFFFAOYSA-N 0.000 description 3
- 102100036009 5'-AMP-activated protein kinase catalytic subunit alpha-2 Human genes 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 3
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 3
- 102000015781 Dietary Proteins Human genes 0.000 description 3
- 108010010256 Dietary Proteins Proteins 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- 101000783681 Homo sapiens 5'-AMP-activated protein kinase catalytic subunit alpha-2 Proteins 0.000 description 3
- 102000001702 Intracellular Signaling Peptides and Proteins Human genes 0.000 description 3
- 108010068964 Intracellular Signaling Peptides and Proteins Proteins 0.000 description 3
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 3
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 235000004279 alanine Nutrition 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- 235000009697 arginine Nutrition 0.000 description 3
- 235000009582 asparagine Nutrition 0.000 description 3
- 229960001230 asparagine Drugs 0.000 description 3
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 235000021245 dietary protein Nutrition 0.000 description 3
- 235000015872 dietary supplement Nutrition 0.000 description 3
- 230000003828 downregulation Effects 0.000 description 3
- XMOCLSLCDHWDHP-IUODEOHRSA-N epi-Gallocatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-IUODEOHRSA-N 0.000 description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
- 235000004554 glutamine Nutrition 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000007407 health benefit Effects 0.000 description 3
- 235000008085 high protein diet Nutrition 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 229960000310 isoleucine Drugs 0.000 description 3
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 235000021073 macronutrients Nutrition 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 230000013663 muscle adaptation Effects 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 230000037074 physically active Effects 0.000 description 3
- 230000006461 physiological response Effects 0.000 description 3
- 239000003075 phytoestrogen Substances 0.000 description 3
- 235000021118 plant-derived protein Nutrition 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- SUVMJBTUFCVSAD-UHFFFAOYSA-N sulforaphane Chemical compound CS(=O)CCCCN=C=S SUVMJBTUFCVSAD-UHFFFAOYSA-N 0.000 description 3
- 150000003505 terpenes Chemical class 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 2
- MJYQFWSXKFLTAY-OVEQLNGDSA-N (2r,3r)-2,3-bis[(4-hydroxy-3-methoxyphenyl)methyl]butane-1,4-diol;(2r,3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O.C1=C(O)C(OC)=CC(C[C@@H](CO)[C@H](CO)CC=2C=C(OC)C(O)=CC=2)=C1 MJYQFWSXKFLTAY-OVEQLNGDSA-N 0.000 description 2
- GTBJRWFFEQJCHN-REOHCLBHSA-N (2s)-3-hydroxy-2-(hydroxyamino)propanoic acid Chemical compound OC[C@H](NO)C(O)=O GTBJRWFFEQJCHN-REOHCLBHSA-N 0.000 description 2
- ATCICVFRSJQYDV-UHFFFAOYSA-N (6E,8E,10E,12E,14E,16E,18E,20E,22E,26E)-2,6,10,14,19,23,27,31-octamethyldotriaconta-2,6,8,10,12,14,16,18,20,22,26,30-dodecaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC=C(C)CCC=C(C)C ATCICVFRSJQYDV-UHFFFAOYSA-N 0.000 description 2
- YVLPJIGOMTXXLP-UHFFFAOYSA-N 15-cis-phytoene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC(C)=CC=CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C YVLPJIGOMTXXLP-UHFFFAOYSA-N 0.000 description 2
- VFTRKSBEFQDZKX-UHFFFAOYSA-N 3,3'-diindolylmethane Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4NC=3)=CNC2=C1 VFTRKSBEFQDZKX-UHFFFAOYSA-N 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- QQRSPHJOOXUALR-UHFFFAOYSA-N Apiole Chemical compound COC1=CC(CC=C)=C(OC)C2=C1OCO2 QQRSPHJOOXUALR-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 206010007733 Catabolic state Diseases 0.000 description 2
- 241000195493 Cryptophyta Species 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- UBJVUCKUDDKUJF-UHFFFAOYSA-N Diallyl sulfide Chemical compound C=CCSCC=C UBJVUCKUDDKUJF-UHFFFAOYSA-N 0.000 description 2
- LIKYNOPXHGPMIH-UHFFFAOYSA-N Dillapiole Chemical compound C=CCC1=C(OC)C(OC)=C2OCOC2=C1 LIKYNOPXHGPMIH-UHFFFAOYSA-N 0.000 description 2
- 101710088791 Elongation factor 2 Proteins 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 102100022466 Eukaryotic translation initiation factor 4E-binding protein 1 Human genes 0.000 description 2
- 108050000946 Eukaryotic translation initiation factor 4E-binding protein 1 Proteins 0.000 description 2
- 241000239366 Euphausiacea Species 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 2
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 229920002527 Glycogen Polymers 0.000 description 2
- BTEISVKTSQLKST-UHFFFAOYSA-N Haliclonasterol Natural products CC(C=CC(C)C(C)(C)C)C1CCC2C3=CC=C4CC(O)CCC4(C)C3CCC12C BTEISVKTSQLKST-UHFFFAOYSA-N 0.000 description 2
- LCWXJXMHJVIJFK-UHFFFAOYSA-N Hydroxylysine Natural products NCC(O)CC(N)CC(O)=O LCWXJXMHJVIJFK-UHFFFAOYSA-N 0.000 description 2
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 2
- JUUBCHWRXWPFFH-UHFFFAOYSA-N Hydroxytyrosol Chemical compound OCCC1=CC=C(O)C(O)=C1 JUUBCHWRXWPFFH-UHFFFAOYSA-N 0.000 description 2
- GRSZFWQUAKGDAV-KQYNXXCUSA-N IMP Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NC=NC2=O)=C2N=C1 GRSZFWQUAKGDAV-KQYNXXCUSA-N 0.000 description 2
- GRSZFWQUAKGDAV-UHFFFAOYSA-N Inosinic acid Natural products OC1C(O)C(COP(O)(O)=O)OC1N1C(NC=NC2=O)=C2N=C1 GRSZFWQUAKGDAV-UHFFFAOYSA-N 0.000 description 2
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 2
- 240000007049 Juglans regia Species 0.000 description 2
- 235000009496 Juglans regia Nutrition 0.000 description 2
- 102000014171 Milk Proteins Human genes 0.000 description 2
- 108010011756 Milk Proteins Proteins 0.000 description 2
- 102000004472 Myostatin Human genes 0.000 description 2
- 108010056852 Myostatin Proteins 0.000 description 2
- CNIUEVQJABPUIJ-QMMMGPOBSA-N N-hydroxytyrosine Chemical compound ON[C@H](C(O)=O)CC1=CC=C(O)C=C1 CNIUEVQJABPUIJ-QMMMGPOBSA-N 0.000 description 2
- SEBFKMXJBCUCAI-UHFFFAOYSA-N NSC 227190 Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC=C(C=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-UHFFFAOYSA-N 0.000 description 2
- 108010038807 Oligopeptides Proteins 0.000 description 2
- 102000015636 Oligopeptides Human genes 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- GPLOTACQBREROW-UHFFFAOYSA-N Phlegmanol A-acetat Natural products OC1CC2=C(O)C=C(O)C=C2OC1C(=CC1=2)C=C(O)C(=O)C1=C(O)C(O)=CC=2C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 GPLOTACQBREROW-UHFFFAOYSA-N 0.000 description 2
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 108091006920 SLC38A2 Proteins 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 102100033774 Sodium-coupled neutral amino acid transporter 2 Human genes 0.000 description 2
- 108010073771 Soybean Proteins Proteins 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- KMJPKUVSXFVQGZ-UHFFFAOYSA-N TF2B Natural products OC1CC2=C(O)C=C(O)C=C2OC1C(C1=C2)=CC(O)=C(O)C1=C(O)C(=O)C=C2C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 KMJPKUVSXFVQGZ-UHFFFAOYSA-N 0.000 description 2
- 235000021307 Triticum Nutrition 0.000 description 2
- 244000098338 Triticum aestivum Species 0.000 description 2
- 239000005862 Whey Substances 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- 230000008649 adaptation response Effects 0.000 description 2
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 2
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 2
- ZOJBYZNEUISWFT-UHFFFAOYSA-N allyl isothiocyanate Chemical compound C=CCN=C=S ZOJBYZNEUISWFT-UHFFFAOYSA-N 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 229940009098 aspartate Drugs 0.000 description 2
- 230000003190 augmentative effect Effects 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 235000013734 beta-carotene Nutrition 0.000 description 2
- 239000011648 beta-carotene Substances 0.000 description 2
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 2
- 229960002747 betacarotene Drugs 0.000 description 2
- WUADCCWRTIWANL-UHFFFAOYSA-N biochanin A Chemical compound C1=CC(OC)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O WUADCCWRTIWANL-UHFFFAOYSA-N 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- FDSDTBUPSURDBL-LOFNIBRQSA-N canthaxanthin Chemical compound CC=1C(=O)CCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)CCC1(C)C FDSDTBUPSURDBL-LOFNIBRQSA-N 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- KZJWDPNRJALLNS-FBZNIEFRSA-N clionasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-FBZNIEFRSA-N 0.000 description 2
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 2
- ZZIALNLLNHEQPJ-UHFFFAOYSA-N coumestrol Chemical compound C1=C(O)C=CC2=C1OC(=O)C1=C2OC2=CC(O)=CC=C12 ZZIALNLLNHEQPJ-UHFFFAOYSA-N 0.000 description 2
- VEVZSMAEJFVWIL-UHFFFAOYSA-O cyanidin cation Chemical compound [O+]=1C2=CC(O)=CC(O)=C2C=C(O)C=1C1=CC=C(O)C(O)=C1 VEVZSMAEJFVWIL-UHFFFAOYSA-O 0.000 description 2
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N daidzein Chemical compound C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 2
- WGIYGODPCLMGQH-UHFFFAOYSA-N delta-carotene Chemical compound CC(C)=CCCC(C)=CC=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1C(C)=CCCC1(C)C WGIYGODPCLMGQH-UHFFFAOYSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 2
- 238000013401 experimental design Methods 0.000 description 2
- 235000019688 fish Nutrition 0.000 description 2
- 235000021323 fish oil Nutrition 0.000 description 2
- 125000004387 flavanoid group Chemical group 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 235000004426 flaxseed Nutrition 0.000 description 2
- HKQYGTCOTHHOMP-UHFFFAOYSA-N formononetin Chemical compound C1=CC(OC)=CC=C1C1=COC2=CC(O)=CC=C2C1=O HKQYGTCOTHHOMP-UHFFFAOYSA-N 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 229930195712 glutamate Natural products 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 229940096919 glycogen Drugs 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- RQFCJASXJCIDSX-UUOKFMHZSA-N guanosine 5'-monophosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O RQFCJASXJCIDSX-UUOKFMHZSA-N 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- QJHBJHUKURJDLG-UHFFFAOYSA-N hydroxy-L-lysine Natural products NCCCCC(NO)C(O)=O QJHBJHUKURJDLG-UHFFFAOYSA-N 0.000 description 2
- 229960002591 hydroxyproline Drugs 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempferol Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 2
- 238000012417 linear regression Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- KZMACGJDUUWFCH-UHFFFAOYSA-O malvidin Chemical compound COC1=C(O)C(OC)=CC(C=2C(=CC=3C(O)=CC(O)=CC=3[O+]=2)O)=C1 KZMACGJDUUWFCH-UHFFFAOYSA-O 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 239000011785 micronutrient Substances 0.000 description 2
- 235000013369 micronutrients Nutrition 0.000 description 2
- 235000021239 milk protein Nutrition 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000000050 nutritive effect Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- NDTYTMIUWGWIMO-UHFFFAOYSA-N perillyl alcohol Chemical compound CC(=C)C1CCC(CO)=CC1 NDTYTMIUWGWIMO-UHFFFAOYSA-N 0.000 description 2
- 150000002989 phenols Chemical class 0.000 description 2
- 229940068041 phytic acid Drugs 0.000 description 2
- 238000007747 plating Methods 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 238000010149 post-hoc-test Methods 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- SEBFKMXJBCUCAI-HKTJVKLFSA-N silibinin Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-HKTJVKLFSA-N 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 229940001941 soy protein Drugs 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 229960005559 sulforaphane Drugs 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- ULSUXBXHSYSGDT-UHFFFAOYSA-N tangeretin Chemical compound C1=CC(OC)=CC=C1C1=CC(=O)C2=C(OC)C(OC)=C(OC)C(OC)=C2O1 ULSUXBXHSYSGDT-UHFFFAOYSA-N 0.000 description 2
- 229960003080 taurine Drugs 0.000 description 2
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 2
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 2
- GPPXJZIENCGNKB-UHFFFAOYSA-N vanadium Chemical compound [V]#[V] GPPXJZIENCGNKB-UHFFFAOYSA-N 0.000 description 2
- 235000020234 walnut Nutrition 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 2
- XMOCLSLCDHWDHP-SWLSCSKDSA-N (+)-Epigallocatechin Natural products C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-SWLSCSKDSA-N 0.000 description 1
- 229930013915 (+)-catechin Natural products 0.000 description 1
- 235000007219 (+)-catechin Nutrition 0.000 description 1
- 229930013884 (+)-gallocatechin Natural products 0.000 description 1
- 235000007243 (+)-gallocatechin Nutrition 0.000 description 1
- MHXCIKYXNYCMHY-AUSJPIAWSA-N (+)-lariciresinol Chemical compound C1=C(O)C(OC)=CC(C[C@@H]2[C@@H]([C@H](OC2)C=2C=C(OC)C(O)=CC=2)CO)=C1 MHXCIKYXNYCMHY-AUSJPIAWSA-N 0.000 description 1
- HGXBRUKMWQGOIE-AFHBHXEDSA-N (+)-pinoresinol Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@@H]3[C@@H]([C@H](OC3)C=3C=C(OC)C(O)=CC=3)CO2)=C1 HGXBRUKMWQGOIE-AFHBHXEDSA-N 0.000 description 1
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 description 1
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 description 1
- 229930013783 (-)-epicatechin Natural products 0.000 description 1
- 235000007355 (-)-epicatechin Nutrition 0.000 description 1
- LSHVYAFMTMFKBA-TZIWHRDSSA-N (-)-epicatechin-3-O-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=CC=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-TZIWHRDSSA-N 0.000 description 1
- 229930014124 (-)-epigallocatechin gallate Natural products 0.000 description 1
- 235000004911 (-)-epigallocatechin gallate Nutrition 0.000 description 1
- 229930007631 (-)-perillyl alcohol Natural products 0.000 description 1
- PUETUDUXMCLALY-HOTGVXAUSA-N (-)-secoisolariciresinol Chemical compound C1=C(O)C(OC)=CC(C[C@@H](CO)[C@H](CO)CC=2C=C(OC)C(O)=CC=2)=C1 PUETUDUXMCLALY-HOTGVXAUSA-N 0.000 description 1
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- YDNYEJZZJXFADP-SNVBAGLBSA-N (2r)-5-amino-2-[(4-methylphenyl)sulfonylamino]-5-oxopentanoic acid Chemical compound CC1=CC=C(S(=O)(=O)N[C@H](CCC(N)=O)C(O)=O)C=C1 YDNYEJZZJXFADP-SNVBAGLBSA-N 0.000 description 1
- DMASLKHVQRHNES-UPOGUZCLSA-N (3R)-beta,beta-caroten-3-ol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C DMASLKHVQRHNES-UPOGUZCLSA-N 0.000 description 1
- ABTRFGSPYXCGMR-KXQOOQHDSA-N (3R)-beta,psi-caroten-3-ol Chemical compound CC(C)=CCCC(C)=CC=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C ABTRFGSPYXCGMR-KXQOOQHDSA-N 0.000 description 1
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 1
- UMYJVVZWBKIXQQ-QALSDZMNSA-N (4aS,6aR,6bR,8aR,12aR,12bR,14aS)-2,2,6a,6b,9,9,12a-heptamethyl-10-oxo-2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14,14a-icosahydropicene-4a-carboxylic acid Chemical compound C1CC(=O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C=C5[C@H]4CC[C@@H]3[C@]21C UMYJVVZWBKIXQQ-QALSDZMNSA-N 0.000 description 1
- XBZYWSMVVKYHQN-MYPRUECHSA-N (4as,6as,6br,8ar,9r,10s,12ar,12br,14bs)-10-hydroxy-2,2,6a,6b,9,12a-hexamethyl-9-[(sulfooxy)methyl]-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-4a-carboxylic acid Chemical compound C1C[C@H](O)[C@@](C)(COS(O)(=O)=O)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C XBZYWSMVVKYHQN-MYPRUECHSA-N 0.000 description 1
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 1
- FTVWIRXFELQLPI-CYBMUJFWSA-N (R)-naringenin Chemical compound C1=CC(O)=CC=C1[C@@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 FTVWIRXFELQLPI-CYBMUJFWSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- YVLPJIGOMTXXLP-UUKUAVTLSA-N 15,15'-cis-Phytoene Natural products C(=C\C=C/C=C(\CC/C=C(\CC/C=C(\CC/C=C(\C)/C)/C)/C)/C)(\CC/C=C(\CC/C=C(\CC/C=C(\C)/C)/C)/C)/C YVLPJIGOMTXXLP-UUKUAVTLSA-N 0.000 description 1
- YVLPJIGOMTXXLP-BAHRDPFUSA-N 15Z-phytoene Natural products CC(=CCCC(=CCCC(=CCCC(=CC=C/C=C(C)/CCC=C(/C)CCC=C(/C)CCC=C(C)C)C)C)C)C YVLPJIGOMTXXLP-BAHRDPFUSA-N 0.000 description 1
- YEDFEBOUHSBQBT-UHFFFAOYSA-N 2,3-dihydroflavon-3-ol Chemical class O1C2=CC=CC=C2C(=O)C(O)C1C1=CC=CC=C1 YEDFEBOUHSBQBT-UHFFFAOYSA-N 0.000 description 1
- YMHOBZXQZVXHBM-UHFFFAOYSA-N 2,5-dimethoxy-4-bromophenethylamine Chemical compound COC1=CC(CCN)=C(OC)C=C1Br YMHOBZXQZVXHBM-UHFFFAOYSA-N 0.000 description 1
- PHZOWSSBXJXFOR-UHFFFAOYSA-N 2-Propenyl glucosinolate Natural products OCC1OC(SC(CC=C)=NOS(O)(=O)=O)C(O)C(O)C1O PHZOWSSBXJXFOR-UHFFFAOYSA-N 0.000 description 1
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
- 235000010045 3,3'-diindolylmethane Nutrition 0.000 description 1
- 229940093768 3,3'-diindolylmethane Drugs 0.000 description 1
- QGJZLNKBHJESQX-UHFFFAOYSA-N 3-Epi-Betulin-Saeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(=C)C)C5C4CCC3C21C QGJZLNKBHJESQX-UHFFFAOYSA-N 0.000 description 1
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- CLOUCVRNYSHRCF-UHFFFAOYSA-N 3beta-Hydroxy-20(29)-Lupen-3,27-oic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C(O)=O)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C CLOUCVRNYSHRCF-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 1
- SUVMJBTUFCVSAD-JTQLQIEISA-N 4-Methylsulfinylbutyl isothiocyanate Natural products C[S@](=O)CCCCN=C=S SUVMJBTUFCVSAD-JTQLQIEISA-N 0.000 description 1
- GWNBMLCISLLOAU-UHFFFAOYSA-N 4-oxo-2-phenylchromene-3-carbaldehyde Chemical class O1C2=CC=CC=C2C(=O)C(C=O)=C1C1=CC=CC=C1 GWNBMLCISLLOAU-UHFFFAOYSA-N 0.000 description 1
- UPJKSWLLCONYMW-UHFFFAOYSA-N 5'-Adenosine monophosphate Natural products COc1cc(O)c(C(=O)C)c(OC2OC(COC3OC(C)C(O)C(O)C3O)C(O)C(O)C2O)c1 UPJKSWLLCONYMW-UHFFFAOYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- ZEASWHWETFMWCV-UHFFFAOYSA-N 7-O-(2-O-Acetyl-6-O-Methyl-beta-D-glucuronoside)-4',5,7-Trihydroxyflavone Natural products C=1C(O)=C(O)C2=C(O)C(=O)C=C(C3C(CC4=C(O)C=C(O)C=C4O3)OC(=O)C=3C=C(O)C(O)=C(O)C=3)C=C2C=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 ZEASWHWETFMWCV-UHFFFAOYSA-N 0.000 description 1
- RFWGABANNQMHMZ-UHFFFAOYSA-N 8-acetoxy-7-acetyl-6,7,7a,8-tetrahydro-5H-benzo[g][1,3]dioxolo[4',5':4,5]benzo[1,2,3-de]quinoline Natural products CC=C1C(CC(=O)OCCC=2C=C(O)C(O)=CC=2)C(C(=O)OC)=COC1OC1OC(CO)C(O)C(O)C1O RFWGABANNQMHMZ-UHFFFAOYSA-N 0.000 description 1
- AEOBEOJCBAYXBA-UHFFFAOYSA-N A2P5P Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1OP(O)(O)=O AEOBEOJCBAYXBA-UHFFFAOYSA-N 0.000 description 1
- 230000005730 ADP ribosylation Effects 0.000 description 1
- 238000012232 AGPC extraction Methods 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 230000007730 Akt signaling Effects 0.000 description 1
- JDLKFOPOAOFWQN-VIFPVBQESA-N Allicin Natural products C=CCS[S@](=O)CC=C JDLKFOPOAOFWQN-VIFPVBQESA-N 0.000 description 1
- XUHLIQGRKRUKPH-GCXOYZPQSA-N Alliin Natural products N[C@H](C[S@@](=O)CC=C)C(O)=O XUHLIQGRKRUKPH-GCXOYZPQSA-N 0.000 description 1
- 241000234282 Allium Species 0.000 description 1
- 235000017060 Arachis glabrata Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000018262 Arachis monticola Nutrition 0.000 description 1
- 235000007319 Avena orientalis Nutrition 0.000 description 1
- 241000209763 Avena sativa Species 0.000 description 1
- 235000007558 Avena sp Nutrition 0.000 description 1
- HRQKOYFGHJYEFS-UHFFFAOYSA-N Beta psi-carotene Chemical compound CC(C)=CCCC(C)=CC=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C HRQKOYFGHJYEFS-UHFFFAOYSA-N 0.000 description 1
- DHHFDKNIEVKVKS-FMOSSLLZSA-N Betanin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)O)=CC(C[C@H]2C([O-])=O)=C1[N+]2=C\C=C\1C=C(C(O)=O)N[C@H](C(O)=O)C/1 DHHFDKNIEVKVKS-FMOSSLLZSA-N 0.000 description 1
- DHHFDKNIEVKVKS-MVUYWVKGSA-N Betanin Natural products O=C(O)[C@@H]1NC(C(=O)O)=C/C(=C\C=[N+]/2\[C@@H](C(=O)[O-])Cc3c\2cc(O)c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)c3)/C1 DHHFDKNIEVKVKS-MVUYWVKGSA-N 0.000 description 1
- DIZWSDNSTNAYHK-XGWVBXMLSA-N Betulinic acid Natural products CC(=C)[C@@H]1C[C@H]([C@H]2CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(=O)O DIZWSDNSTNAYHK-XGWVBXMLSA-N 0.000 description 1
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 description 1
- 241000186012 Bifidobacterium breve Species 0.000 description 1
- 241001608472 Bifidobacterium longum Species 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 235000014698 Brassica juncea var multisecta Nutrition 0.000 description 1
- 235000006008 Brassica napus var napus Nutrition 0.000 description 1
- 240000000385 Brassica napus var. napus Species 0.000 description 1
- 235000006618 Brassica rapa subsp oleifera Nutrition 0.000 description 1
- 235000004977 Brassica sinapistrum Nutrition 0.000 description 1
- 101100093804 Caenorhabditis elegans rps-6 gene Proteins 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- SGNBVLSWZMBQTH-FGAXOLDCSA-N Campesterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1 SGNBVLSWZMBQTH-FGAXOLDCSA-N 0.000 description 1
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 description 1
- XUSYGBPHQBWGAD-PJSUUKDQSA-N Carnosol Chemical compound CC([C@@H]1C2)(C)CCC[C@@]11C(=O)O[C@@H]2C2=C1C(O)=C(O)C(C(C)C)=C2 XUSYGBPHQBWGAD-PJSUUKDQSA-N 0.000 description 1
- MMFRMKXYTWBMOM-UHFFFAOYSA-N Carnosol Natural products CCc1cc2C3CC4C(C)(C)CCCC4(C(=O)O3)c2c(O)c1O MMFRMKXYTWBMOM-UHFFFAOYSA-N 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- DQFBYFPFKXHELB-UHFFFAOYSA-N Chalcone Natural products C=1C=CC=CC=1C(=O)C=CC1=CC=CC=C1 DQFBYFPFKXHELB-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 208000028399 Critical Illness Diseases 0.000 description 1
- 239000004212 Cryptoxanthin Substances 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- GCPYCNBGGPHOBD-UHFFFAOYSA-N Delphinidin Natural products OC1=Cc2c(O)cc(O)cc2OC1=C3C=C(O)C(=O)C(=C3)O GCPYCNBGGPHOBD-UHFFFAOYSA-N 0.000 description 1
- UBSCDKPKWHYZNX-UHFFFAOYSA-N Demethoxycapillarisin Natural products C1=CC(O)=CC=C1OC1=CC(=O)C2=C(O)C=C(O)C=C2O1 UBSCDKPKWHYZNX-UHFFFAOYSA-N 0.000 description 1
- HKVGJQVJNQRJPO-UHFFFAOYSA-N Demethyloleuropein Natural products O1C=C(C(O)=O)C(CC(=O)OCCC=2C=C(O)C(O)=CC=2)C(=CC)C1OC1OC(CO)C(O)C(O)C1O HKVGJQVJNQRJPO-UHFFFAOYSA-N 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- LSHVYAFMTMFKBA-UHFFFAOYSA-N ECG Natural products C=1C=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-UHFFFAOYSA-N 0.000 description 1
- AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 description 1
- 229920002079 Ellagic acid Polymers 0.000 description 1
- ATJXMQHAMYVHRX-CPCISQLKSA-N Ellagic acid Natural products OC1=C(O)[C@H]2OC(=O)c3cc(O)c(O)c4OC(=O)C(=C1)[C@H]2c34 ATJXMQHAMYVHRX-CPCISQLKSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 240000008620 Fagopyrum esculentum Species 0.000 description 1
- 235000009419 Fagopyrum esculentum Nutrition 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 101000652292 Homo sapiens Serotonin N-acetyltransferase Proteins 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- RJIIQBYZGJSODH-QWRGUYRKSA-N Indicaxanthin Chemical compound C1=C(C(O)=O)N[C@H](C(=O)O)C\C1=C/C=[N+]/1[C@H](C([O-])=O)CCC\1 RJIIQBYZGJSODH-QWRGUYRKSA-N 0.000 description 1
- SOKRTWSMFOUWEI-UHFFFAOYSA-N Indicaxanthin Natural products OC(=O)C1CC(=C/CN2CCCC2C(=O)O)C=C(N1)C(=O)O SOKRTWSMFOUWEI-UHFFFAOYSA-N 0.000 description 1
- IVYPNXXAYMYVSP-UHFFFAOYSA-N Indole-3-carbinol Natural products C1=CC=C2C(CO)=CNC2=C1 IVYPNXXAYMYVSP-UHFFFAOYSA-N 0.000 description 1
- DHHFDKNIEVKVKS-RYGANQNKSA-N Isobetanin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)O)=CC(C[C@H]2C([O-])=O)=C1[N+]2=C\C=C/1C=C(C(O)=O)N[C@@H](C(O)=O)C\1 DHHFDKNIEVKVKS-RYGANQNKSA-N 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- GQODBWLKUWYOFX-UHFFFAOYSA-N Isorhamnetin Natural products C1=C(O)C(C)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 GQODBWLKUWYOFX-UHFFFAOYSA-N 0.000 description 1
- FDQAOULAVFHKBX-UHFFFAOYSA-N Isosilybin A Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC(=CC=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 FDQAOULAVFHKBX-UHFFFAOYSA-N 0.000 description 1
- IPMYMEWFZKHGAX-UHFFFAOYSA-N Isotheaflavin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C(C1=C2)=CC(O)=C(O)C1=C(O)C(=O)C=C2C1C(O)CC2=C(O)C=C(O)C=C2O1 IPMYMEWFZKHGAX-UHFFFAOYSA-N 0.000 description 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- DBLDQZASZZMNSL-QMMMGPOBSA-N L-tyrosinol Natural products OC[C@@H](N)CC1=CC=C(O)C=C1 DBLDQZASZZMNSL-QMMMGPOBSA-N 0.000 description 1
- 241000186605 Lactobacillus paracasei Species 0.000 description 1
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 1
- 235000019687 Lamb Nutrition 0.000 description 1
- YVRYZXAHRGGELT-UHFFFAOYSA-N Lariciresinol Natural products C1=C2OCOC2=CC(C2C(C)C3(OC)C=C(CC=C)C(=O)CC3(O2)OC)=C1 YVRYZXAHRGGELT-UHFFFAOYSA-N 0.000 description 1
- 235000014647 Lens culinaris subsp culinaris Nutrition 0.000 description 1
- 244000043158 Lens esculenta Species 0.000 description 1
- MZSGWZGPESCJAN-MOBFUUNNSA-N Melitric acid A Natural products O([C@@H](C(=O)O)Cc1cc(O)c(O)cc1)C(=O)/C=C/c1cc(O)c(O/C(/C(=O)O)=C/c2cc(O)c(O)cc2)cc1 MZSGWZGPESCJAN-MOBFUUNNSA-N 0.000 description 1
- 241000736262 Microbiota Species 0.000 description 1
- UMYJVVZWBKIXQQ-UHFFFAOYSA-N Moronic acid Natural products C1CC(=O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)C=C5C4CCC3C21C UMYJVVZWBKIXQQ-UHFFFAOYSA-N 0.000 description 1
- 206010028289 Muscle atrophy Diseases 0.000 description 1
- IKMDFBPHZNJCSN-UHFFFAOYSA-N Myricetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC(O)=C(O)C(O)=C1 IKMDFBPHZNJCSN-UHFFFAOYSA-N 0.000 description 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
- JGRJFJIJVQCUMW-HQSRNOONSA-N Neobetanin Chemical compound OC[C@H]1O[C@@H](Oc2cc3C[C@H](N(\C=C\c4cc(nc(c4)C(O)=O)C(O)=O)c3cc2O)C(O)=O)[C@H](O)[C@@H](O)[C@@H]1O JGRJFJIJVQCUMW-HQSRNOONSA-N 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- ATCICVFRSJQYDV-DDRHJXQASA-N Neurosporene Natural products C(=C\C=C\C(=C/C=C/C=C(\C=C\C=C(/CC/C=C(\CC/C=C(\C)/C)/C)\C)/C)\C)(\C=C\C=C(/CC/C=C(\C)/C)\C)/C ATCICVFRSJQYDV-DDRHJXQASA-N 0.000 description 1
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 1
- RFWGABANNQMHMZ-HYYSZPHDSA-N Oleuropein Chemical compound O([C@@H]1OC=C([C@H](C1=CC)CC(=O)OCCC=1C=C(O)C(O)=CC=1)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RFWGABANNQMHMZ-HYYSZPHDSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108010084695 Pea Proteins Proteins 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- OOUTWVMJGMVRQF-DOYZGLONSA-N Phoenicoxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)C(=O)C(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)C(=O)CCC2(C)C OOUTWVMJGMVRQF-DOYZGLONSA-N 0.000 description 1
- IIXHQGSINFQLRR-UHFFFAOYSA-N Piceatannol Natural products Oc1ccc(C=Cc2c(O)c(O)c3CCCCc3c2O)cc1O IIXHQGSINFQLRR-UHFFFAOYSA-N 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- XUHLIQGRKRUKPH-UHFFFAOYSA-N S-allyl-L-cysteine sulfoxide Natural products OC(=O)C(N)CS(=O)CC=C XUHLIQGRKRUKPH-UHFFFAOYSA-N 0.000 description 1
- 102100030547 Serotonin N-acetyltransferase Human genes 0.000 description 1
- VLGROHBNWZUINI-UHFFFAOYSA-N Silybin Natural products COc1cc(ccc1O)C2OC3C=C(C=CC3OC2CO)C4Oc5cc(O)cc(O)c5C(=O)C4O VLGROHBNWZUINI-UHFFFAOYSA-N 0.000 description 1
- PHZOWSSBXJXFOR-MYMDCHNCSA-N Sinigrin Natural products S(=O)(=O)(O/N=C(\S[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O1)/CC=C)O PHZOWSSBXJXFOR-MYMDCHNCSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- UXRMWRBWCAGDQB-UHFFFAOYSA-N Theaflavin Natural products C1=CC(C2C(CC3=C(O)C=C(O)C=C3O2)O)=C(O)C(=O)C2=C1C(C1OC3=CC(O)=CC(O)=C3CC1O)=CC(O)=C2O UXRMWRBWCAGDQB-UHFFFAOYSA-N 0.000 description 1
- BVMDSEFJGKQBKJ-UHFFFAOYSA-N Theaflavin 3'-gallate Natural products O1C(C(O)=O)C(O)C(O)C(O)C1OC1=C(O)C=C(O)C2=C1OC(C=1C=C(O)C(O)=CC=1)=CC2=O BVMDSEFJGKQBKJ-UHFFFAOYSA-N 0.000 description 1
- ZEASWHWETFMWCV-ISBUVJFSSA-N Theaflavin 3,3'-digallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C2=CC(=CC(=O)C(O)=C2C(O)=C(O)C=1)[C@@H]1[C@@H](CC2=C(O)C=C(O)C=C2O1)OC(=O)C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 ZEASWHWETFMWCV-ISBUVJFSSA-N 0.000 description 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 1
- 108020004566 Transfer RNA Proteins 0.000 description 1
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 description 1
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 description 1
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 description 1
- DJJCXFVJDGTHFX-UHFFFAOYSA-N Uridinemonophosphate Natural products OC1C(O)C(COP(O)(O)=O)OC1N1C(=O)NC(=O)C=C1 DJJCXFVJDGTHFX-UHFFFAOYSA-N 0.000 description 1
- 241000545067 Venus Species 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 229920002494 Zein Polymers 0.000 description 1
- 230000002350 accommodative effect Effects 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 235000010081 allicin Nutrition 0.000 description 1
- JDLKFOPOAOFWQN-UHFFFAOYSA-N allicin Chemical compound C=CCSS(=O)CC=C JDLKFOPOAOFWQN-UHFFFAOYSA-N 0.000 description 1
- 235000015295 alliin Nutrition 0.000 description 1
- XUHLIQGRKRUKPH-DYEAUMGKSA-N alliin Chemical compound OC(=O)[C@@H](N)C[S@@](=O)CC=C XUHLIQGRKRUKPH-DYEAUMGKSA-N 0.000 description 1
- 235000016720 allyl isothiocyanate Nutrition 0.000 description 1
- JGMPRNFEEAJLAJ-UHFFFAOYSA-N allyl methyl trisulphide Natural products CSSSCC=C JGMPRNFEEAJLAJ-UHFFFAOYSA-N 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- IGABZIVJSNQMPZ-UHFFFAOYSA-N alpha-Zeacarotene Natural products CC(C)=CCCC(C)=CCCC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1C(C)=CCCC1(C)C IGABZIVJSNQMPZ-UHFFFAOYSA-N 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 235000014398 anacardic acid Nutrition 0.000 description 1
- KAOMOVYHGLSFHQ-UTOQUPLUSA-N anacardic acid Chemical compound CCC\C=C/C\C=C/CCCCCCCC1=CC=CC(O)=C1C(O)=O KAOMOVYHGLSFHQ-UTOQUPLUSA-N 0.000 description 1
- ADFWQBGTDJIESE-UHFFFAOYSA-N anacardic acid 15:0 Natural products CCCCCCCCCCCCCCCC1=CC=CC(O)=C1C(O)=O ADFWQBGTDJIESE-UHFFFAOYSA-N 0.000 description 1
- 235000021120 animal protein Nutrition 0.000 description 1
- 229930014669 anthocyanidin Natural products 0.000 description 1
- 235000008758 anthocyanidins Nutrition 0.000 description 1
- 235000010208 anthocyanin Nutrition 0.000 description 1
- 239000004410 anthocyanin Substances 0.000 description 1
- 229930002877 anthocyanin Natural products 0.000 description 1
- 150000004636 anthocyanins Chemical class 0.000 description 1
- XADJWCRESPGUTB-UHFFFAOYSA-N apigenin Natural products C1=CC(O)=CC=C1C1=CC(=O)C2=CC(O)=C(O)C=C2O1 XADJWCRESPGUTB-UHFFFAOYSA-N 0.000 description 1
- 235000008714 apigenin Nutrition 0.000 description 1
- KZNIFHPLKGYRTM-UHFFFAOYSA-N apigenin Chemical compound C1=CC(O)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 KZNIFHPLKGYRTM-UHFFFAOYSA-N 0.000 description 1
- 229940117893 apigenin Drugs 0.000 description 1
- 235000002484 apiole Nutrition 0.000 description 1
- 229940070436 apiole Drugs 0.000 description 1
- 230000010516 arginylation Effects 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 239000001654 beetroot red Substances 0.000 description 1
- 235000012677 beetroot red Nutrition 0.000 description 1
- 229940076810 beta sitosterol Drugs 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 235000002360 beta-cryptoxanthin Nutrition 0.000 description 1
- DMASLKHVQRHNES-ITUXNECMSA-N beta-cryptoxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CCCC2(C)C DMASLKHVQRHNES-ITUXNECMSA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- 235000000842 betacyanins Nutrition 0.000 description 1
- 235000016614 betalains Nutrition 0.000 description 1
- 235000002185 betanin Nutrition 0.000 description 1
- 235000016411 betaxanthins Nutrition 0.000 description 1
- QGJZLNKBHJESQX-FZFNOLFKSA-N betulinic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C QGJZLNKBHJESQX-FZFNOLFKSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 229940009289 bifidobacterium lactis Drugs 0.000 description 1
- 229940009291 bifidobacterium longum Drugs 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000004883 caffeic acid Nutrition 0.000 description 1
- 229940074360 caffeic acid Drugs 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 235000000431 campesterol Nutrition 0.000 description 1
- SGNBVLSWZMBQTH-PODYLUTMSA-N campesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](C)C(C)C)[C@@]1(C)CC2 SGNBVLSWZMBQTH-PODYLUTMSA-N 0.000 description 1
- 235000012682 canthaxanthin Nutrition 0.000 description 1
- 239000001659 canthaxanthin Substances 0.000 description 1
- 229940008033 canthaxanthin Drugs 0.000 description 1
- 235000004654 carnosol Nutrition 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 235000007746 carvacrol Nutrition 0.000 description 1
- RECUKUPTGUEGMW-UHFFFAOYSA-N carvacrol Chemical compound CC(C)C1=CC=C(C)C(O)=C1 RECUKUPTGUEGMW-UHFFFAOYSA-N 0.000 description 1
- HHTWOMMSBMNRKP-UHFFFAOYSA-N carvacrol Natural products CC(=C)C1=CC=C(C)C(O)=C1 HHTWOMMSBMNRKP-UHFFFAOYSA-N 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- 108010079058 casein hydrolysate Proteins 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000001925 catabolic effect Effects 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 150000001765 catechin Chemical class 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 235000005513 chalcones Nutrition 0.000 description 1
- 150000001789 chalcones Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 1
- OVSVTCFNLSGAMM-KGBODLQUSA-N cis-phytofluene Natural products CC(=CCCC(=CCCC(=CCCC(=CC=C/C=C(C)/C=C/C=C(C)/CCC=C(/C)CCC=C(C)C)C)C)C)C OVSVTCFNLSGAMM-KGBODLQUSA-N 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 235000013477 citrulline Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 229960000956 coumarin Drugs 0.000 description 1
- 229930016834 coumestan Natural products 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 235000019244 cryptoxanthin Nutrition 0.000 description 1
- 235000007336 cyanidin Nutrition 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- IERHLVCPSMICTF-XVFCMESISA-N cytidine 5'-monophosphate Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(O)=O)O1 IERHLVCPSMICTF-XVFCMESISA-N 0.000 description 1
- IERHLVCPSMICTF-UHFFFAOYSA-N cytidine monophosphate Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(COP(O)(O)=O)O1 IERHLVCPSMICTF-UHFFFAOYSA-N 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- GYOZYWVXFNDGLU-XLPZGREQSA-N dTMP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)C1 GYOZYWVXFNDGLU-XLPZGREQSA-N 0.000 description 1
- 235000007240 daidzein Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 235000007242 delphinidin Nutrition 0.000 description 1
- FFNDMZIBVDSQFI-UHFFFAOYSA-N delphinidin chloride Chemical compound [Cl-].[O+]=1C2=CC(O)=CC(O)=C2C=C(O)C=1C1=CC(O)=C(O)C(O)=C1 FFNDMZIBVDSQFI-UHFFFAOYSA-N 0.000 description 1
- WGIYGODPCLMGQH-ZNTKZCHQSA-N delta-Carotene Natural products C(=C\C=C\C(=C/C=C/C=C(\C=C\C=C(/C=C/[C@H]1C(C)=CCCC1(C)C)\C)/C)\C)(\C=C\C=C(/CC/C=C(\C)/C)\C)/C WGIYGODPCLMGQH-ZNTKZCHQSA-N 0.000 description 1
- 235000001581 delta-carotene Nutrition 0.000 description 1
- 230000017858 demethylation Effects 0.000 description 1
- 238000010520 demethylation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000000881 depressing effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 235000021196 dietary intervention Nutrition 0.000 description 1
- PZXJOHSZQAEJFE-UHFFFAOYSA-N dihydrobetulinic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(C)C)C5C4CCC3C21C PZXJOHSZQAEJFE-UHFFFAOYSA-N 0.000 description 1
- 235000004211 dillapiole Nutrition 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 229960002852 ellagic acid Drugs 0.000 description 1
- 235000004132 ellagic acid Nutrition 0.000 description 1
- 229940082150 encore Drugs 0.000 description 1
- 235000021035 energy-restricted diet Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- VFSWRBJYBQXUTE-UHFFFAOYSA-N epi-Gallocatechin 3-O-gallate Natural products Oc1ccc2C(=O)C(OC(=O)c3cc(O)c(O)c(O)c3)C(Oc2c1)c4cc(O)c(O)c(O)c4 VFSWRBJYBQXUTE-UHFFFAOYSA-N 0.000 description 1
- SBHXYTNGIZCORC-ZDUSSCGKSA-N eriodictyol Chemical compound C1([C@@H]2CC(=O)C3=C(O)C=C(C=C3O2)O)=CC=C(O)C(O)=C1 SBHXYTNGIZCORC-ZDUSSCGKSA-N 0.000 description 1
- TUJPOVKMHCLXEL-UHFFFAOYSA-N eriodictyol Natural products C1C(=O)C2=CC(O)=CC(O)=C2OC1C1=CC=C(O)C(O)=C1 TUJPOVKMHCLXEL-UHFFFAOYSA-N 0.000 description 1
- 235000011797 eriodictyol Nutrition 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- SBHXYTNGIZCORC-UHFFFAOYSA-N eriodyctiol Natural products O1C2=CC(O)=CC(O)=C2C(=O)CC1C1=CC=C(O)C(O)=C1 SBHXYTNGIZCORC-UHFFFAOYSA-N 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 1
- 235000001785 ferulic acid Nutrition 0.000 description 1
- 229940114124 ferulic acid Drugs 0.000 description 1
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 1
- 229930182497 flavan-3-ol Natural products 0.000 description 1
- 150000002206 flavan-3-ols Chemical class 0.000 description 1
- 229930003949 flavanone Natural products 0.000 description 1
- 150000002208 flavanones Chemical class 0.000 description 1
- 235000011981 flavanones Nutrition 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- HVQAJTFOCKOKIN-UHFFFAOYSA-N flavonol Natural products O1C2=CC=CC=C2C(=O)C(O)=C1C1=CC=CC=C1 HVQAJTFOCKOKIN-UHFFFAOYSA-N 0.000 description 1
- 150000002216 flavonol derivatives Chemical class 0.000 description 1
- 235000011957 flavonols Nutrition 0.000 description 1
- NWKFECICNXDNOQ-UHFFFAOYSA-N flavylium Chemical compound C1=CC=CC=C1C1=CC=C(C=CC=C2)C2=[O+]1 NWKFECICNXDNOQ-UHFFFAOYSA-N 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- RIKPNWPEMPODJD-UHFFFAOYSA-N formononetin Natural products C1=CC(OC)=CC=C1C1=COC2=CC=CC=C2C1=O RIKPNWPEMPODJD-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000022244 formylation Effects 0.000 description 1
- 238000006170 formylation reaction Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- LRBQNJMCXXYXIU-QWKBTXIPSA-N gallotannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@H]2[C@@H]([C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-QWKBTXIPSA-N 0.000 description 1
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 description 1
- 230000006251 gamma-carboxylation Effects 0.000 description 1
- 239000011663 gamma-carotene Substances 0.000 description 1
- 235000000633 gamma-carotene Nutrition 0.000 description 1
- HRQKOYFGHJYEFS-RZWPOVEWSA-N gamma-carotene Natural products C(=C\C=C\C(=C/C=C/C=C(\C=C\C=C(/C=C/C=1C(C)(C)CCCC=1C)\C)/C)\C)(\C=C\C=C(/CC/C=C(\C)/C)\C)/C HRQKOYFGHJYEFS-RZWPOVEWSA-N 0.000 description 1
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 description 1
- 235000020664 gamma-linolenic acid Nutrition 0.000 description 1
- KZJWDPNRJALLNS-STIDJNKJSA-N gamma-sitosterol Natural products CC[C@@H](CC[C@@H](C)[C@@H]1CC[C@H]2[C@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C KZJWDPNRJALLNS-STIDJNKJSA-N 0.000 description 1
- 229960002733 gamolenic acid Drugs 0.000 description 1
- 210000005095 gastrointestinal system Anatomy 0.000 description 1
- 229940045109 genistein Drugs 0.000 description 1
- 235000006539 genistein Nutrition 0.000 description 1
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 1
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 1
- 125000004383 glucosinolate group Chemical group 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 230000036252 glycation Effects 0.000 description 1
- 235000008466 glycitein Nutrition 0.000 description 1
- DXYUAIFZCFRPTH-UHFFFAOYSA-N glycitein Chemical compound C1=C(O)C(OC)=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 DXYUAIFZCFRPTH-UHFFFAOYSA-N 0.000 description 1
- NNUVCMKMNCKPKN-UHFFFAOYSA-N glycitein Natural products COc1c(O)ccc2OC=C(C(=O)c12)c3ccc(O)cc3 NNUVCMKMNCKPKN-UHFFFAOYSA-N 0.000 description 1
- 229930004094 glycosylphosphatidylinositol Natural products 0.000 description 1
- 231100000001 growth retardation Toxicity 0.000 description 1
- 150000003278 haem Chemical group 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229930005346 hydroxycinnamic acid Natural products 0.000 description 1
- DEDGUGJNLNLJSR-UHFFFAOYSA-N hydroxycinnamic acid group Chemical class OC(C(=O)O)=CC1=CC=CC=C1 DEDGUGJNLNLJSR-UHFFFAOYSA-N 0.000 description 1
- 235000010359 hydroxycinnamic acids Nutrition 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 235000003248 hydroxytyrosol Nutrition 0.000 description 1
- 229940095066 hydroxytyrosol Drugs 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000003116 impacting effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 235000016241 indicaxanthin Nutrition 0.000 description 1
- CCXPAUKIWRMEET-QWRGUYRKSA-N indicaxanthin Natural products OC(=O)[C@@H]1CCCN1C=CC1=CC(=N[C@@H](C1)C(O)=O)C(O)=O CCXPAUKIWRMEET-QWRGUYRKSA-N 0.000 description 1
- 235000002279 indole-3-carbinol Nutrition 0.000 description 1
- RUMVKBSXRDGBGO-UHFFFAOYSA-N indole-3-carbinol Chemical compound C1=CC=C[C]2C(CO)=CN=C21 RUMVKBSXRDGBGO-UHFFFAOYSA-N 0.000 description 1
- 150000002475 indoles Chemical class 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000026045 iodination Effects 0.000 description 1
- 238000006192 iodination reaction Methods 0.000 description 1
- 235000017088 isobetanin Nutrition 0.000 description 1
- CTMLKIKAUFEMLE-RYGANQNKSA-N isobetanin Natural products OC[C@H]1O[C@@H](Oc2cc3C[C@H](N(C=CC4=CC(=N[C@H](C4)C(=O)O)C(=O)O)c3cc2O)C(=O)O)[C@H](O)[C@@H](O)[C@@H]1O CTMLKIKAUFEMLE-RYGANQNKSA-N 0.000 description 1
- WYXXLXHHWYNKJF-UHFFFAOYSA-N isocarvacrol Natural products CC(C)C1=CC=C(O)C(C)=C1 WYXXLXHHWYNKJF-UHFFFAOYSA-N 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 150000002515 isoflavone derivatives Chemical class 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 235000008800 isorhamnetin Nutrition 0.000 description 1
- IZQSVPBOUDKVDZ-UHFFFAOYSA-N isorhamnetin Chemical compound C1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 IZQSVPBOUDKVDZ-UHFFFAOYSA-N 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 210000001630 jejunum Anatomy 0.000 description 1
- 235000008777 kaempferol Nutrition 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 235000006826 lariciresinol Nutrition 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 235000001510 limonene Nutrition 0.000 description 1
- 229940087305 limonene Drugs 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000003137 locomotive effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 description 1
- 235000009498 luteolin Nutrition 0.000 description 1
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 description 1
- 230000003050 macronutrient Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 235000009584 malvidin Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- OGFXBIXJCWAUCH-UHFFFAOYSA-N meso-secoisolariciresinol Natural products C1=2C=C(O)C(OC)=CC=2CC(CO)C(CO)C1C1=CC=C(O)C(OC)=C1 OGFXBIXJCWAUCH-UHFFFAOYSA-N 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000010197 meta-analysis Methods 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 235000020938 metabolic status Nutrition 0.000 description 1
- QCAWEPFNJXQPAN-UHFFFAOYSA-N methoxyfenozide Chemical compound COC1=CC=CC(C(=O)NN(C(=O)C=2C=C(C)C=C(C)C=2)C(C)(C)C)=C1C QCAWEPFNJXQPAN-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- FAARLWTXUUQFSN-UHFFFAOYSA-N methylellagic acid Natural products O1C(=O)C2=CC(O)=C(O)C3=C2C2=C1C(OC)=C(O)C=C2C(=O)O3 FAARLWTXUUQFSN-UHFFFAOYSA-N 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 229930003658 monoterpene Natural products 0.000 description 1
- 150000002773 monoterpene derivatives Chemical class 0.000 description 1
- 235000002577 monoterpenes Nutrition 0.000 description 1
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 1
- 230000020763 muscle atrophy Effects 0.000 description 1
- 230000004220 muscle function Effects 0.000 description 1
- 230000037257 muscle growth Effects 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 210000003365 myofibril Anatomy 0.000 description 1
- PCOBUQBNVYZTBU-UHFFFAOYSA-N myricetin Natural products OC1=C(O)C(O)=CC(C=2OC3=CC(O)=C(O)C(O)=C3C(=O)C=2)=C1 PCOBUQBNVYZTBU-UHFFFAOYSA-N 0.000 description 1
- 235000007743 myricetin Nutrition 0.000 description 1
- 229940116852 myricetin Drugs 0.000 description 1
- 230000007498 myristoylation Effects 0.000 description 1
- WGEYAGZBLYNDFV-UHFFFAOYSA-N naringenin Natural products C1(=O)C2=C(O)C=C(O)C=C2OC(C1)C1=CC=C(CC1)O WGEYAGZBLYNDFV-UHFFFAOYSA-N 0.000 description 1
- 235000007625 naringenin Nutrition 0.000 description 1
- 229940117954 naringenin Drugs 0.000 description 1
- 235000018842 neobetanin Nutrition 0.000 description 1
- KRZLUOUGQYWELW-UHFFFAOYSA-N neobetanin Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1)O)=CC(CC\2C([O-])=O)=C1[N+]/2=C/C=C1C=C(C(O)=O)NC(C(O)=O)=C1 KRZLUOUGQYWELW-UHFFFAOYSA-N 0.000 description 1
- MQYXUWHLBZFQQO-UHFFFAOYSA-N nepehinol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C MQYXUWHLBZFQQO-UHFFFAOYSA-N 0.000 description 1
- 235000008665 neurosporene Nutrition 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 235000014571 nuts Nutrition 0.000 description 1
- 229940100243 oleanolic acid Drugs 0.000 description 1
- 235000008531 oleocanthal Nutrition 0.000 description 1
- VPOVFCBNUOUZGG-VAKDEWRISA-N oleocanthal Chemical compound C\C=C(\C=O)[C@@H](CC=O)CC(=O)OCCC1=CC=C(O)C=C1 VPOVFCBNUOUZGG-VAKDEWRISA-N 0.000 description 1
- 235000011576 oleuropein Nutrition 0.000 description 1
- RFWGABANNQMHMZ-CARRXEGNSA-N oleuropein Natural products COC(=O)C1=CO[C@@H](O[C@H]2O[C@@H](CO)[C@H](O)[C@@H](O)[C@@H]2O)C(=CC)[C@H]1CC(=O)OCCc3ccc(O)c(O)c3 RFWGABANNQMHMZ-CARRXEGNSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000002894 organic compounds Chemical group 0.000 description 1
- 239000002357 osmotic agent Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 235000019702 pea protein Nutrition 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- HKUHOPQRJKPJCJ-UHFFFAOYSA-N pelargonidin Natural products OC1=Cc2c(O)cc(O)cc2OC1c1ccc(O)cc1 HKUHOPQRJKPJCJ-UHFFFAOYSA-N 0.000 description 1
- 235000006251 pelargonidin Nutrition 0.000 description 1
- YPVZJXMTXCOTJN-UHFFFAOYSA-N pelargonidin chloride Chemical compound [Cl-].C1=CC(O)=CC=C1C(C(=C1)O)=[O+]C2=C1C(O)=CC(O)=C2 YPVZJXMTXCOTJN-UHFFFAOYSA-N 0.000 description 1
- 229930015721 peonidin Natural products 0.000 description 1
- 235000006404 peonidin Nutrition 0.000 description 1
- OGBSHLKSHNAPEW-UHFFFAOYSA-N peonidin chloride Chemical compound [Cl-].C1=C(O)C(OC)=CC(C=2C(=CC=3C(O)=CC(O)=CC=3[O+]=2)O)=C1 OGBSHLKSHNAPEW-UHFFFAOYSA-N 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 235000005693 perillyl alcohol Nutrition 0.000 description 1
- 229930015717 petunidin Natural products 0.000 description 1
- 235000006384 petunidin Nutrition 0.000 description 1
- QULMBDNPZCFSPR-UHFFFAOYSA-N petunidin chloride Chemical compound [Cl-].OC1=C(O)C(OC)=CC(C=2C(=CC=3C(O)=CC(O)=CC=3[O+]=2)O)=C1 QULMBDNPZCFSPR-UHFFFAOYSA-N 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 235000009048 phenolic acids Nutrition 0.000 description 1
- 150000007965 phenolic acids Chemical class 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 235000002949 phytic acid Nutrition 0.000 description 1
- 239000000467 phytic acid Substances 0.000 description 1
- 235000011765 phytoene Nutrition 0.000 description 1
- 235000002677 phytofluene Nutrition 0.000 description 1
- OVSVTCFNLSGAMM-UZFNGAIXSA-N phytofluene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC(C)=CC=C\C=C(/C)\C=C\C=C(C)CCC=C(C)CCC=C(C)C OVSVTCFNLSGAMM-UZFNGAIXSA-N 0.000 description 1
- ZYSFBWMZMDHGOJ-SGKBLAECSA-N phytofluene Natural products CC(=CCCC(=CCCC(=CCCC(=CC=C/C=C(C)/CCC=C(/C)C=CC=C(/C)CCC=C(C)C)C)C)C)C ZYSFBWMZMDHGOJ-SGKBLAECSA-N 0.000 description 1
- 229940068065 phytosterols Drugs 0.000 description 1
- CDRPUGZCRXZLFL-OWOJBTEDSA-N piceatannol Chemical compound OC1=CC(O)=CC(\C=C\C=2C=C(O)C(O)=CC=2)=C1 CDRPUGZCRXZLFL-OWOJBTEDSA-N 0.000 description 1
- 235000007221 pinoresinol Nutrition 0.000 description 1
- OHOPKHNWLCMLSW-UHFFFAOYSA-N pinoresinol Natural products C1=C(O)C(OC)=CC(C2C3C(C(OC3)C=3C=C(CO)C(O)=CC=3)CO2)=C1 OHOPKHNWLCMLSW-UHFFFAOYSA-N 0.000 description 1
- 235000019100 piperine Nutrition 0.000 description 1
- MXXWOMGUGJBKIW-YPCIICBESA-N piperine Chemical compound C=1C=C2OCOC2=CC=1/C=C/C=C/C(=O)N1CCCCC1 MXXWOMGUGJBKIW-YPCIICBESA-N 0.000 description 1
- WVWHRXVVAYXKDE-UHFFFAOYSA-N piperine Natural products O=C(C=CC=Cc1ccc2OCOc2c1)C3CCCCN3 WVWHRXVVAYXKDE-UHFFFAOYSA-N 0.000 description 1
- 229940075559 piperine Drugs 0.000 description 1
- 229940081857 plasma protein fraction Drugs 0.000 description 1
- 108010058237 plasma protein fraction Proteins 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001190 pomegranate ellagitannin Polymers 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- QKFAFSGJTMHRRY-OCFLFPRFSA-M potassium;[(e)-1-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]sulfanylbut-3-enylideneamino] sulfate Chemical compound [K+].OC[C@H]1O[C@@H](S\C(CC=C)=N\OS([O-])(=O)=O)[C@H](O)[C@@H](O)[C@@H]1O QKFAFSGJTMHRRY-OCFLFPRFSA-M 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 235000013594 poultry meat Nutrition 0.000 description 1
- 230000013823 prenylation Effects 0.000 description 1
- 235000021455 prepackaged meals Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 235000013167 probetanin Nutrition 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- BAZSXBOAXJLRNH-UHFFFAOYSA-N propanethial S-oxide Chemical compound CCC=S=O BAZSXBOAXJLRNH-UHFFFAOYSA-N 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 1
- 229940121649 protein inhibitor Drugs 0.000 description 1
- 239000012268 protein inhibitor Substances 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- VLEUZFDZJKSGMX-ONEGZZNKSA-N pterostilbene Chemical compound COC1=CC(OC)=CC(\C=C\C=2C=CC(O)=CC=2)=C1 VLEUZFDZJKSGMX-ONEGZZNKSA-N 0.000 description 1
- VLEUZFDZJKSGMX-UHFFFAOYSA-N pterostilbene Natural products COC1=CC(OC)=CC(C=CC=2C=CC(O)=CC=2)=C1 VLEUZFDZJKSGMX-UHFFFAOYSA-N 0.000 description 1
- 235000021251 pulses Nutrition 0.000 description 1
- LMIBIMUSUFYFJN-RSVYENFWSA-N punicalagin Natural products O[C@@H]1O[C@@H]2COC(=O)c3cc(O)c(O)c(O)c3c4c(O)cc5OC(=O)c6c(c(O)c(O)c7OC(=O)c4c5c67)c8c(O)c(O)c(O)cc8C(=O)O[C@H]2[C@@H]9OC(=O)c%10cc(O)c(O)c(O)c%10c%11c(O)c(O)c(O)cc%11C(=O)O[C@@H]19 LMIBIMUSUFYFJN-RSVYENFWSA-N 0.000 description 1
- 229940043131 pyroglutamate Drugs 0.000 description 1
- 210000003314 quadriceps muscle Anatomy 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 235000021283 resveratrol Nutrition 0.000 description 1
- 229940016667 resveratrol Drugs 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 235000010272 rosemarinol Nutrition 0.000 description 1
- 235000009514 rubixanthin Nutrition 0.000 description 1
- 239000000455 rubixanthin Substances 0.000 description 1
- ABTRFGSPYXCGMR-SDPRXREBSA-N rubixanthin Natural products O[C@H]1CC(C)(C)C(/C=C/C(=C\C=C\C(=C/C=C/C=C(\C=C\C=C(/C=C/C=C(\CC/C=C(\C)/C)/C)\C)/C)\C)/C)=C(C)C1 ABTRFGSPYXCGMR-SDPRXREBSA-N 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000014102 seafood Nutrition 0.000 description 1
- 235000004239 secoisolariciresinol Nutrition 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 235000014899 silybin Nutrition 0.000 description 1
- 229940043175 silybin Drugs 0.000 description 1
- 235000017700 silymarin Nutrition 0.000 description 1
- 229960004245 silymarin Drugs 0.000 description 1
- 108010027322 single cell proteins Proteins 0.000 description 1
- 235000017291 sinigrin Nutrition 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- NLQLSVXGSXCXFE-UHFFFAOYSA-N sitosterol Natural products CC=C(/CCC(C)C1CC2C3=CCC4C(C)C(O)CCC4(C)C3CCC2(C)C1)C(C)C NLQLSVXGSXCXFE-UHFFFAOYSA-N 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 235000014268 sports nutrition Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 229940032091 stigmasterol Drugs 0.000 description 1
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 description 1
- 235000016831 stigmasterol Nutrition 0.000 description 1
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 description 1
- 150000003436 stilbenoids Chemical class 0.000 description 1
- 230000019635 sulfation Effects 0.000 description 1
- 238000005670 sulfation reaction Methods 0.000 description 1
- 235000015487 sulforaphane Nutrition 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 235000008603 tangeritin Nutrition 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 235000019529 tetraterpenoid Nutrition 0.000 description 1
- 235000014620 theaflavin Nutrition 0.000 description 1
- IPMYMEWFZKHGAX-ZKSIBHASSA-N theaflavin Chemical compound C1=C2C([C@H]3OC4=CC(O)=CC(O)=C4C[C@H]3O)=CC(O)=C(O)C2=C(O)C(=O)C=C1[C@@H]1[C@H](O)CC2=C(O)C=C(O)C=C2O1 IPMYMEWFZKHGAX-ZKSIBHASSA-N 0.000 description 1
- 229940026509 theaflavin Drugs 0.000 description 1
- IKLDTEFDTLKDRK-UHFFFAOYSA-N theaflavin 3'-gallate Natural products OC1Cc2c(O)cc(O)cc2OC1c3cc4C=C(C=C(O)C(=O)c4c(O)c3O)C5Oc6cc(O)cc(O)c6CC5OC(=O)c7cc(O)c(O)c(O)c7 IKLDTEFDTLKDRK-UHFFFAOYSA-N 0.000 description 1
- DZGQZNRJDFZFLV-UHFFFAOYSA-N theaflavin 3,3'-digallate Natural products OC1=CC(=Cc2cc(C3Oc4cc(O)cc(O)c4CC3OC(=O)c5cc(O)c(O)c(O)c5)c(O)c(O)c2C1=O)C6Oc7cc(O)cc(O)c7CC6OC(=O)c8cc(O)c(O)c(O)c8 DZGQZNRJDFZFLV-UHFFFAOYSA-N 0.000 description 1
- AATSUYYYTHJRJO-UHFFFAOYSA-N theaflavin 3-gallate Natural products OC1CC2=C(O)C=C(O)C=C2OC1C(=CC(=O)C(O)=C1C(O)=C2O)C=C1C=C2C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 AATSUYYYTHJRJO-UHFFFAOYSA-N 0.000 description 1
- 235000002365 theaflavin-3'-gallate Nutrition 0.000 description 1
- 235000008230 theaflavin-3,3'-digallate Nutrition 0.000 description 1
- 235000007900 theaflavin-3-gallate Nutrition 0.000 description 1
- AATSUYYYTHJRJO-RZYARBFNSA-N theaflavin-3-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(O)C=C2O[C@@H]1C1=C(O)C(O)=C2C(=O)C(O)=CC(=CC2=C1)[C@H]1OC2=CC(O)=CC(O)=C2C[C@H]1O)C(=O)C1=CC(O)=C(O)C(O)=C1 AATSUYYYTHJRJO-RZYARBFNSA-N 0.000 description 1
- 235000008118 thearubigins Nutrition 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000000779 thoracic wall Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 125000002640 tocopherol group Chemical class 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- ZIUDAKDLOLDEGU-UHFFFAOYSA-N trans-Phytofluen Natural products CC(C)=CCCC(C)CCCC(C)CC=CC(C)=CC=CC=C(C)C=CCC(C)CCCC(C)CCC=C(C)C ZIUDAKDLOLDEGU-UHFFFAOYSA-N 0.000 description 1
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 235000004330 tyrosol Nutrition 0.000 description 1
- 235000011557 tyrosol esters Nutrition 0.000 description 1
- 230000034512 ubiquitination Effects 0.000 description 1
- 238000010798 ubiquitination Methods 0.000 description 1
- DJJCXFVJDGTHFX-XVFCMESISA-N uridine 5'-monophosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1 DJJCXFVJDGTHFX-XVFCMESISA-N 0.000 description 1
- 229940096998 ursolic acid Drugs 0.000 description 1
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- 229940117960 vanillin Drugs 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 235000008964 vulgaxanthin Nutrition 0.000 description 1
- 229930185155 vulgaxanthin Natural products 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 235000008210 xanthophylls Nutrition 0.000 description 1
- 150000003735 xanthophylls Chemical class 0.000 description 1
- BURBOJZOZGMMQF-UHFFFAOYSA-N xanthoxylol Natural products C1=C(O)C(OC)=CC=C1C1C(COC2C=3C=C4OCOC4=CC=3)C2CO1 BURBOJZOZGMMQF-UHFFFAOYSA-N 0.000 description 1
- 229940093612 zein Drugs 0.000 description 1
- 239000005019 zein Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/19—Dairy proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
Definitions
- the present disclosure relates generally to health and nutrition. More specifically, the present disclosure relates to methods for enhancing muscle protein synthesis during energy deficit.
- Negative energy balance or energy deficit can be achieved through reduced energy intake and/or increase energy expenditure and leads to fat mass (FM) loss.
- FM fat mass
- a reduction in FM is a common goal for both athletic performance and improved health outcomes (Hansen D. Dendale P, Berger J, van Loon LJ, Meeusen R, The effects of exercise training on fat-mass loss in obese patients during energy intake restriction. Sports Med 2007; 37: 31-46: Mettler S, Mitchell N, Tipton KD, Increased protein intake reduces lean body mass loss during weight loss in athletes. Medicine and science in sports and exercise 2007; 42: 326-337).
- the present disclosure is related to methods for enhancing muscle protein synthesis. Specifically, the present disclosure is directed to recovery of the attenuation in muscle protein synthesis observed with periods of acute dietary energy restriction with ingestion of whey protein (in different amounts) following resistance exercise. As discussed above, there is no existing evidence that the established beneficial effects of protein ingestion on maintaining/enhancing muscle protein synthesis following resistance exercise are equally effective during periods of energy deficit. In contrast, Applicants have developed methods that provide a beneficial outcome for individuals in short-term ( e.g., 5 days) energy deficit for maintenance of the anabolic response to protein ingestion following exercise. Therefore, the present disclosure provides a unique outcome that is highly applicable to sports nutrition consumers that intentionally undergo periods of energy deficit to optimize body composition during which they aim to avoid any skeletal muscle loss.
- the present disclosure provides methods of off-setting the muscle catabolic state observed during energy deficit by provision of high quality protein (e.g., 15-30 g) post-exercise.
- the present disclosure also provides a method of augmenting the anabolic effects of resistance exercise with protein ingestion during short- term energy deficit in a dosage that is higher than those reported for individuals in energy balance (e.g., 20-25g) ((Moore DR, Robinson MJ, Fry JL, Tang JE, Glover EI, Wilkinson SB, Prior T, Tarnopolsky MA, Phillips SM, Ingested protein dose response of muscle and albumin protein synthesis after resistance exercise in young men. American Journal of Clinical Nutrition 2009;89: 161-168).
- the present disclosure provides for restoration/augmentation of muscle protein synthesis, which is an early measure of muscle growth and adaptation (Cermak NM, Res PT, de Groot LC, Saris WH, van Loon LJ. Protein supplementation augments the adaptive response of skeletal muscle to resistance-type exercise training: a meta-analysis. American Journal of Clinical Nutrition (2012)). Indeed, no evidence currently exists to show the beneficial effects in individuals undergoing short-term energy deficit where the goal is to optimize body composition without loss of skeletal muscle mass.
- a method for enhancing muscle protein synthesis in an individual suffering from energy deficit includes administering to the individual a composition comprising protein in an amount from about 15 g to about 30 g during a time period selected from the group consisting of during exercise, post-exercise, or combinations thereof.
- a method for enhancing skeletal muscle translation initiation signaling in an individual suffering from energy deficit includes administering to the individual a composition comprising protein in an amount from about 15 g to about 30 g during a time period selected from the group consisting of during exercise, post-exercise, and combinations thereof.
- a method for enhancing messenger ribonucleic acid (mRNA) expression in an individual suffering from energy deficit includes administering to the individual a composition comprising protein in an amount from about 15 g to about 30 g during a time period selected from the group consisting of during exercise, post-exercise, and combinations thereof.
- a method for enhancing myofibrillar protein synthesis in an individual suffering from energy deficit includes administering to the individual a composition comprising protein in an amount from about 15 g to about 30 g during a time period selected from the group consisting of during exercise, post-exercise, and combinations thereof.
- a method for reducing a loss of fat free mass in an individual suffering from energy deficit includes administering to the individual a composition comprising protein in an amount from about 15 g to about 30 g during a time period selected from the group consisting of during exercise, post-exercise, and combinations thereof.
- a method for enhancing muscle protein synthesis in an individual suffering from energy deficit includes administering to the individual a composition comprising protein during a time period selected from the group consisting of during exercise, post-exercise, and combinations thereof, wherein the protein is administered in a dose that is higher than a dose typically recommended for individuals experiencing energy balance.
- a method for enhancing skeletal muscle translation initiation signaling in an individual suffering from energy deficit includes administering to the individual a composition comprising protein during a time period selected from the group consisting of during exercise, post-exercise, and combinations thereof, wherein the protein is administered in a dose that is higher than a dose typically recommended for individuals experiencing energy balance.
- a method for enhancing messenger ribonucleic acid (mRNA) expression in an individual suffering from energy deficit is provided. The method includes administering to the individual a composition comprising protein during a time period selected from the group consisting of during exercise, post- exercise, and combinations thereof, wherein the protein is administered in a dose that is higher than a dose typically recommended for individuals experiencing energy balance.
- mRNA messenger ribonucleic acid
- a method for enhancing myofibrillar protein synthesis in an individual suffering from energy deficit includes administering to the individual a composition comprising protein during a time period selected from the group consisting of during exercise, post-exercise, and combinations thereof, wherein the protein is administered in a dose that is higher than a dose typically recommended for individuals experiencing energy balance.
- a method for reducing a loss of fat free mass in an individual suffering from energy deficit includes administering to the individual a composition comprising protein during a time period selected from the group consisting of during exercise, post-exercise, and combinations thereof, wherein the protein is administered in a dose that is higher than a dose typically recommended for individuals experiencing energy balance.
- the composition is administered immediately following a resistance exercise.
- the protein is whey protein.
- the protein may also be a high-quality protein.
- the protein may have a PDCAAS of greater than 0.7, or greater than 0.8, or greater than 0.9, or the like.
- high quality protein can be mixed with a lower quality protein wherein the resulting PDCAAS of the mixture is 0.65 or greater, or 0.7 or greater, or the like.
- the individual is suffering from a short-term energy deficit.
- the short-term energy deficit may range from about 1 day to about 10 days, or from about 2 days to about 9 days, or from about 3 days to about 8 days, or from about 4 days to about 7 days, or from about 5 days to about 6 days. In an embodiment, the short- term energy deficit is about 5 days.
- the composition is formulated for administration to an individual selected from one of an infant, a child, a young adult, an elderly adult, an athlete, an individual undergoing rehabilitation, an individual in need of weight management, an individual suffering from malnutrition, a febrile individual, a sick individual, or combinations thereof.
- the administration occurs through an administration route selected from the group consisting of orally, a tube, a catheter, or combinations thereof.
- the composition further comprises a source of ⁇ -3 fatty acids selected from the group consisting of fish oil, krill, plant sources containing co-3 fatty acids, flaxseed, walnut, algae, or combinations thereof.
- the ⁇ -3 fatty acids are selected from the group consisting of a-linolenic acid (“ALA”), docosahexaenoic acid (“DHA”), eicosapentaenoic acid (“EPA”), or combinations thereof.
- ALA a-linolenic acid
- DHA docosahexaenoic acid
- EPA eicosapentaenoic acid
- the composition further comprises at least one nucleotide selected from the group consisting of a subunit of deoxyribonucleic acid (“DNA”), a subunit of ribonucleic acid (“RNA”), polymeric forms of DNA and RNA, yeast RNA, or combinations thereof.
- the at least one nucleotide is an exogenous nucleotide.
- the composition further comprises a phytonutrient selected from the group consisting of flavanoids, allied phenolic compounds, polyphenolic compounds, terpenoids, alkaloids, sulphur- containing compounds, or combinations thereof.
- a phytonutrient selected from the group consisting of flavanoids, allied phenolic compounds, polyphenolic compounds, terpenoids, alkaloids, sulphur- containing compounds, or combinations thereof.
- the phytonutrient is selected from the group consisting of carotenoids, plant sterols, quercetin, curcumin, limonin, or combinations thereof.
- the composition further comprises a prebiotic selected from the group consisting of acacia gum, alpha glucan, arabinogalactans, beta glucan, dextrans, fructooligosaccharides, fucosyllactose, galactooligosaccharides, galactomannans, gentiooligosaccharides, glucooligosaccharides, guar gum, inulin, isomaltooligosaccharides, lactoneotetraose, lactosucrose, lactulose, levan, maltodextrins, milk oligosaccharides, partially hydrolyzed guar gum, pecticoligosaccharides, resistant starches, retrograded starch, sialooligosaccharides, sialyllactose, soyoligosaccharides, sugar alcohols, xylooligosaccharides, their hydrolysates, or combinations thereof.
- a prebiotic selected from the group consisting
- the composition further comprises a probiotic selected from the group consisting of Aerococcus, Aspergillus, Bacteroides, Bifidobacterium, Candida, Clostridium, Debaromyces, Enterococcus, Fusobacterium, Lactobacillus, Lactococcus, Leuconostoc, Melissococcus, Micrococcus, Mucor, Oenococcus, Pediococcus, Penicillium, Peptostrepococcus, Pichia, Propionibacterium, Pseudocatenulatum, Rhizopus, Saccharomyces, Staphylococcus, Streptococcus, Torulopsis, Weissella, non-replicating microorganisms, or combinations thereof.
- a probiotic selected from the group consisting of Aerococcus, Aspergillus, Bacteroides, Bifidobacterium, Candida, Clostridium, Debaromyces, Enterococcus, Fus
- the composition further comprises an amino acid selected from the group consisting of alanine, arginine, asparagine, aspartate, cysteine, glutamate, glutamine, glycine, histidine, hydroxyproline, hydroxyserine, hydroxytyrosine, hydroxylysine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, taurine, threonine, tryptophan, tyrosine, valine, or combinations thereof.
- an amino acid selected from the group consisting of alanine, arginine, asparagine, aspartate, cysteine, glutamate, glutamine, glycine, histidine, hydroxyproline, hydroxyserine, hydroxytyrosine, hydroxylysine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, taurine, threonine
- the composition further comprises an antioxidant selected from the group consisting of astaxanthin, carotenoids, coenzyme Q10 ("CoQIO"), flavonoids, glutathione, Goji (wolfberry), hesperidin, lactowolfberry, lignan, lutein, lycopene, polyphenols, selenium, vitamin A, vitamin C, vitamin E, zeaxanthin, or combinations thereof.
- an antioxidant selected from the group consisting of astaxanthin, carotenoids, coenzyme Q10 ("CoQIO"), flavonoids, glutathione, Goji (wolfberry), hesperidin, lactowolfberry, lignan, lutein, lycopene, polyphenols, selenium, vitamin A, vitamin C, vitamin E, zeaxanthin, or combinations thereof.
- the composition further comprises a vitamin selected from the group consisting of vitamin A, Vitamin Bl (thiamine), Vitamin B2 (riboflavin), Vitamin B3 (niacin or niacinamide), Vitamin B5 (pantothenic acid), Vitamin B6 (pyridoxine, pyridoxal, or pyridoxamine, or pyridoxine hydrochloride), Vitamin B7 (biotin), Vitamin B9 (folic acid), and Vitamin B12 (various cobalamins; commonly cyanocobalamin in vitamin supplements) , vitamin C, vitamin D, vitamin E, vitamin K, Kl and K2 (i.e., MK-4, MK-7), folic acid, biotin, or combinations thereof.
- a vitamin selected from the group consisting of vitamin A, Vitamin Bl (thiamine), Vitamin B2 (riboflavin), Vitamin B3 (niacin or niacinamide), Vitamin B5 (pantothenic acid), Vitamin B6 (pyridoxine, pyridoxal, or pyridox
- the composition further comprises a mineral selected from the group consisting of boron, calcium, chromium, copper, iodine, iron, magnesium, manganese, molybdenum, nickel, phosphorus, potassium, selenium, silicon, tin, vanadium, zinc, or combinations thereof.
- a mineral selected from the group consisting of boron, calcium, chromium, copper, iodine, iron, magnesium, manganese, molybdenum, nickel, phosphorus, potassium, selenium, silicon, tin, vanadium, zinc, or combinations thereof.
- the composition is an oral nutritional supplement.
- the nutritional composition may be a tube feeding.
- the composition is a source of complete nutrition.
- the nutritional composition may be a source of incomplete nutrition.
- An advantage of the present disclosure is to provide methods for enhancing muscle protein synthesis.
- Yet another advantage of the present disclosure is to provide methods for enhancing muscle protein synthesis.
- Another advantage of the present disclosure is to provide methods for enhancing muscle anabolism.
- Yet another advantage of the present disclosure is to demonstrate the impact of exercise and post-exercise protein intake on muscle protein synthesis during periods of energy deficit.
- Another advantage of the present disclosure is to demonstrate the impact of exercise and post-exercise protein intake on skeletal muscle translation initiation signaling, mRNA expression, and rates of muscle protein synthesis during periods of energy deficit.
- Still yet another advantage of the present disclosure is to provide methods for enhancing physical rehabilitation.
- Yet another advantage of the present disclosure is to provide methods for muscle recovery after exercise.
- FIG. 1 shows a schematic of an experimental design in accordance with an embodiment of the present disclosure.
- the resting energy balance (EB) trial was preceded by five (5) days of controlled diet providing 45 kcal ⁇ kg _1 FFM ⁇ day.
- the resting/exercise in energy deficit (ED) trials were preceded by five (5) days of controlled diet providing 30 kcal ⁇ kg _1 FFM ⁇ day.
- Solid arrow, muscle biopsy sample; *, blood sample; REX, resistance exercise; 0 g, 15 g and 30 g represent the respective placebo or whey protein drinks (500 mL).
- Dashed time-line represent trials undertaken a single time by each subject. Times in parentheses are for ED trials involving exercise and protein intake.
- FIG. 2 shows plasma insulin concentration after five (5) days of energy deficit (30 kcal ⁇ kg _1 FFM ⁇ day ) following a bout of leg press (6 sets x 8 repetitions at 80% one repetition maximum) and post-exercise ingestion of a placebo (PL) or 15 or 30g of whey protein drinks. Data were analyzed by two way repeated measures ANOVA with Student-Newman-Keuls post hoc analysis. Values are mean ⁇ SD. Different vs a, rest within treatment; *, PL , ⁇ , 15g; ⁇ , 30 g at equivalent time point (P ⁇ 0.05).
- FIG. 3 shows (A) plasma essential amino acids (EAA), (B) branched- chain amino acids (BCAA), and (C) leucine concentration after five (5) days of energy deficit (30 kcal ⁇ kg _1 FFM ⁇ day) and following a bout of leg press (6 sets x 8 repetitions at 80% one repetition maximum) and post-exercise ingestion of a placebo (PL), 15 or 30 g of whey protein drinks. Data were analyzed by using two way repeated measures ANOVA with Student-Newman-Keuls post hoc analysis. Values are mean ⁇ SD. Different vs. a, rest within treatment; ⁇ , 15 g; ⁇ , 30 g at equivalent time point (P ⁇ 0.05).
- FIG. 4 shows myofibrillar fractional synthetic rate (FSR) at rest after five (5) days of energy balance (45 kcal ⁇ kg _1 FFM ⁇ day; EB), after five (5) days of energy deficit (30 kcal ⁇ kg _1 FFM ⁇ day; ED) and following a bout of leg press (6 sets x 8 repetitions at 80% one repetition maximum) and post-exercise ingestion of a placebo (PL), 15 or 30 g of whey protein drinks.
- Data were analyzed by using repeated measures ANOVA with Student-Newman-Keuls post hoc analysis. Values are mean ⁇ SD. Different vs. a, EB; b, ED; c, PL; d, 15 g (P ⁇ 0.02).
- FIG. 5 shows myofibrillar fractional synthetic rates (FSR) after five (5) days of energy deficit (30 kcal ⁇ kg _1 FFM ⁇ day) following bout of leg press (6 sets x 8 repetitions at 80% one repetition maximum) plotted against post exercise protein intake in grams of protein per kg of (A) body mass (BM) and (B) fat free mass (FFM). Data were analyzed using linear regression.
- FSR myofibrillar fractional synthetic rates
- FIG. 6 shows phosphorylation of (A) skeletal muscle Akt ber4 , (B) mTOR Ser2448 , (C) p70 S6K Thr389 , and (D) rpS6 Ser235/236 at rest after five (5) days of energy balance (45 kcal ⁇ kg _1 FFM ⁇ day; EB), after five (5) days of energy deficit (30 kcal ⁇ kg _1 FFM ⁇ day; ED) and following a bout of leg press (6 sets x 8 repetitions at 80% one repetition maximum) and post-exercise ingestion of a placebo (PL), 15 or 30g of whey protein drinks. Data were analyzed by repeated measures ANOVA with Student-Newman- Keuls post hoc analysis.
- FIG. 7 shows (A) MuRF-1, (B) Atrogin-1, (C) SLC38A2/SNAT 2, and (D) SLC7A5/LAT1 mRNA abundance at rest after give (5) days of energy balance (45 kcal ⁇ kg -1 FFM ⁇ day; EB), after five (5) days of energy deficit (30 kcal ⁇ kg _1 FFM ⁇ day; ED) and following a bout of leg press (6 sets x 8 repetitions at 80% one repetition maximum) and post-exercise ingestion of a placebo (PL), 15 or 30 g of whey protein drinks. Data were analyzed by repeated measures ANOVA with Student-Newman-Keuls post hoc analysis. Values are mean ⁇ SD. Different vs. (a) EB; (b) ED; (c) PL 1.5h; (d) PL 4.5 h; (e) 15g, 1.5 g; (g) 30 g, 1.5 hour (P ⁇ 0.05).
- amino acid is understood to include one or more amino acids.
- the amino acid can be, for example, alanine, arginine, asparagine, aspartate, citrulline, cysteine, glutamate, glutamine, glycine, histidine, hydroxyproline, hydroxyserine, hydroxytyrosine, hydroxylysine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, taurine, threonine, tryptophan, tyrosine, valine, or combinations thereof.
- animal includes, but is not limited to, mammals, which include but is not limited to, rodents, aquatic mammals, domestic animals such as dogs and cats, farm animals such as sheep, pigs, cows and horses, and humans. Wherein the terms “animal” or “mammal” or their plurals are used, it is contemplated that it also applies to any animals that are capable of the effect exhibited or intended to be exhibited by the context of the passage.
- antioxidant is understood to include any one or more of various substances such as beta-carotene (a vitamin A precursor), vitamin C, vitamin E, and selenium) that inhibit oxidation or reactions promoted by Reactive Oxygen Species ("ROS”) and other radical and non-radical species. Additionally, antioxidants are molecules capable of slowing or preventing the oxidation of other molecules.
- ROS Reactive Oxygen Species
- Non- limiting examples of antioxidants include astaxanthin, carotenoids, coenzyme Q10 ("CoQIO"), flavonoids, glutathione, Goji (wolfberry), hesperidin, lactowolfberry, lignan, lutein, lycopene, polyphenols, selenium, vitamin A, vitamin C, vitamin E, zeaxanthin, or combinations thereof.
- complete nutrition includes nutritional products and compositions that contain sufficient types and levels of macronutrients (protein, fats and carbohydrates) and micronutrients to be sufficient to be a sole source of nutrition for the animal to which it is being administered to. Patients can receive 100% of their nutritional requirements from such complete nutritional compositions.
- macronutrients protein, fats and carbohydrates
- micronutrients to be sufficient to be a sole source of nutrition for the animal to which it is being administered to. Patients can receive 100% of their nutritional requirements from such complete nutritional compositions.
- an effective amount is an amount that prevents a deficiency, treats a disease or medical condition in an individual or, more generally, reduces symptoms, manages progression of the diseases or provides a nutritional, physiological, or medical benefit to the individual.
- a treatment can be patient- or doctor- related.
- the terms “individual” and “patient” are often used herein to refer to a human, the invention is not so limited. Accordingly, the terms “individual” and “patient” refer to any animal, mammal or human having or at risk for a medical condition that can benefit from the treatment.
- sources of co-3 fatty acids include, for example, fish oil, krill, plant sources of co-3, flaxseed, walnut, and algae.
- co-3 fatty acids include, for example, a-linolenic acid (“ALA”), docosahexaenoic acid (“DHA”), eicosapentaenoic acid (“EPA”), or combinations thereof.
- ALA a-linolenic acid
- DHA docosahexaenoic acid
- EPA eicosapentaenoic acid
- food grade micro-organisms means micro- organisms that are used and generally regarded as safe for use in food.
- high-quality protein refers to protein that has a specific Protein Digestibility Corrected Amino Acid Score (PDCAAS).
- the PDCAAS is a method of evaluating the quality of protein based on both the amino acid requirements of humans and their ability to digest it. Indeed, the quality of protein depends on the level at which it provides the nutritional amounts of essential amino acids needed for overall body health, maintenance, and growth. For example, animal proteins, such as eggs, cheese, milk, meat, and fish, are considered complete proteins because they provide sufficient amounts of the essential amino acids. Plant proteins, such as grain, corn, nuts, vegetables and fruits, are considered incomplete proteins because many plant proteins lack one or more of the essential amino acids, or because they lack a proper balance of amino acids.
- Incomplete proteins can, however, be combined to provide all the essential amino acids, though combinations of incomplete proteins must be consumed at the same time, or within a short period of time (within four hours), to obtain the maximum nutritive value from the amino acids.
- Such combination diets generally yield a high-quality protein meal, providing sufficient amounts and proper balance of the essential amino acids needed by the body to function.
- amino acids There are 20 primary amino acids, which include alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, seronine, threonine, tryptophan, tyrosine, and valine.
- the human body is unable to make 9 of these amino acids on its own, so these amino acids are considered "essential" and must come from our diet.
- amino acids regarded as essential for humans are phenylalanine, valine, threonine, tryptophan, isoieucme, methionine, leucine, lysine, and histidine. Additionally, cysteine (or sulphur-containing amino acids), tyrosine (or aromatic amino acids), and argmine are required by infants and growing children.
- a protein's quality is determined by investigating whether all 9 essential amino acids are present in the protein and whether the ratios of essential amino acids in the protein are ideal. With respect to the presence of the 9 essential amino acids, pretty much every source of protein has at least some of all the essential amino acids. However, if the protein is deficient in 1 or more essential amino acid then it is considered incomplete. As a point of reference, grains are typically low in the amino acid lysine, while legumes are low in methionine. Animal products, on the other hand, are high in all the essential amino acids and are usually considered complete. Regarding whether the ratios of essential amino acids in the protein are ideal, basically, the body needs a certain proportion of essential amino acids in the protein in order for it to be used most effectively. If all 9 are present yet 1 or more are not very abundant then the protein is of lower quality because the body will not be able to use the protein to its fullest potential.
- a PDCAAS value of 1 is the highest quality protein, and a value of 0 is the lowest quality protein.
- high quality protein is be defined as a PDCAAS of 0.7 or greater, or 0.8 or greater, or 0.9 of greater, or the like. In an embodiment, however, high quality protein may be mixed with a lower quality protein wherein the resulting PDCAAS of the protein mixture is 0.65 or greater, or 0.7 or greater, or the like.
- infant nutrition includes nutritional products or compositions that do not contain sufficient levels of macronutrients (protein, fats and carbohydrates) or micronutrients to be sufficient to be a sole source of nutrition for the animal to which it is being administered to. Partial or incomplete nutritional compositions can be used as a nutritional supplement.
- long term administrations are preferably continuous administrations for more than 6 weeks. Alternatively, “short term administrations,” as used herein, are continuous administrations for less than 6 weeks.
- mammal includes, but is not limited to, rodents, aquatic mammals, domestic animals such as dogs and cats, farm animals such as sheep, pigs, cows and horses, and humans. Wherein the term “mammal” is used, it is contemplated that it also applies to other animals that are capable of the effect exhibited or intended to be exhibited by the mammal.
- microorganism is meant to include the bacterium, yeast and/or fungi, a cell growth medium with the microorganism, or a cell growth medium in which microorganism was cultivated.
- the term “minerals” is understood to include boron, calcium, chromium, copper, iodine, iron, magnesium, manganese, molybdenum, nickel, phosphorus, potassium, selenium, silicon, tin, vanadium, zinc, or combinations thereof.
- a "non-replicating" microorganism means that no viable cells and/or colony forming units can be detected by classical plating methods.
- classical plating methods are summarized in the microbiology book: James Monroe Jay, et al., Modern food microbiology, 7th edition, Springer Science, New York, N. Y. p. 790 (2005).
- the absence of viable cells can be shown as follows: no visible colony on agar plates or no increasing turbidity in liquid growth medium after inoculation with different concentrations of bacterial preparations ('non replicating' samples) and incubation under appropriate conditions (aerobic and/or anaerobic atmosphere for at least 24h).
- bifidobacteria such as Bifidobacterium longum, Bifidobacterium lactis and Bifidobacterium breve or lactobacilli, such as Lactobacillus paracasei or Lactobacillus rhamnosus, may be rendered non-replicating by heat treatment, in particular low temperature/long time heat treatment.
- nucleotide is understood to be a subunit of deoxyribonucleic acid (“DNA”), ribonucleic acid (“RNA”), polymeric RNA, polymeric DNA, or combinations thereof. It is an organic compound made up of a nitrogenous base, a phosphate molecule, and a sugar molecule (deoxyribose in DNA and ribose in RNA). Individual nucleotide monomers (single units) are linked together to form polymers, or long chains. Exogenous nucleotides are specifically provided by dietary supplementation.
- the exogenous nucleotide can be in a monomeric form such as, for example, 5'-Adenosine Monophosphate (“5'-AMP”), 5'-Guanosine Monophosphate (“5'-GMP”), 5'-Cytosine Monophosphate (“5'-CMP”), 5'-Uracil Monophosphate (“5'-UMP”), 5'-Inosine Monophosphate (“5'-IMP”), 5'-Thymine Monophosphate (“5'-TMP”), or combinations thereof.
- the exogenous nucleotide can also be in a polymeric form such as, for example, an intact RNA. There can be multiple sources of the polymeric form such as, for example, yeast RNA.
- Nutritional products or “nutritional compositions,” as used herein, are understood to include any number of optional additional ingredients, including conventional food additives (synthetic or natural), for example one or more acidulants, additional thickeners, buffers or agents for pH adjustment, chelating agents, colorants, emulsifies, excipient, flavor agent, mineral, osmotic agents, a pharmaceutically acceptable carrier, preservatives, stabilizers, sugar, sweeteners, texturizers, and/or vitamins.
- the optional ingredients can be added in any suitable amount.
- the nutritional products or compositions may be a source of complete nutrition or may be a source of incomplete nutrition.
- the term "patient” is understood to include an animal, especially a mammal, and more especially a human that is receiving or intended to receive treatment, as it is herein defined.
- phytochemicals or “phytonutrients” are non-nutritive compounds that are found in many foods. Phytochemicals are functional foods that have health benefits beyond basic nutrition, are health promoting compounds that come from plant sources, and may be natural or purified. "Phytochemicals” and “Phytonutrients” refers to any chemical produced by a plant that imparts one or more health benefit on the user. Non-limiting examples of phytochemicals and phytonutrients include those that are:
- phenolic compounds which include monophenols (such as, for example, apiole, carnosol, carvacrol, dillapiole, rosemarinol); flavonoids (polyphenols) including flavonols (such as, for example, quercetin, fingerol, kaempferol, myricetin, rutin, isorhamnetin), flavanones (such as, for example, fesperidin, naringenin, silybin, eriodictyol), flavones (such as, for example, apigenin, tangeritin, luteolin), flavan-3-ols (such as, for example, catechins, (+)-catechin, (+)-gallocatechin, (-)-epicatechin, (-)- epigallocatechin, (-)-epigallocatechin gallate (EGCG), (-)-epicatechin 3-gallate, theaflavin, theafla
- terpenes which include carotenoids (tetraterpenoids) including carotenes (such as, for example, a-carotene, ⁇ -carotene, ⁇ -carotene, ⁇ -carotene, lycopene, neurosporene, phytofluene, phytoene), and xanthophylls (such as, for example, canthaxanthin, cryptoxanthin, aeaxanthin, astaxanthin, lutein, rubixanthin); monoterpenes (such as, for example, limonene, perillyl alcohol); saponins; lipids including: phytosterols (such as, for example, campesterol, beta sitosterol, gamma sitosterol, stigmasterol), tocopherols (vitamin E), and omega-3, 6, and 9 fatty acids (such as, for example, gamma- linolenic acid);
- carotenoids tetraterpenoids
- Betacyanins such as: betanin, isobetanin, probetanin, neobetanin
- betaxanthins non glycosidic versions
- organosulfides which include, for example, dithiolthiones (isothiocyanates) (such as, for example, sulphoraphane); and thiosulphonates (allium compounds) (such as, for example, allyl methyl trisulfide, and diallyl sulfide), indoles, glucosinolates, which include, for example, indole-3-carbinol; sulforaphane; 3,3'- diindolylmethane; sinigrin; allicin; alliin; allyl isothiocyanate; piperine; syn-propanethial- S-oxide;
- v) protein inhibitors which include, for example, protease inhibitors
- a "prebiotic” is a food substance that selectively promotes the growth of beneficial bacteria or inhibits the growth or mucosal adhesion of pathogenic bacteria in the intestines. They are not inactivated in the stomach and/or upper intestine or absorbed in the gastrointestinal tract of the person ingesting them, but they are fermented by the gastrointestinal microflora and/or by probiotics. Prebiotics are, for example, defined by Glenn R. Gibson and Marcel B. Roberfroid, "Dietary Modulation of the Human Colonic Microbiota: Introducing the Concept of Prebiotics," J. Nutr., 125: 1401-1412 (1995).
- Non-limiting examples of prebiotics include acacia gum, alpha glucan, arabinogalactans, beta glucan, dextrans, fructooligosaccharides, fucosyllactose, galactooligosaccharides, galactomannans, gentiooligosaccharides, glucooligosaccharides, guar gum, inulin, isomaltooligosaccharides, lactoneotetraose, lactosucrose, lactulose, levan, maltodextrins, milk oligosaccharides, partially hydrolyzed guar gum, pecticoligosaccharides, resistant starches, retrograded starch, sialooligosaccharides, sialyllactose, soyoligosaccharides, sugar alcohols, xylooligosaccharides, or their hydrolysates, or combinations thereof.
- probiotic micro-organisms are food-grade microorganisms (alive, including semi-viable or weakened, and/or non- replicating), metabolites, microbial cell preparations or components of microbial cells that could confer health benefits on the host when administered in adequate amounts, more specifically, that beneficially affect a host by improving its intestinal microbial balance, leading to effects on the health or well-being of the host. See, Salminen S, Ouwehand A. Benno Y. et al, "Probiotics: how should they be defined?,” Trends Food Sci. TechnoL, 10, 107-10 (1999).
- micro-organisms inhibit or influence the growth and/or metabolism of pathogenic bacteria in the intestinal tract.
- the probiotics may also activate the immune function of the host. For this reason, there have been many different approaches to include probiotics into food products.
- Non-limiting examples of probiotics include Aerococcus, Aspergillus, Bacteroides, Bifidobacterium, Candida, Clostridium, Debaromyces, Enterococcus, Fusobacterium, Lactobacillus, Lactococcus, Leuconostoc, Melissococcus, Micrococcus, Mucor, Oenococcus, Pediococcus, Penicillium, Peptostrepococcus, Pichia, Propionibacterium, Pseudocatenulatum, Rhizopus, Saccharomyces, Staphylococcus, Streptococcus, Torulopsis, Weissella, or combinations thereof.
- protein protein
- peptide oligopeptides
- polypeptide as used herein, are understood to refer to any composition that includes, a single amino acids (monomers), two or more amino acids joined together by a peptide bond (dipeptide, tripeptide, or polypeptide), collagen, precursor, homolog, analog, mimetic, salt, prodrug, metabolite, or fragment thereof or combinations thereof.
- peptide bond dipeptide, tripeptide, or polypeptide
- collagen precursor, homolog, analog, mimetic, salt, prodrug, metabolite, or fragment thereof or combinations thereof.
- polypeptides or peptides or proteins or oligopeptides
- polypeptides often contain amino acids other than the 20 amino acids commonly referred to as the 20 naturally occurring amino acids, and that many amino acids, including the terminal amino acids, may be modified in a given polypeptide, either by natural processes such as glycosylation and other post-translational modifications, or by chemical modification techniques which are well known in the art.
- polypeptides of the present invention include, but are not limited to, acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of a flavanoid or a heme moiety, covalent attachment of a polynucleotide or polynucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphatidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cystine, formation of pyroglutamate, formylation, gamma-carboxylation, glycation, glycosylation, glycosylphosphatidyl inositol ("GPI") membrane anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, proteolytic processing, phosphorylation, prenylation, racemization, selen
- Non-limiting examples of proteins include dairy based proteins, plant based proteins, animal based proteins and artificial proteins.
- Dairy based proteins may be selected from the group consisting of casein, caseinates, casein hydrolysate, whey, whey hydrolysates, whey concentrates, whey isolates, milk protein concentrate, milk protein isolate, or combinations thereof.
- Plant based proteins include, for example, soy protein (e.g., all forms including concentrate and isolate), pea protein (e.g., all forms including concentrate and isolate), canola protein (e.g., all forms including concentrate and isolate), other plant proteins that commercially are wheat and fractionated wheat proteins, corn and it fractions including zein, rice, oat, potato, peanut, and any proteins derived from beans, buckwheat, lentils, pulses, single cell proteins, or combinations thereof.
- Animal based proteins may be selected from the group consisting of beef, poultry, fish, lamb, seafood, or combinations thereof.
- rehabilitation refers to the process of restoring an individual to good, physical condition, operation, or capacity after decrease of same. Accordingly, rehabilitation may include physical therapy, exercise or the like. Examples of individuals in need of rehabilitation include, but are not limited to, individuals having had muscle losses due to immobilization/bed rest, individuals in the hospital, individuals recovering from a critical illness or acute disease, individuals suffering from physical limitations, elderly individuals, athletes, infants experiencing growth retardation, etc.
- treatment includes both prophylactic or preventive treatment (that prevent and/or slow the development of a targeted pathologic condition or disorder) and curative, therapeutic or disease-modifying treatment, including therapeutic measures that cure, slow down, lessen symptoms of, and/or halt progression of a diagnosed pathologic condition or disorder; and treatment of patients at risk of contracting a disease or suspected to have contracted a disease, as well as patients who are ill or have been diagnosed as suffering from a disease or medical condition.
- prophylactic or preventive treatment that prevent and/or slow the development of a targeted pathologic condition or disorder
- curative, therapeutic or disease-modifying treatment including therapeutic measures that cure, slow down, lessen symptoms of, and/or halt progression of a diagnosed pathologic condition or disorder
- treatment of patients at risk of contracting a disease or suspected to have contracted a disease as well as patients who are ill or have been diagnosed as suffering from a disease or medical condition.
- the term does not necessarily imply that a subject is treated until total recovery.
- treatment also refer to the maintenance and/or promotion of health in an individual not suffering from a disease but who may be susceptible to the development of an unhealthy condition, such as nitrogen imbalance or muscle loss.
- treatment also intended to include the potentiation or otherwise enhancement of one or more primary prophylactic or therapeutic measure.
- treatment also intended to include the dietary management of a disease or condition or the dietary management for prophylaxis or prevention a disease or condition.
- a “tube feed” is a complete or incomplete nutritional product or composition that is administered to an animal's gastrointestinal system, other than through oral administration, including but not limited to a nasogastric tube, orogastric tube, gastric tube, jejunostomy tube (“J-tube”), percutaneous endoscopic gastrostomy (“PEG”), port, such as a chest wall port that provides access to the stomach, jejunum and other suitable access ports.
- a nasogastric tube orogastric tube
- gastric tube jejunostomy tube
- PEG percutaneous endoscopic gastrostomy
- port such as a chest wall port that provides access to the stomach, jejunum and other suitable access ports.
- vitamin is understood to include any of various fat-soluble or water-soluble organic substances (non-limiting examples include vitamin A, Vitamin Bl (thiamine), Vitamin B2 (riboflavin), Vitamin B3 (niacin or niacinamide), Vitamin B5 (pantothenic acid), Vitamin B6 (pyridoxine, pyridoxal, or pyridoxamine, or pyridoxine hydrochloride), Vitamin B7 (biotin), Vitamin B9 (folic acid), and Vitamin B12 (various cobalamins; commonly cyanocobalamin in vitamin supplements) , vitamin C, vitamin D, vitamin E, vitamin K, Kl and K2 (i.e. MK-4, MK-7), folic acid and biotin) essential in minute amounts for normal growth and activity of the body and obtained naturally from plant and animal foods or synthetically made, provitamins, derivatives, analogs.
- vitamin A vitamin A
- Vitamin Bl thiamine
- Vitamin B2 riboflavin
- Vitamin B3 niacin or
- the present disclosure is related to methods for enhancing muscle protein synthesis.
- negative energy balance or energy deficit (ED) can be achieved through reduced energy intake and/or increase energy expenditure and lead to fat mass (FM) loss.
- FM fat mass
- a reduction in FM is a common goal for both athletic performance and improved health outcomes (Mettler S, Mitchell N, Tipton KD.
- Increased protein intake reduces lean body mass loss during weight loss in athletes, Med Sci Sports Exerc 2010;42(2):326-37; Hansen D, Dendale P, Berger J, van Loon LJ, Meeusen R, The effects of exercise training on fat-mass loss in obese patients during energy intake restriction. Sports Med 2007;37(l):31-46).
- Applicant's data confirmed the physiological response to energy deficit in vivo skeletal muscle and provided novel data to show there is a similar detrimental 27% decrease on myofibrillar FSR after only 5 days of moderate energy restriction.
- Applicant chose the model of energy availability to set the energy deficit in our subjects, with a level of 30 kcal-kg "1 FFM-day "1 corresponding to a de facto threshold below which there is significant disruption to metabolic and hormonal systems within the body. See, Loucks AB, Kiens B, Wright HH. Energy availability in athletes. J Sports Sci 2011;29 Suppl 1 : S7-15.
- Rapid aminoacidemia enhances myofibrillar protein synthesis and anabolic intramuscular signaling responses after resistance exercise.
- Subjects were each provided with individualized pre-packaged meals for 5 days before each experimental trial. Before the resting EB trial, subjects were provided with meals equivalent to an energy availability (EA) of 45 kcal-kg "1 FFM ⁇ day "1 , where EA is defined as energy intake minus the energy cost of exercise. For all ED trials, diets consisted of an energy availability of 30 kcal-kg "1 FFM -day "1 . Between days 1-3 of the dietary control period subjects were permitted to exercise and the diet adjusted to account for the energy expenditure of the exercise sessions and thus restore EA to the set level. The total protein content was 1.4 g-kg "1 BM- day "1 for both dietary treatments. No alcohol was consumed by the subjects during the 5-day dietary control period, and they refrained from caffeine intake 24 hours before each trial day. Between experimental trials, there was a 9 day 'washout' period during which subjects were encouraged to continue their normal exercise and dietary habits.
- EA energy availability
- a muscle biopsy was obtained.
- the first muscle biopsy was taken before the infusion started for their EB trial.
- the ED trials were undertaken after the resting EB trial with the protein/placebo ingestion randomized and counterbalanced.
- Drinks contained 15 g or 30 g of protein (IS08 WPI; 86.8 g protein, 1.5 g fat, 3.1 g carbohydrates per 100 g) or no protein in form of a flavour and volume matched placebo drink.
- Each protein drink was enriched with 5% L-[n ' «g- 13 C6]phenylalanine and mixed with water to a total volume of 500 mL.
- the first ED trial for each subject was divided in two periods.
- the first (pre- exercise) period of the trial determined resting ED and was identical to the EB trial with the exception of an initial muscle biopsy.
- the remaining ED trials were identical but primed constant infusion of tracer commenced prior to exercise.
- Plasma insulin concentration was measured using an automated enzyme amplified chemiluminescence Immulite® 1000 system (Siemens diagnostics, Australia) according to manufacturer's guidelines.
- Plasma amino acids (AA) were analyzed by high performance liquid chromatography to determine amino acid concentrations as described previously (see, West DW, Burd NA, Coffey VG, Baker SK, Burke LM, Hawley JA, Moore DR, Stellingwerff T, Phillips SM. Rapid aminoacidemia enhances myofibrillar protein synthesis and anabolic intramuscular signaling responses after resistance exercise.
- Pre-infusion plasma sample proteins were utilized as the baseline enrichment in tracer naive subjects (see, Burd NA, Groen BB, Beelen M, Senden JM, Gijsen AP, van Loon LJ. The reliability of using the single-biopsy approach to assess basal muscle protein synthesis rates in vivo in humans. Metabolism 2012;61(7):931-6).
- a pre-infusion muscle biopsy was used for baseline enrichment. Muscle tissue was processed as previously described (see, Moore DR, Tang JE, Burd NA, Rerecich T, Tarnopolsky MA, Phillips SM. Differential stimulation of myofibrillar and sarcoplasmic protein synthesis with protein ingestion at rest and after resistance exercise. J Physiol 2009;587(4): 897-904).
- FSR (%-h -1 ) [E p2 - E p i]/E ic x 1/t x 100
- E p2 - E p i represents the change in bound protein enrichment between two biopsy samples
- Ei C is the average enrichment of intracellular phenylalanine between the two biopsy samples
- t is the time between biopsies.
- Skeletal muscle tissue (-20 mg) was used to isolate RNA using a modification of the acid guanidinium thiocyanate-phenol-chloroform extraction, as previously described (see, Coffey VG, Reeder DW, Lancaster GI, Yeo WK, Febbraio MA, Yaspelkis BB, 3rd, Hawley JA. Effect of high-frequency resistance exercise on adaptive responses in skeletal muscle. Med Sci Sports Exerc 2007;39(12):2135-44). Reverse transcription and real-time Polymerase Chain Reaction (RT-PCR) was performed as previously described (see, Camera DM, West DWD, Burd NA, Phillips SM, Garnham AP, Hawley JA, Coffey VG.
- Plasma insulin concentration There were no differences in plasma insulin concentration during the resting EB and ED trials. There was a time x group interaction for plasma insulin concentration (P ⁇ 0.001) after exercise and protein feeding. Plasma insulin concentration increased above pre-exercise levels only with 15 and 30 g protein ingestion reaching peak values 20-40 minutes post-exercise (see, FIG. 2). Plasma insulin concentration for the 30 g treatment was above resting values from 20 minutes until 2 hours post-exercise (2-4.5 fold P ⁇ 0.05), whereas for the 15 g group, plasma insulin concentration was elevated above rest from 20 minutes until 1 hour post-exercise (2-3.5 fold; P ⁇ 0.05).
- Plasma insulin was higher in the 15 and 30 g treatments compared to placebo 20-40 minutes post-exercise (2.3-3.8 fold; P ⁇ 0.001), however only 30 g was different compared with PL later at 1 and 2 hours post-exercise (1.7-2 fold; P ⁇ 0.05) and was also higher than 15 g at 2 hours post- exercise (1.9 fold ; P ⁇ 0.02).
- EAA essential amino acids
- BCAA branched chain amino acids
- leucine plasma concentrations were no differences in essential amino acids (EAA), branched chain amino acids (BCAA) or leucine plasma concentrations during the resting EB and ED trials.
- Plasma concentrations of EAA, BCAA and leucine increased above pre-exercise values between 20-120 minutes post exercise (see, FIGS. 3A-C) for both the 15 and 30 g treatments.
- the 30 g protein protocol resulted in higher aminoacidemia at 20 minutes post exercise (1.4 fold; P ⁇ 0.004) compared with 40 minutes post exercise following 15 g protein ingestion (1.7 fold; P ⁇ 0.001).
- Plasma concentration peaked 40-60 minutes post exercise (1.8-1.9 fold; P ⁇ 0.001) and remained above pre exercise values until 2 hours post exercise (1.6-1.9 fold; P ⁇ 0.02) in both the 15 g and 30 g treatments.
- Plasma EAA concentration increased in 30 g compared to 15 g between 20 minutes and 1 hour post exercise (1.2-1.3 fold; P ⁇ 0.03) (see, FIG. 3A).
- Plasma BCAA and leucine concentration followed a similar pattern but differences between 15 and 30 g remained until 2 hours post- exercise (1.2-1.8 fold P ⁇ 0.02) (see, FIGS. 3B and 3C).
- Resting ED myofibrillar FSR was lower compared to resting EB (0.019 vs 0.026 %-h, 27%, P ⁇ 0.001) (see, FIG. 4).
- Resistance exercise in ED with placebo returned myofibrillar FSR to values comparable to resting EB in the acute post exercise recovery period.
- Resistance exercise followed by 15 g and 30 g protein ingestion increased post-exercise myofibrillar FSR -16% and -34% above resting EB, respectively (0.030 and 0.038 %-h respectively; P ⁇ 0.02).
- the 30 g protein treatment also increased myofibrillar FSR above 15 g by -14% (P ⁇ 0.003).
- Phosphorylation of rpS6 Ser 236/237 above resting EB was highest 1 hour after exercise with post exercise protein ingestion (12.5-19.2 fold; P ⁇ 0.001) (see, FIG. 6D).
- MuRF-1 mRNA content was higher than resting EB and ED, and when compared with 1 hour post exercise following 4 hours recovery (1.98-2.27 fold; P ⁇ 0.006) (see, FIG. 7B).
- FFM Fat Free Mass
- EA Energy Balance
Abstract
The present disclosure provides methods for enhancing muscle protein synthesis in an individual in need of same. Specifically, the present disclosure provides methods for enhancing muscle protein synthesis during periods of negative energy balance, or energy deficit. The methods include administering to an individual suffering from energy deficit a composition comprising protein in an amount from about 15 g to about 30 g during a time period selected from the group consisting of during exercise, post-exercise, and combinations thereof. The methods also include administering to an individual suffering from energy deficit a composition comprising protein during a time period selected from the group consisting of during exercise, post-exercise, and combinations thereof, wherein the protein is administered in a dose that is higher than doses typically recommended for individuals experiencing energy balance.
Description
TITLE
METHODS FOR ENHANCING MUSCLE PROTEIN SYNTHESIS DURING ENERGY DEFICIT
BACKGROUND
[0001] The present disclosure relates generally to health and nutrition. More specifically, the present disclosure relates to methods for enhancing muscle protein synthesis during energy deficit.
[0002] Negative energy balance or energy deficit can be achieved through reduced energy intake and/or increase energy expenditure and leads to fat mass (FM) loss. A reduction in FM is a common goal for both athletic performance and improved health outcomes (Hansen D. Dendale P, Berger J, van Loon LJ, Meeusen R, The effects of exercise training on fat-mass loss in obese patients during energy intake restriction. Sports Med 2007; 37: 31-46: Mettler S, Mitchell N, Tipton KD, Increased protein intake reduces lean body mass loss during weight loss in athletes. Medicine and science in sports and exercise 2007; 42: 326-337). However, when a reduction in FM is achieved by energy restriction alone, it results in the concomitant loss of fat free mass (FFM), predominantly skeletal muscle (Parr EB, Coffey VG, Hawley JA, 'Sarcobesity' : a metabolic conundrum. Maturitas 2013;74: 109-113). Given that the quality and quantity of skeletal muscle is a major determinant of athletic performance, whole body metabolic rate and functional capacity throughout the life span, nutritional and exercise strategies to prevent or minimize loss of FFM while losing fat mass are crucial.
[0003] If potential decrease in basal (resting) rates of muscle protein synthesis are not accompanied by a concomitant reduction in muscle protein breakdown, then energy deficit could lead to an imbalance in resting protein turnover that could favor the net loss of skeletal muscle proteins. Indeed, prolonged energy deficit-induced body weight loss can result in up to 60% fat free mass (Paskiakos SM, Cao JJ, Margolis LM, Sauter ER, Whigham LD, McClung JP, Rood JC, Carbone JW, Combs GF, Jr. Young AJ, Effects of
high-protein diets on fat-free mass and muscle protein synthesis following weight loss: a randomized controlled trial. FASEB Journal 2013). In contrast, exercise has been shown to attenuate the loss of lean body mass that can occur with periods of energy deficit (Stiegler P, Cunliffe A, The role of diet and exercise for the maintenance of fat-free mass and resting metabolic rate during weight loss. Sports Medicine 2006;36: 239-262).
[0004] Ingestion of protein/amino acids increases skeletal muscle protein synthesis, an effect that is enhanced by prior resistance exercise (Moore DR, Robinson MJ, Fry JL, Tang JE, Glover EI, Wilkinson SB, Prior T, Tarnopolsky MA, Phillips SM, Ingested protein dose response of muscle and albumin protein synthesis after resistance exercise in young men. American Journal of Clinical Nutrition 2009;89: 161-168). Whether skeletal muscle exhibits 'anabolic resistance' to exercise and protein ingestion following short-term energy deficit has not been determined. Nor has the effect of increased protein availability through post-exercise ingestion.
[0005] Currently it is unknown if the anabolic effects of resistance exercise are decreased during periods of energy deficit. Therefore, there is a need to further understand the effects of energy deficit on the regulation of muscle protein synthesis. There is also a need to show the benefit of exercise and post-exercise protein intake on muscle protein synthesis during periods of energy deficit. More specifically, there is a need to show the impact on skeletal muscle translation initiation signaling, mRNA expression and rates of muscle protein synthesis during energy deficit.
SUMMARY
[0006] The present disclosure is related to methods for enhancing muscle protein synthesis. Specifically, the present disclosure is directed to recovery of the attenuation in muscle protein synthesis observed with periods of acute dietary energy restriction with ingestion of whey protein (in different amounts) following resistance exercise. As discussed above, there is no existing evidence that the established beneficial effects of protein ingestion on maintaining/enhancing muscle protein synthesis following resistance exercise are equally effective during periods of energy deficit. In contrast,
Applicants have developed methods that provide a beneficial outcome for individuals in short-term ( e.g., 5 days) energy deficit for maintenance of the anabolic response to protein ingestion following exercise. Therefore, the present disclosure provides a unique outcome that is highly applicable to sports nutrition consumers that intentionally undergo periods of energy deficit to optimize body composition during which they aim to avoid any skeletal muscle loss.
[0007] More specifically, the present disclosure provides methods of off-setting the muscle catabolic state observed during energy deficit by provision of high quality protein (e.g., 15-30 g) post-exercise. The present disclosure also provides a method of augmenting the anabolic effects of resistance exercise with protein ingestion during short- term energy deficit in a dosage that is higher than those reported for individuals in energy balance (e.g., 20-25g) ((Moore DR, Robinson MJ, Fry JL, Tang JE, Glover EI, Wilkinson SB, Prior T, Tarnopolsky MA, Phillips SM, Ingested protein dose response of muscle and albumin protein synthesis after resistance exercise in young men. American Journal of Clinical Nutrition 2009;89: 161-168).
[0008] Further, the present disclosure provides for restoration/augmentation of muscle protein synthesis, which is an early measure of muscle growth and adaptation (Cermak NM, Res PT, de Groot LC, Saris WH, van Loon LJ. Protein supplementation augments the adaptive response of skeletal muscle to resistance-type exercise training: a meta-analysis. American Journal of Clinical Nutrition (2012)). Indeed, no evidence currently exists to show the beneficial effects in individuals undergoing short-term energy deficit where the goal is to optimize body composition without loss of skeletal muscle mass.
[0009] In a general embodiment, a method for enhancing muscle protein synthesis in an individual suffering from energy deficit is provided. The method includes administering to the individual a composition comprising protein in an amount from about 15 g to about 30 g during a time period selected from the group consisting of during exercise, post-exercise, or combinations thereof.
[0010] In another embodiment, a method for enhancing skeletal muscle translation initiation signaling in an individual suffering from energy deficit is provided.
The method includes administering to the individual a composition comprising protein in an amount from about 15 g to about 30 g during a time period selected from the group consisting of during exercise, post-exercise, and combinations thereof.
[0011] In yet another embodiment, a method for enhancing messenger ribonucleic acid (mRNA) expression in an individual suffering from energy deficit is provided. The method includes administering to the individual a composition comprising protein in an amount from about 15 g to about 30 g during a time period selected from the group consisting of during exercise, post-exercise, and combinations thereof.
[0012] In still yet another embodiment, a method for enhancing myofibrillar protein synthesis in an individual suffering from energy deficit is provided. The method includes administering to the individual a composition comprising protein in an amount from about 15 g to about 30 g during a time period selected from the group consisting of during exercise, post-exercise, and combinations thereof.
[0013] In another embodiment, a method for reducing a loss of fat free mass in an individual suffering from energy deficit is provided. The method includes administering to the individual a composition comprising protein in an amount from about 15 g to about 30 g during a time period selected from the group consisting of during exercise, post-exercise, and combinations thereof.
[0014] In yet another embodiment, a method for enhancing muscle protein synthesis in an individual suffering from energy deficit is provided. The method includes administering to the individual a composition comprising protein during a time period selected from the group consisting of during exercise, post-exercise, and combinations thereof, wherein the protein is administered in a dose that is higher than a dose typically recommended for individuals experiencing energy balance.
[0015] In still yet another embodiment, a method for enhancing skeletal muscle translation initiation signaling in an individual suffering from energy deficit is provided. The method includes administering to the individual a composition comprising protein during a time period selected from the group consisting of during exercise, post-exercise, and combinations thereof, wherein the protein is administered in a dose that is higher than a dose typically recommended for individuals experiencing energy balance.
[0016] In yet another embodiment, a method for enhancing messenger ribonucleic acid (mRNA) expression in an individual suffering from energy deficit is provided. The method includes administering to the individual a composition comprising protein during a time period selected from the group consisting of during exercise, post- exercise, and combinations thereof, wherein the protein is administered in a dose that is higher than a dose typically recommended for individuals experiencing energy balance.
[0017] In another embodiment, a method for enhancing myofibrillar protein synthesis in an individual suffering from energy deficit is provided. The method includes administering to the individual a composition comprising protein during a time period selected from the group consisting of during exercise, post-exercise, and combinations thereof, wherein the protein is administered in a dose that is higher than a dose typically recommended for individuals experiencing energy balance.
[0018] In yet another embodiment, a method for reducing a loss of fat free mass in an individual suffering from energy deficit is provided. The method includes administering to the individual a composition comprising protein during a time period selected from the group consisting of during exercise, post-exercise, and combinations thereof, wherein the protein is administered in a dose that is higher than a dose typically recommended for individuals experiencing energy balance.
[0019] In an embodiment, the composition is administered immediately following a resistance exercise.
[0020] In an embodiment, the protein is whey protein. The protein may also be a high-quality protein. In this regard, the protein may have a PDCAAS of greater than 0.7, or greater than 0.8, or greater than 0.9, or the like. Alternatively, high quality protein can be mixed with a lower quality protein wherein the resulting PDCAAS of the mixture is 0.65 or greater, or 0.7 or greater, or the like.
[0021] In an embodiment, the individual is suffering from a short-term energy deficit. The short-term energy deficit may range from about 1 day to about 10 days, or from about 2 days to about 9 days, or from about 3 days to about 8 days, or from about 4 days to about 7 days, or from about 5 days to about 6 days. In an embodiment, the short- term energy deficit is about 5 days.
[0022] In an embodiment, the composition is formulated for administration to an individual selected from one of an infant, a child, a young adult, an elderly adult, an athlete, an individual undergoing rehabilitation, an individual in need of weight management, an individual suffering from malnutrition, a febrile individual, a sick individual, or combinations thereof.
[0023] In an embodiment, the administration occurs through an administration route selected from the group consisting of orally, a tube, a catheter, or combinations thereof.
[0024] In an embodiment, the composition further comprises a source of ω-3 fatty acids selected from the group consisting of fish oil, krill, plant sources containing co-3 fatty acids, flaxseed, walnut, algae, or combinations thereof. In an embodiment, the ω-3 fatty acids are selected from the group consisting of a-linolenic acid ("ALA"), docosahexaenoic acid ("DHA"), eicosapentaenoic acid ("EPA"), or combinations thereof.
[0025] In an embodiment, the composition further comprises at least one nucleotide selected from the group consisting of a subunit of deoxyribonucleic acid ("DNA"), a subunit of ribonucleic acid ("RNA"), polymeric forms of DNA and RNA, yeast RNA, or combinations thereof. In an embodiment, the at least one nucleotide is an exogenous nucleotide.
[0026] In an embodiment, the composition further comprises a phytonutrient selected from the group consisting of flavanoids, allied phenolic compounds, polyphenolic compounds, terpenoids, alkaloids, sulphur- containing compounds, or combinations thereof.
[0027] In an embodiment, the phytonutrient is selected from the group consisting of carotenoids, plant sterols, quercetin, curcumin, limonin, or combinations thereof.
[0028] In an embodiment, the composition further comprises a prebiotic selected from the group consisting of acacia gum, alpha glucan, arabinogalactans, beta glucan, dextrans, fructooligosaccharides, fucosyllactose, galactooligosaccharides, galactomannans, gentiooligosaccharides, glucooligosaccharides, guar gum, inulin, isomaltooligosaccharides, lactoneotetraose, lactosucrose, lactulose, levan, maltodextrins, milk oligosaccharides, partially hydrolyzed guar gum, pecticoligosaccharides, resistant
starches, retrograded starch, sialooligosaccharides, sialyllactose, soyoligosaccharides, sugar alcohols, xylooligosaccharides, their hydrolysates, or combinations thereof.
[0029] In an embodiment, the composition further comprises a probiotic selected from the group consisting of Aerococcus, Aspergillus, Bacteroides, Bifidobacterium, Candida, Clostridium, Debaromyces, Enterococcus, Fusobacterium, Lactobacillus, Lactococcus, Leuconostoc, Melissococcus, Micrococcus, Mucor, Oenococcus, Pediococcus, Penicillium, Peptostrepococcus, Pichia, Propionibacterium, Pseudocatenulatum, Rhizopus, Saccharomyces, Staphylococcus, Streptococcus, Torulopsis, Weissella, non-replicating microorganisms, or combinations thereof.
[0030] In an embodiment, the composition further comprises an amino acid selected from the group consisting of alanine, arginine, asparagine, aspartate, cysteine, glutamate, glutamine, glycine, histidine, hydroxyproline, hydroxyserine, hydroxytyrosine, hydroxylysine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, taurine, threonine, tryptophan, tyrosine, valine, or combinations thereof.
[0031] In an embodiment, the composition further comprises an antioxidant selected from the group consisting of astaxanthin, carotenoids, coenzyme Q10 ("CoQIO"), flavonoids, glutathione, Goji (wolfberry), hesperidin, lactowolfberry, lignan, lutein, lycopene, polyphenols, selenium, vitamin A, vitamin C, vitamin E, zeaxanthin, or combinations thereof.
[0032] In an embodiment, the composition further comprises a vitamin selected from the group consisting of vitamin A, Vitamin Bl (thiamine), Vitamin B2 (riboflavin), Vitamin B3 (niacin or niacinamide), Vitamin B5 (pantothenic acid), Vitamin B6 (pyridoxine, pyridoxal, or pyridoxamine, or pyridoxine hydrochloride), Vitamin B7 (biotin), Vitamin B9 (folic acid), and Vitamin B12 (various cobalamins; commonly cyanocobalamin in vitamin supplements), vitamin C, vitamin D, vitamin E, vitamin K, Kl and K2 (i.e., MK-4, MK-7), folic acid, biotin, or combinations thereof.
[0033] In an embodiment, the composition further comprises a mineral selected from the group consisting of boron, calcium, chromium, copper, iodine, iron, magnesium, manganese, molybdenum, nickel, phosphorus, potassium, selenium, silicon, tin, vanadium, zinc, or combinations thereof.
[0034] In an embodiment, the composition is an oral nutritional supplement. Alternatively, the nutritional composition may be a tube feeding.
[0035] In an embodiment, the composition is a source of complete nutrition. Alternatively, the nutritional composition may be a source of incomplete nutrition.
[0036] An advantage of the present disclosure is to provide methods for enhancing muscle protein synthesis.
[0037] Yet another advantage of the present disclosure is to provide methods for enhancing muscle protein synthesis.
[0038] Another advantage of the present disclosure is to provide methods for enhancing muscle anabolism.
[0039] Yet another advantage of the present disclosure is to demonstrate the impact of exercise and post-exercise protein intake on muscle protein synthesis during periods of energy deficit.
[0040] Another advantage of the present disclosure is to demonstrate the impact of exercise and post-exercise protein intake on skeletal muscle translation initiation signaling, mRNA expression, and rates of muscle protein synthesis during periods of energy deficit.
[0041] Still yet another advantage of the present disclosure is to provide methods for enhancing physical rehabilitation.
[0042] Yet another advantage of the present disclosure is to provide methods for muscle recovery after exercise.
[0043] Additional features and advantages are described herein, and will be apparent from the following Detailed Description and the figures.
BRIEF DESCRIPTION OF THE FIGURES
[0044] FIG. 1 shows a schematic of an experimental design in accordance with an embodiment of the present disclosure. The resting energy balance (EB) trial was preceded by five (5) days of controlled diet providing 45 kcal · kg _1 FFM · day. The resting/exercise in energy deficit (ED) trials were preceded by five (5) days of controlled
diet providing 30 kcal · kg _1 FFM · day. Solid arrow, muscle biopsy sample; *, blood sample; REX, resistance exercise; 0 g, 15 g and 30 g represent the respective placebo or whey protein drinks (500 mL). Dashed time-line represent trials undertaken a single time by each subject. Times in parentheses are for ED trials involving exercise and protein intake.
[0045] FIG. 2 shows plasma insulin concentration after five (5) days of energy deficit (30 kcal · kg _1 FFM · day ) following a bout of leg press (6 sets x 8 repetitions at 80% one repetition maximum) and post-exercise ingestion of a placebo (PL) or 15 or 30g of whey protein drinks. Data were analyzed by two way repeated measures ANOVA with Student-Newman-Keuls post hoc analysis. Values are mean ± SD. Different vs a, rest within treatment; *, PL ,†, 15g; §, 30 g at equivalent time point (P < 0.05).
[0046] FIG. 3 shows (A) plasma essential amino acids (EAA), (B) branched- chain amino acids (BCAA), and (C) leucine concentration after five (5) days of energy deficit (30 kcal · kg _1 FFM · day) and following a bout of leg press (6 sets x 8 repetitions at 80% one repetition maximum) and post-exercise ingestion of a placebo (PL), 15 or 30 g of whey protein drinks. Data were analyzed by using two way repeated measures ANOVA with Student-Newman-Keuls post hoc analysis. Values are mean ± SD. Different vs. a, rest within treatment;†, 15 g; §, 30 g at equivalent time point (P < 0.05).
[0047] FIG. 4 shows myofibrillar fractional synthetic rate (FSR) at rest after five (5) days of energy balance (45 kcal · kg _1 FFM · day; EB), after five (5) days of energy deficit (30 kcal · kg _1 FFM · day; ED) and following a bout of leg press (6 sets x 8 repetitions at 80% one repetition maximum) and post-exercise ingestion of a placebo (PL), 15 or 30 g of whey protein drinks. Data were analyzed by using repeated measures ANOVA with Student-Newman-Keuls post hoc analysis. Values are mean ± SD. Different vs. a, EB; b, ED; c, PL; d, 15 g (P < 0.02).
[0048] FIG. 5 shows myofibrillar fractional synthetic rates (FSR) after five (5) days of energy deficit (30 kcal · kg _1 FFM · day) following bout of leg press (6 sets x 8 repetitions at 80% one repetition maximum) plotted against post exercise protein intake in grams of protein per kg of (A) body mass (BM) and (B) fat free mass (FFM). Data were analyzed using linear regression.
[0049] FIG. 6 shows phosphorylation of (A) skeletal muscle Aktber4 , (B) mTORSer2448 , (C) p70 S6KThr389, and (D) rpS6Ser235/236 at rest after five (5) days of energy balance (45 kcal · kg _1 FFM · day; EB), after five (5) days of energy deficit (30 kcal · kg _1 FFM · day; ED) and following a bout of leg press (6 sets x 8 repetitions at 80% one repetition maximum) and post-exercise ingestion of a placebo (PL), 15 or 30g of whey protein drinks. Data were analyzed by repeated measures ANOVA with Student-Newman- Keuls post hoc analysis. Values are mean ± SD. Different vs. (a) EB; (b) ED; (c) PL 1.5 h; (d) PL 4.5 h; (f) 15 g, 4.5 h; (h) 30 g, 4.5 hour (P < 0.05).
[0050] FIG. 7 shows (A) MuRF-1, (B) Atrogin-1, (C) SLC38A2/SNAT 2, and (D) SLC7A5/LAT1 mRNA abundance at rest after give (5) days of energy balance (45 kcal · kg -1 FFM · day; EB), after five (5) days of energy deficit (30 kcal · kg _1 FFM · day; ED) and following a bout of leg press (6 sets x 8 repetitions at 80% one repetition maximum) and post-exercise ingestion of a placebo (PL), 15 or 30 g of whey protein drinks. Data were analyzed by repeated measures ANOVA with Student-Newman-Keuls post hoc analysis. Values are mean ± SD. Different vs. (a) EB; (b) ED; (c) PL 1.5h; (d) PL 4.5 h; (e) 15g, 1.5 g; (g) 30 g, 1.5 hour (P < 0.05).
DETAILED DESCRIPTION
[0051] All dosage ranges contained within this application are intended to include all numbers, whole or fractions, contained within said range.
[0052] As used in this disclosure and the appended claims, the singular forms "a," "an" and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "a polypeptide" includes a mixture of two or more polypeptides, and the like.
[0053] As used herein, "about" is understood to refer to numbers in a range of numerals. Moreover, all numerical ranges herein should be understood to include all integer, whole or fractions, within the range.
[0054] As used herein the term "amino acid" is understood to include one or more amino acids. The amino acid can be, for example, alanine, arginine, asparagine,
aspartate, citrulline, cysteine, glutamate, glutamine, glycine, histidine, hydroxyproline, hydroxyserine, hydroxytyrosine, hydroxylysine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, taurine, threonine, tryptophan, tyrosine, valine, or combinations thereof.
[0055] As used herein, "animal" includes, but is not limited to, mammals, which include but is not limited to, rodents, aquatic mammals, domestic animals such as dogs and cats, farm animals such as sheep, pigs, cows and horses, and humans. Wherein the terms "animal" or "mammal" or their plurals are used, it is contemplated that it also applies to any animals that are capable of the effect exhibited or intended to be exhibited by the context of the passage.
[0056] As used herein, the term "antioxidant" is understood to include any one or more of various substances such as beta-carotene (a vitamin A precursor), vitamin C, vitamin E, and selenium) that inhibit oxidation or reactions promoted by Reactive Oxygen Species ("ROS") and other radical and non-radical species. Additionally, antioxidants are molecules capable of slowing or preventing the oxidation of other molecules. Non- limiting examples of antioxidants include astaxanthin, carotenoids, coenzyme Q10 ("CoQIO"), flavonoids, glutathione, Goji (wolfberry), hesperidin, lactowolfberry, lignan, lutein, lycopene, polyphenols, selenium, vitamin A, vitamin C, vitamin E, zeaxanthin, or combinations thereof.
[0057] As used herein, "complete nutrition" includes nutritional products and compositions that contain sufficient types and levels of macronutrients (protein, fats and carbohydrates) and micronutrients to be sufficient to be a sole source of nutrition for the animal to which it is being administered to. Patients can receive 100% of their nutritional requirements from such complete nutritional compositions.
[0058] As used herein, "effective amount" is an amount that prevents a deficiency, treats a disease or medical condition in an individual or, more generally, reduces symptoms, manages progression of the diseases or provides a nutritional, physiological, or medical benefit to the individual. A treatment can be patient- or doctor- related.
[0059] While the terms "individual" and "patient" are often used herein to refer to a human, the invention is not so limited. Accordingly, the terms "individual" and "patient" refer to any animal, mammal or human having or at risk for a medical condition that can benefit from the treatment.
[0060] As used herein, sources of co-3 fatty acids include, for example, fish oil, krill, plant sources of co-3, flaxseed, walnut, and algae. Examples of co-3 fatty acids include, for example, a-linolenic acid ("ALA"), docosahexaenoic acid ("DHA"), eicosapentaenoic acid ("EPA"), or combinations thereof.
[0061] As used herein, "food grade micro-organisms" means micro- organisms that are used and generally regarded as safe for use in food.
[0062] As used herein, "high-quality protein" refers to protein that has a specific Protein Digestibility Corrected Amino Acid Score (PDCAAS). The PDCAAS is a method of evaluating the quality of protein based on both the amino acid requirements of humans and their ability to digest it. Indeed, the quality of protein depends on the level at which it provides the nutritional amounts of essential amino acids needed for overall body health, maintenance, and growth. For example, animal proteins, such as eggs, cheese, milk, meat, and fish, are considered complete proteins because they provide sufficient amounts of the essential amino acids. Plant proteins, such as grain, corn, nuts, vegetables and fruits, are considered incomplete proteins because many plant proteins lack one or more of the essential amino acids, or because they lack a proper balance of amino acids. Incomplete proteins can, however, be combined to provide all the essential amino acids, though combinations of incomplete proteins must be consumed at the same time, or within a short period of time (within four hours), to obtain the maximum nutritive value from the amino acids. Such combination diets generally yield a high-quality protein meal, providing sufficient amounts and proper balance of the essential amino acids needed by the body to function.
[0063] There are 20 primary amino acids, which include alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, seronine, threonine, tryptophan, tyrosine, and valine. The human body, however, is unable to make 9 of these amino acids
on its own, so these amino acids are considered "essential" and must come from our diet. The amino acids regarded as essential for humans are phenylalanine, valine, threonine, tryptophan, isoieucme, methionine, leucine, lysine, and histidine. Additionally, cysteine (or sulphur-containing amino acids), tyrosine (or aromatic amino acids), and argmine are required by infants and growing children.
[0064] A protein's quality is determined by investigating whether all 9 essential amino acids are present in the protein and whether the ratios of essential amino acids in the protein are ideal. With respect to the presence of the 9 essential amino acids, pretty much every source of protein has at least some of all the essential amino acids. However, if the protein is deficient in 1 or more essential amino acid then it is considered incomplete. As a point of reference, grains are typically low in the amino acid lysine, while legumes are low in methionine. Animal products, on the other hand, are high in all the essential amino acids and are usually considered complete. Regarding whether the ratios of essential amino acids in the protein are ideal, basically, the body needs a certain proportion of essential amino acids in the protein in order for it to be used most effectively. If all 9 are present yet 1 or more are not very abundant then the protein is of lower quality because the body will not be able to use the protein to its fullest potential.
[0065] A PDCAAS value of 1 is the highest quality protein, and a value of 0 is the lowest quality protein. As used herein, high quality protein is be defined as a PDCAAS of 0.7 or greater, or 0.8 or greater, or 0.9 of greater, or the like. In an embodiment, however, high quality protein may be mixed with a lower quality protein wherein the resulting PDCAAS of the protein mixture is 0.65 or greater, or 0.7 or greater, or the like.
[0066] As used herein, "incomplete nutrition" includes nutritional products or compositions that do not contain sufficient levels of macronutrients (protein, fats and carbohydrates) or micronutrients to be sufficient to be a sole source of nutrition for the animal to which it is being administered to. Partial or incomplete nutritional compositions can be used as a nutritional supplement.
[0067] As used herein, "long term administrations" are preferably continuous administrations for more than 6 weeks. Alternatively, "short term administrations," as used herein, are continuous administrations for less than 6 weeks.
[0068] As used herein, "mammal" includes, but is not limited to, rodents, aquatic mammals, domestic animals such as dogs and cats, farm animals such as sheep, pigs, cows and horses, and humans. Wherein the term "mammal" is used, it is contemplated that it also applies to other animals that are capable of the effect exhibited or intended to be exhibited by the mammal.
[0069] The term "microorganism" is meant to include the bacterium, yeast and/or fungi, a cell growth medium with the microorganism, or a cell growth medium in which microorganism was cultivated.
[0070] As used herein, the term "minerals" is understood to include boron, calcium, chromium, copper, iodine, iron, magnesium, manganese, molybdenum, nickel, phosphorus, potassium, selenium, silicon, tin, vanadium, zinc, or combinations thereof.
[0071] As used herein, a "non-replicating" microorganism means that no viable cells and/or colony forming units can be detected by classical plating methods. Such classical plating methods are summarized in the microbiology book: James Monroe Jay, et al., Modern food microbiology, 7th edition, Springer Science, New York, N. Y. p. 790 (2005). Typically, the absence of viable cells can be shown as follows: no visible colony on agar plates or no increasing turbidity in liquid growth medium after inoculation with different concentrations of bacterial preparations ('non replicating' samples) and incubation under appropriate conditions (aerobic and/or anaerobic atmosphere for at least 24h). For example, bifidobacteria such as Bifidobacterium longum, Bifidobacterium lactis and Bifidobacterium breve or lactobacilli, such as Lactobacillus paracasei or Lactobacillus rhamnosus, may be rendered non-replicating by heat treatment, in particular low temperature/long time heat treatment.
[0072] As used herein, a "nucleotide" is understood to be a subunit of deoxyribonucleic acid ("DNA"), ribonucleic acid ("RNA"), polymeric RNA, polymeric DNA, or combinations thereof. It is an organic compound made up of a nitrogenous base, a phosphate molecule, and a sugar molecule (deoxyribose in DNA and ribose in RNA).
Individual nucleotide monomers (single units) are linked together to form polymers, or long chains. Exogenous nucleotides are specifically provided by dietary supplementation. The exogenous nucleotide can be in a monomeric form such as, for example, 5'-Adenosine Monophosphate ("5'-AMP"), 5'-Guanosine Monophosphate ("5'-GMP"), 5'-Cytosine Monophosphate ("5'-CMP"), 5'-Uracil Monophosphate ("5'-UMP"), 5'-Inosine Monophosphate ("5'-IMP"), 5'-Thymine Monophosphate ("5'-TMP"), or combinations thereof. The exogenous nucleotide can also be in a polymeric form such as, for example, an intact RNA. There can be multiple sources of the polymeric form such as, for example, yeast RNA.
[0073] "Nutritional products," or "nutritional compositions," as used herein, are understood to include any number of optional additional ingredients, including conventional food additives (synthetic or natural), for example one or more acidulants, additional thickeners, buffers or agents for pH adjustment, chelating agents, colorants, emulsifies, excipient, flavor agent, mineral, osmotic agents, a pharmaceutically acceptable carrier, preservatives, stabilizers, sugar, sweeteners, texturizers, and/or vitamins. The optional ingredients can be added in any suitable amount. The nutritional products or compositions may be a source of complete nutrition or may be a source of incomplete nutrition.
[0074] As used herein the term "patient" is understood to include an animal, especially a mammal, and more especially a human that is receiving or intended to receive treatment, as it is herein defined.
[0075] As used herein, "phytochemicals" or "phytonutrients" are non-nutritive compounds that are found in many foods. Phytochemicals are functional foods that have health benefits beyond basic nutrition, are health promoting compounds that come from plant sources, and may be natural or purified. "Phytochemicals" and "Phytonutrients" refers to any chemical produced by a plant that imparts one or more health benefit on the user. Non-limiting examples of phytochemicals and phytonutrients include those that are:
[0076] i) phenolic compounds which include monophenols (such as, for example, apiole, carnosol, carvacrol, dillapiole, rosemarinol); flavonoids (polyphenols) including flavonols (such as, for example, quercetin, fingerol, kaempferol, myricetin, rutin,
isorhamnetin), flavanones (such as, for example, fesperidin, naringenin, silybin, eriodictyol), flavones (such as, for example, apigenin, tangeritin, luteolin), flavan-3-ols (such as, for example, catechins, (+)-catechin, (+)-gallocatechin, (-)-epicatechin, (-)- epigallocatechin, (-)-epigallocatechin gallate (EGCG), (-)-epicatechin 3-gallate, theaflavin, theaflavin-3 -gallate, theaflavin- 3 '-gallate, theaflavin-3,3'-digallate, thearubigins), anthocyanins (flavonals) and anthocyanidins (such as, for example, pelargonidin, peonidin, cyanidin, delphinidin, malvidin, petunidin), isoflavones (phytoestrogens) (such as, for example, daidzein (formononetin), genistein (biochanin A), glycitein), dihydroflavonols, chalcones, coumestans (phytoestrogens), and Coumestrol; Phenolic acids (such as: Ellagic acid, Gallic acid, Tannic acid, Vanillin, curcumin); hydroxycinnamic acids (such as, for example, caffeic acid, chlorogenic acid, cinnamic acid, ferulic acid, coumarin); lignans (phytoestrogens), silymarin, secoisolariciresinol, pinoresinol and lariciresinol); tyrosol esters (such as, for example, tyrosol, hydroxytyrosol, oleocanthal, oleuropein); stilbenoids (such as, for example, resveratrol, pterostilbene, piceatannol) and punicalagins;
[0077] ii) terpenes (isoprenoids) which include carotenoids (tetraterpenoids) including carotenes (such as, for example, a-carotene, β-carotene, γ-carotene, δ-carotene, lycopene, neurosporene, phytofluene, phytoene), and xanthophylls (such as, for example, canthaxanthin, cryptoxanthin, aeaxanthin, astaxanthin, lutein, rubixanthin); monoterpenes (such as, for example, limonene, perillyl alcohol); saponins; lipids including: phytosterols (such as, for example, campesterol, beta sitosterol, gamma sitosterol, stigmasterol), tocopherols (vitamin E), and omega-3, 6, and 9 fatty acids (such as, for example, gamma- linolenic acid); triterpenoid (such as, for example, oleanolic acid, ursolic acid, betulinic acid, moronic acid);
[0078] iii) betalains which include Betacyanins (such as: betanin, isobetanin, probetanin, neobetanin); and betaxanthins (non glycosidic versions) (such as, for example, indicaxanthin, and vulgaxanthin);
[0079] iv) organosulfides, which include, for example, dithiolthiones (isothiocyanates) (such as, for example, sulphoraphane); and thiosulphonates (allium compounds) (such as, for example, allyl methyl trisulfide, and diallyl sulfide), indoles, glucosinolates, which include, for example, indole-3-carbinol; sulforaphane; 3,3'-
diindolylmethane; sinigrin; allicin; alliin; allyl isothiocyanate; piperine; syn-propanethial- S-oxide;
[0080] v) protein inhibitors, which include, for example, protease inhibitors;
[0081] vi) other organic acids which include oxalic acid, phytic acid (inositol hexaphosphate); tartaric acid; and anacardic acid; or
[0082] vii) combinations thereof.
[0083] As used herein, a "prebiotic" is a food substance that selectively promotes the growth of beneficial bacteria or inhibits the growth or mucosal adhesion of pathogenic bacteria in the intestines. They are not inactivated in the stomach and/or upper intestine or absorbed in the gastrointestinal tract of the person ingesting them, but they are fermented by the gastrointestinal microflora and/or by probiotics. Prebiotics are, for example, defined by Glenn R. Gibson and Marcel B. Roberfroid, "Dietary Modulation of the Human Colonic Microbiota: Introducing the Concept of Prebiotics," J. Nutr., 125: 1401-1412 (1995). Non-limiting examples of prebiotics include acacia gum, alpha glucan, arabinogalactans, beta glucan, dextrans, fructooligosaccharides, fucosyllactose, galactooligosaccharides, galactomannans, gentiooligosaccharides, glucooligosaccharides, guar gum, inulin, isomaltooligosaccharides, lactoneotetraose, lactosucrose, lactulose, levan, maltodextrins, milk oligosaccharides, partially hydrolyzed guar gum, pecticoligosaccharides, resistant starches, retrograded starch, sialooligosaccharides, sialyllactose, soyoligosaccharides, sugar alcohols, xylooligosaccharides, or their hydrolysates, or combinations thereof.
[0084] As used herein, probiotic micro-organisms (hereinafter "probiotics") are food-grade microorganisms (alive, including semi-viable or weakened, and/or non- replicating), metabolites, microbial cell preparations or components of microbial cells that could confer health benefits on the host when administered in adequate amounts, more specifically, that beneficially affect a host by improving its intestinal microbial balance, leading to effects on the health or well-being of the host. See, Salminen S, Ouwehand A. Benno Y. et al, "Probiotics: how should they be defined?," Trends Food Sci. TechnoL, 10, 107-10 (1999). In general, it is believed that these micro-organisms inhibit or influence the growth and/or metabolism of pathogenic bacteria in the intestinal tract. The probiotics
may also activate the immune function of the host. For this reason, there have been many different approaches to include probiotics into food products. Non-limiting examples of probiotics include Aerococcus, Aspergillus, Bacteroides, Bifidobacterium, Candida, Clostridium, Debaromyces, Enterococcus, Fusobacterium, Lactobacillus, Lactococcus, Leuconostoc, Melissococcus, Micrococcus, Mucor, Oenococcus, Pediococcus, Penicillium, Peptostrepococcus, Pichia, Propionibacterium, Pseudocatenulatum, Rhizopus, Saccharomyces, Staphylococcus, Streptococcus, Torulopsis, Weissella, or combinations thereof.
[0085] The terms "protein," "peptide," "oligopeptides" or "polypeptide," as used herein, are understood to refer to any composition that includes, a single amino acids (monomers), two or more amino acids joined together by a peptide bond (dipeptide, tripeptide, or polypeptide), collagen, precursor, homolog, analog, mimetic, salt, prodrug, metabolite, or fragment thereof or combinations thereof. For the sake of clarity, the use of any of the above terms is interchangeable unless otherwise specified. It will be appreciated that polypeptides (or peptides or proteins or oligopeptides) often contain amino acids other than the 20 amino acids commonly referred to as the 20 naturally occurring amino acids, and that many amino acids, including the terminal amino acids, may be modified in a given polypeptide, either by natural processes such as glycosylation and other post-translational modifications, or by chemical modification techniques which are well known in the art. Among the known modifications which may be present in polypeptides of the present invention include, but are not limited to, acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of a flavanoid or a heme moiety, covalent attachment of a polynucleotide or polynucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphatidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cystine, formation of pyroglutamate, formylation, gamma-carboxylation, glycation, glycosylation, glycosylphosphatidyl inositol ("GPI") membrane anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to polypeptides such as arginylation, and ubiquitination.
The term "protein" also includes "artificial proteins" which refers to linear or non-linear polypeptides, consisting of alternating repeats of a peptide.
[0086] Non-limiting examples of proteins include dairy based proteins, plant based proteins, animal based proteins and artificial proteins. Dairy based proteins may be selected from the group consisting of casein, caseinates, casein hydrolysate, whey, whey hydrolysates, whey concentrates, whey isolates, milk protein concentrate, milk protein isolate, or combinations thereof. Plant based proteins include, for example, soy protein (e.g., all forms including concentrate and isolate), pea protein (e.g., all forms including concentrate and isolate), canola protein (e.g., all forms including concentrate and isolate), other plant proteins that commercially are wheat and fractionated wheat proteins, corn and it fractions including zein, rice, oat, potato, peanut, and any proteins derived from beans, buckwheat, lentils, pulses, single cell proteins, or combinations thereof. Animal based proteins may be selected from the group consisting of beef, poultry, fish, lamb, seafood, or combinations thereof.
[0087] As used herein, the term "rehabilitation" refers to the process of restoring an individual to good, physical condition, operation, or capacity after decrease of same. Accordingly, rehabilitation may include physical therapy, exercise or the like. Examples of individuals in need of rehabilitation include, but are not limited to, individuals having had muscle losses due to immobilization/bed rest, individuals in the hospital, individuals recovering from a critical illness or acute disease, individuals suffering from physical limitations, elderly individuals, athletes, infants experiencing growth retardation, etc.
[0088] As used herein, the terms "treatment," "treat" and "to alleviate" include both prophylactic or preventive treatment (that prevent and/or slow the development of a targeted pathologic condition or disorder) and curative, therapeutic or disease-modifying treatment, including therapeutic measures that cure, slow down, lessen symptoms of, and/or halt progression of a diagnosed pathologic condition or disorder; and treatment of patients at risk of contracting a disease or suspected to have contracted a disease, as well as patients who are ill or have been diagnosed as suffering from a disease or medical condition. The term does not necessarily imply that a subject is treated until total recovery.
The terms "treatment" and "treat" also refer to the maintenance and/or promotion of health in an individual not suffering from a disease but who may be susceptible to the development of an unhealthy condition, such as nitrogen imbalance or muscle loss. The terms "treatment," "treat" and "to alleviate" are also intended to include the potentiation or otherwise enhancement of one or more primary prophylactic or therapeutic measure. The terms "treatment," "treat" and "to alleviate" are further intended to include the dietary management of a disease or condition or the dietary management for prophylaxis or prevention a disease or condition.
[0089] As used herein, a "tube feed" is a complete or incomplete nutritional product or composition that is administered to an animal's gastrointestinal system, other than through oral administration, including but not limited to a nasogastric tube, orogastric tube, gastric tube, jejunostomy tube ("J-tube"), percutaneous endoscopic gastrostomy ("PEG"), port, such as a chest wall port that provides access to the stomach, jejunum and other suitable access ports.
[0090] As used herein the term "vitamin" is understood to include any of various fat-soluble or water-soluble organic substances (non-limiting examples include vitamin A, Vitamin Bl (thiamine), Vitamin B2 (riboflavin), Vitamin B3 (niacin or niacinamide), Vitamin B5 (pantothenic acid), Vitamin B6 (pyridoxine, pyridoxal, or pyridoxamine, or pyridoxine hydrochloride), Vitamin B7 (biotin), Vitamin B9 (folic acid), and Vitamin B12 (various cobalamins; commonly cyanocobalamin in vitamin supplements), vitamin C, vitamin D, vitamin E, vitamin K, Kl and K2 (i.e. MK-4, MK-7), folic acid and biotin) essential in minute amounts for normal growth and activity of the body and obtained naturally from plant and animal foods or synthetically made, provitamins, derivatives, analogs.
[0091] The present disclosure is related to methods for enhancing muscle protein synthesis. As discussed previously, negative energy balance or energy deficit (ED) can be achieved through reduced energy intake and/or increase energy expenditure and lead to fat mass (FM) loss. A reduction in FM is a common goal for both athletic performance and improved health outcomes (Mettler S, Mitchell N, Tipton KD. Increased protein intake reduces lean body mass loss during weight loss in athletes, Med Sci Sports
Exerc 2010;42(2):326-37; Hansen D, Dendale P, Berger J, van Loon LJ, Meeusen R, The effects of exercise training on fat-mass loss in obese patients during energy intake restriction. Sports Med 2007;37(l):31-46). However, when a reduction in fat mass is achieved by energy restriction alone, it typically results in the concomitant loss of fat free mass FFM, predominantly skeletal muscle (Parr EB, Coffey VG, Hawley JA. 'Sarcobesity': a metabolic conundrum. Maturitas 2013;74(2): 109-13). Given that the quality and quantity of skeletal muscle is a major determinant of athletic performance, whole body metabolic rate and functional capacity throughout the life span (Karagounis LG, Hawley JA. Skeletal muscle: increasing the size of the locomotor cell. Int J Biochem Cell Biol 2010;42(9): 1376-9), nutritional and exercise strategies to prevent or minimize loss of FFM while losing fat mass are crucial.
[0092] Pasiakos and colleagues (Pasiakos SM, Vislocky LM, Carbone JW, Altieri N, Konopelski K, Freake HC, Anderson JM, Ferrando AA, Wolfe RR, Rodriguez NR. Acute Energy Deprivation Affects Skeletal Muscle Protein Synthesis and Associated Intracellular Signaling Proteins in Physically Active Adults. J Nutr 2010;140(4):745-51) reported a 19% reduction in basal rates of mixed muscle protein synthesis in young healthy males and females after 10 days of ED (-500 kcal/day). In contrast, a recent study (Pasiakos SM, Cao JJ, Margo s LM, Sauter ER, Whigham LD, McClung JP, Rood JC, Carbone JW, Combs GF, Young AJ. Effects of high-protein diets on fat-free mass and muscle protein synthesis following weight loss: a randomized controlled trial. The FASEB Journal (2013)) from the same group reported no decrease in rates of resting muscle protein synthesis after 30 day of moderate ED. If potential decrease in basal rates of muscle protein synthesis are not accompanied by a concomitant reduction in muscle protein breakdown, then ED could lead to an imbalance in resting protein turnover that could favour the net loss of skeletal muscle proteins. Indeed, prolonged ED-induced body weight loss can be comprised of up to 60% fat free mass (see, id.). In contrast, exercise has been shown to attenuate the loss of lean body mass that can occur with periods of ED. See, Stiegler P, Cunliffe A. The role of diet and exercise for the maintenance of fat-free mass and resting metabolic rate during weight loss. Sports Med 2006;36(3):239-62. However, currently it is unknown if the anabolic effects of resistance exercise are
attenuated during periods of ED. Therefore, there is a clear need to further understand the effects of ED on the regulation of muscle protein synthesis.
[0093] Provision of dietary amino acids increases skeletal myofibrillar protein synthesis (MPS), an effect that is enhanced by prior resistance exercise. See, Biolo G, Tipton KD, Klein S, Wolfe RR. An abundant supply of amino acids enhances the metabolic effect of exercise on muscle protein. Am J Physiol 1997;273(1 Pt l):E122-9; Moore DR, Tang JE, Burd NA, Rerecich T, Tarnopolsky MA, Phillips SM. Differential stimulation of myofibrillar and sarcoplasmic protein synthesis with protein ingestion at rest and after resistance exercise. J Physiol 2009;587(4):897-904. Whether skeletal muscle exhibits 'anabolic resistance' to exercise and protein ingestion following short-term ED has not been determined. Moreover, the effects of increased protein availability in this situation are not known. Hence, the primary aim of the study described herein was to determine the effects of resistance exercise and post-exercise protein intake on skeletal muscle translation initiation signaling, mRNA expression and rates of muscle protein synthesis after short-term, moderate energy restriction. In addition, as women may be more susceptible to disregulations of normal metabolism during periods of ED (Loucks AB, Kiens B, Wright HH. Energy availability in athletes. J Sports Sci 2011;29 Suppl 1 :S7- 15), a second aim of the study was to identify potential sex based differences in skeletal muscle anabolism in response to energy deficit.
[0094] Indeed, Applicant surprisingly determined that five days of moderate energy deficit (Energy availability; 30 kcal-kg"1 FFM- day"1) resulted in a reduction (27%) of resting MPS in young, healthy subjects. However, resistance exercise undertaken in a fasted, energy restricted state enhanced MPS but only to basal values in energy balance. Ingestion of protein following resistance exercise undertaken in energy deficit enhanced the anabolic (MPS and signaling) response above resting energy balance the amino acid transporter transcriptional response to resistance exercise and protein ingestion are down regulated in healthy individuals in ED.
[0095] Pasiakos and colleagues have previously reported that 10 days of energy deficit (-500 kcal · day"1) reduced resting rates of mixed muscle protein synthesis by -19%. See, Pasiakos SM, Vislocky LM, Carbone JW, Altieri N, Konopelski K, Freake HC,
Anderson JM, Ferrando AA, Wolfe RR, Rodriguez NR. Acute Energy Deprivation Affects Skeletal Muscle Protein Synthesis and Associated Intracellular Signaling Proteins in Physically Active Adults. J Nutr 2010;140(4):745-51. Applicant's data confirmed the physiological response to energy deficit in vivo skeletal muscle and provided novel data to show there is a similar detrimental 27% decrease on myofibrillar FSR after only 5 days of moderate energy restriction. Applicant chose the model of energy availability to set the energy deficit in our subjects, with a level of 30 kcal-kg"1 FFM-day"1 corresponding to a de facto threshold below which there is significant disruption to metabolic and hormonal systems within the body. See, Loucks AB, Kiens B, Wright HH. Energy availability in athletes. J Sports Sci 2011;29 Suppl 1 : S7-15. The notional energy deficit of -15 kcal-kg"1 FFM-day"1 in Applicant's subjects was typically equivalent to 1690-2200 kcal · day"1 in the male and 1210-1640 kcal · day"1 in the female subjects. To our surprise, the extensive resistance training history of our subjects coupled with the high relative dietary protein intake (1.4 g-kg"1 BM-day"1) during this energy deficit was still unable to "protect" the muscle and preserve resting rates of MPS. Given that protein synthesis is an energetically expensive process, Applicant proposes that the decrease in muscle protein synthesis observed in the present and previous studies (Pasiakos SM, Vislocky LM, Carbone JW, Altieri N, Konopelski K, Freake HC, Anderson JM, Ferrando AA, Wolfe RR, Rodriguez NR. Acute Energy Deprivation Affects Skeletal Muscle Protein Synthesis and Associated Intracellular Signaling Proteins in Physically Active Adults. J Nutr 2010;140(4):745-51) may represent an accommodative physiological response to the reduced energy availability that subsequently down regulates non-essential metabolic pathways.
[0096] Consistent with observations in energy balance (Moore DR, Tang JE, Burd NA, Rerecich T, Tarnopolsky MA, Phillips SM. Differential stimulation of myofibrillar and sarcoplasmic protein synthesis with protein ingestion at rest and after resistance exercise. J Physiol 2009;587(4): 897-904; Phillips SM, Tipton KD, Aarsland A, Wolf SE, Wolfe RR. Mixed muscle protein synthesis and breakdown after resistance exercise in humans. Am J Physiol 1997;273(1 Pt 1):E99-107), the anabolic stimulus generated by resistance exercise in the fasted state elevated MPS above resting levels in the early post-exercise period, during energy restriction. However, despite this elevation,
exercise merely "rescued" the rate of MPS in energy restriction to a level that was similar to, but did not exceed, rates measured at rest when in EB. Accordingly, it appears the metabolic status of the muscle during short-term (e.g., 5 days) energy deficit plus an approximately 10 hour fast may dictate that contractile overload in isolation is not enough to increase FSR to values that otherwise would be reached in EB.
[0097] The anabolic effect of protein ingestion is well-accepted. See, Breen L, Phillips SM. Nutrient interaction for optimal protein anabolism in resistance exercise. Curr Opin Clin Nutr Metab Care 2012;15(3):226-32. A recent study on young healthy subjects involving 21 days of high (1.6 and 2.4 g-kg"1 BM-day"1) protein intake while in moderate ED (750 kcal-day"1) rescued the FFM loss seen with normal (RDA, 0.8 g-kg"1 BM) protein intake diet group. Applicant's study described below is the first study to determine the acute muscle anabolic response to different quantities of protein ingested after exercise undertaken during short-term ED. The results from the present study also highlight the importance of resistance exercise together with increasing doses of protein to maximize protein accretion in a chronic intervention. As discussed below, Applicant surprisingly reports that a dose-dependent response MPS to protein ingestion remains evident despite ED as Applicant observed a hierarchical increase above resting energy balance rates of muscle protein synthesis with ingestion of 15 and 30 g whey protein (see, FIG. 4). This effect is evident when protein ingestion is considered in both absolute and relative terms to body mass and fat free mass (see, FIGS. 5). Therefore, exogenous amino acid provision in ED appears to be pre-requisite for supporting muscle protein synthesis that may result in net new muscle protein synthesis above resting energy balance. See, Phillips SM, Tipton KD, Aarsland A, Wolf SE, Wolfe RR. Mixed muscle protein synthesis and breakdown after resistance exercise in humans. Am J Physiol 1997;273(1 Pt 1):E99-107; Biolo G, Maggi SP, Williams BD, Tipton KD, Wolfe RR. Increased rates of muscle protein turnover and amino acid transport after resistance exercise in humans. Am J Physiol 1995;268(3):E514-E20. It is tempting to speculate that the rates of protein synthesis in the present study were inferior to those induced by comparable resistance exercise and post exercise protein ingestion undertaken in energy balance (West DW, Burd NA, Coffey VG, Baker SK, Burke LM, Hawley J A, Moore DR, Stellingwerff T, Phillips SM. Rapid
aminoacidemia enhances myofibrillar protein synthesis and anabolic intramuscular signaling responses after resistance exercise. Am J Clin Nutr 2011;94(3):795-803; Areta JL, Burke LM, Ross ML, Camera DM, West DWD, Broad EM, Jeacocke NA, Moore DR, Stellingwerff T, Phillips SM, et al. Timing and distribution of protein ingestion during prolonged recovery from resistance exercise alters myofibrillar protein synthesis. J Physiol 2013). For example, increases in myofibrillar rates of protein synthesis above rest when employing similar resistance exercise and protein ingestion protocols in energy balance are typically greater than 100% (Moore DR, Tang JE, Burd NA, Rerecich T, Tarnopolsky MA, Phillips SM. Differential stimulation of myofibrillar and sarcoplasmic protein synthesis with protein ingestion at rest and after resistance exercise. J Physiol 2009;587(4):897-904; West DW, Burd NA, Coffey VG, Baker SK, Burke LM, Hawley JA, Moore DR, Stellingwerff T, Phillips SM. Rapid aminoacidemia enhances myofibrillar protein synthesis and anabolic intramuscular signaling responses after resistance exercise. Am J Clin Nutr 2011;94(3):795-803; Areta JL, Burke LM, Ross ML, Camera DM, West DWD, Broad EM, Jeacocke NA, Moore DR, Stellingwerff T, Phillips SM, et al. Timing and distribution of protein ingestion during prolonged recovery from resistance exercise alters myofibrillar protein synthesis. J Physiol 2013; Moore DR, Robinson MJ, Fry JL, Tang JE, Glover EI, Wilkinson SB, Prior T, Tarnopolsky MA, Phillips SM. Ingested protein dose response of muscle and albumin protein synthesis after resistance exercise in young men. Am J Clin Nutr 2009;89(1): 161-8) compared with -60-80% in ED in the current study. Applicant's study is limited to quantification of muscle protein synthesis and the effect of ED on muscle protein breakdown is unknown. Whether resistance exercise and amino acid provision can generate positive net protein balance in skeletal muscle during ED remains to be established; however, there are published examples of individuals concurrently gaining or maintaining LBM while losing total body mass and fat mass in prolonged training studies involving ED (Mettler S, Mitchell N, Tipton KD. Increased protein intake reduces lean body mass loss during weight loss in athletes. Med Sci Sports Exerc 2010;42(2): 326-37; Garthe I, Raastad T, Egil Refsnes P, Koivisto A, Sundgot- Borgen J. Effect of two different weight-loss rates on body composition and strength and power-related performance in elite athletes. International Journal of Sport Nutrition
andExercise Metabolism 2011;21(2):97; Haakonssen EC, Martin DT, Burke LM, Jenkins DG. Increased Lean Mass with Reduced Fat Mass in an Elite Female Cyclist Returning to Competition: Case Study. Int J Sports Physiol Perform 2013).
[0098] In the present study, Applicant found no sex-based differences for any of the cellular markers of 'muscle anabolism' measured, providing further support for the notion that both acute and chronic responses to resistance exercise and/or protein ingestion are similar between younger men and women (West DWD, Burd NA, Churchward- Venne TA, Camera DM, Mitchell CJ, Baker SK, Hawley J A, Coffey VG, Phillips SM. Sex-based comparisons of myofibrillar protein synthesis after resistance exercise in the fed state. J Appl Physiol 2012;112(11): 1805-13; Phillips BE, Williams JP, Gustafsson T, Bouchard C, Rankinen T, Knudsen S, Smith K, Timmons JA, Atherton PJ. Molecular networks of human muscle adaptation to exercise and age. PLoS Genet 2013;9(3); Smith GI, Mittendorfer B. Similar muscle protein synthesis rates in young men and women: men aren't from Mars and women aren't from Venus. J Appl Physiol 2012;112(11); Smith G, Reeds D, Hall A, Chambers K, Finck B, Mittendorfer B. Sexually dimorphic effect of aging on skeletal muscle protein synthesis. Biology of Sex Differences 2012;3(1): 11.
[0099] The muscle anabolic responses in ED that Applicant found were evident despite differences in body mass and body composition (see, Table 1 below). However, there was a moderate relationship between the relative quantity of protein ingested and the muscle fractional synthetic rate such that Applicant cannot rule out that the (smaller) females may have benefited, at least in part, from a greater relative protein dose (see, FIGS. 5A-B). Whether a greater relative effect on muscle protein synthesis in females would ameliorate any potential sex-based difference in ED seems unlikely. Indeed, Phillips and co-workers (Phillips BE, Williams JP, Gustafsson T, Bouchard C, Rankinen T, Knudsen S, Smith K, Timmons JA, Atherton PJ. Molecular networks of human muscle adaptation to exercise and age. PLoS Genet 2013 ;9(3): el 003389) have recently reported the capacity of skeletal muscle to hypertrophy during 20-week resistance training program as being, to a large extent, genetically determined, is not sex-dependent. Regardless, Applicant's data indicates that the physiological response in skeletal muscle following the short-term ED
protocol employed in the current study was similar in male and female subjects and they appear equally responsive to an acute bout of REX and post exercise protein intake in ED.
[00100] TABLE 1. - Subjects characteristics. 1 Repetition Maximum (1 RM); Body Mass (BM); Fat Free Mass (FFM). Data was analyzed by using multiple T-tests. Values are mean ± SD.* different between sexes (P < 0.05).
Males Females
N 8 7
Age (Years) 27 ± 5 28 ± 4
Body mass (kg) * 82.7 ± 6.6 70.3 ± 7
Fat (% BM) * 14.9 ± 3.5 28.7 ± 5.3
Lean Mass (kg) * 67.2 ± 6.2 48.1 ± 4.3
1 RM (kg) * 300 ± 70 200 ± 38
1 RM (kg)/BM (kg) * 3.6 ± 0.8 2.8 ± 0.3
1 RM (kg)/ FFM (kg) 4.5 ± 0.9 4.2 ± 0.7
[00101] The mTOR associated translational signaling data found by Applicant did not reveal any differences at rest between EB and ED, which are in agreement with recent observations by others (Pasiakos SM, Cao JJ, Margolis LM, Sauter ER, Whigham LD, McClung JP, Rood JC, Carbone JW, Combs GF, Young AJ. Effects of high-protein diets on fat-free mass and muscle protein synthesis following weight loss: a randomized controlled trial. The FASEB Journal 2013). As shown below, in the present study, resistance exercise alone undertaken in energy deficit had little effect in promoting the phosphorylation of any of the proteins of interest. This finding is in contrast to Applicant's previous study (Camera DM, Edge J, Short MJ, Hawley JA, Coffey VG. Early time course of Akt phosphorylation after endurance and resistance exercise. Med Sci Sports Exerc 2010;42(10): 1843-52) and the results from several other groups (Creer A, Gallagher P, Slivka D, Jemiolo B, Fink W, Trappe S. Influence of muscle glycogen availability on ERKl/2 and Akt signaling after resistance exercise in human skeletal muscle. J Appl Physiol 2005;99(3): 950-6; Dreyer HC, Fujita S, Cadenas JG, Chinkes DL, Volpi E,
Rasmussen BB. Resistance exercise increases AMPK activity and reduces 4E-BP1 phosphorylation and protein synthesis in human skeletal muscle. J Physiol 2006;576(2):613-24) when resistance exercise is undertaken in the fasted state in EB. However, Applicant did observe a marked increase in translational signaling following the post exercise ingestion of protein, albeit with only subtle differences between the response to 15 g and 30 g of whey protein. Moreover, Applicant has previously shown a hierarchical signaling response to increasing quantities of whey protein ingestion i.e., more protein ingested resulted in greater phosphorylation of p70 S6K (Areta JL, Burke LM, Ross ML, Camera DM, West DWD, Broad EM, Jeacocke NA, Moore DR, Stellmgwerff T, Phillips SM, et al. Timing and distribution of protein ingestion during prolonged recovery from resistance exercise alters myofibrillar protein synthesis. J Physiol 2013); the results of the current study indicate that energy deficit may alter the magnitude of signal for translation initiation in response to acute exercise and protein intake (see, FIGS. 6A-D). Importantly, the similar phosphorylation responses were not mirrored by myofibrillar FSR and support previous work showing translation initiation signaling can be indicative of elevated muscle protein synthesis compared to baseline (Burd NA, Holwerda AM, Selby KC, West DWD, Staples AW, Cain NE, Cashaback JGA, Potvin JR, Baker SK, Phillips SM. Resistance exercise volume affects myofibrillar protein synthesis and anabolic signalling molecule phosphorylation in young men. J Physiol 2010;588(16):3119-30; Kumar V, Atherton P, Smith K, Rennie MJ. Human muscle protein synthesis and breakdown during and after exercise. J Appl Physiol 2009;106(6):2026-39; Fry CS, Drummond MJ, Glynn EL, Dickinson JM, Gundermann DM, Timmerman KL, Walker DK, Dhanani S, Volpi E, Rasmussen BB. Aging impairs contraction-induced human skeletal muscle mTORCl signaling and protein synthesis. Skelet Muscle 2011 ;1(1): 11), but does not accurately reflect the magnitude or duration of the muscle protein synthesis response (Areta JL, Burke LM, Ross ML, Camera DM, West DWD, Broad EM, Jeacocke NA, Moore DR, Stellingwerff T, Phillips SM, et al. Timing and distribution of protein ingestion during prolonged recovery from resistance exercise alters myofibrillar protein synthesis. J Physiol 2013).
[00102] As shown below, energy deficit did not generate any differences in muscle transcriptional activity of any gene of interest at rest compared with resting energy balance (see, FIGS. 7A-D). The ubiquitin ligases MuRF-1, and Atrogin are key regulatory steps of the ubiquitin-proteasomal protein degradation. Originally linked to muscle atrophy they seem to be important in the myofibril remodelling process after a bout of resistance exercise. The mRNA abundance of MuRF-1 increased above rest and placebo following post exercise ingestion of 15 g protein, but was not different to the higher (30 g) protein dose. Protein intake in sufficient quantities has been previously shown to blunt the exercise induced increase in MuRF-1 mRNA abundance (Areta JL, Burke LM, Ross ML, Camera DM, West DWD, Broad EM, Jeacocke NA, Moore DR, Stellmgwerff T, Phillips SM, et al. Timing and distribution of protein ingestion during prolonged recovery from resistance exercise alters myofibrillar protein synthesis. J Physiol 2013; Borgenvik M, Apro W, Blomstrand E. Intake of branched-chain amino acids influences the levels of MAFbx mRNA and MuRF-1 total protein in resting and exercising human muscle. Am J Physiol 2012;302(5):E510-E21; Louis E, Raue U, Yang Y, Jemiolo B, Trappe S. Time course of proteolytic, cytokine, and myostatin gene expression after acute exercise in human skeletal muscle. J Appl Physiol 2007;103(5): 1744-51). Interestingly, increases in Atrogin mRNA abundance following high intensity exercise is not consistently observed in vivo humans (Areta JL, Burke LM, Ross ML, Camera DM, West DWD, Broad EM, Jeacocke NA, Moore DR, Stellingwerff T, Phillips SM, et al. Timing and distribution of protein ingestion during prolonged recovery from resistance exercise alters myofibrillar protein synthesis. J Physiol 2013; Louis E, Raue U, Yang Y, Jemiolo B, Trappe S. Time course of proteolytic, cytokine, and myostatin gene expression after acute exercise in human skeletal muscle. J Appl Physiol 2007; 103(5): 1744-51 ; Raue U, Slivka D, Jemiolo B, Hollon C, Trappe S. Proteolytic gene expression differs at rest and after resistance exercise between young and old women. J Gerontol A Biol Sci Med Sci 2007;62(12): 1407-12) and Applicant's results showing elevated Atrogin mRNA following resistance exercise in all treatments indicates energy deficit may promote the catabolic activity of this specific atrogene. Importantly, protein ingestion did not alter the elevated transcriptional activity of Atrogin during recovery from resistance exercise in energy deficit but direct measures
of protein breakdown are required to determine the physiological relevance of the increase in Atrogin mRNA expression when exercising in ED.
[00103] The results from previous studies have shown resistance exercise and protein feeding augments amino acid transporter mRNA and protein abundance in skeletal muscle (Areta JL, Burke LM, Ross ML, Camera DM, West DWD, Broad EM, Jeacocke NA, Moore DR, Stellingwerff T, Phillips SM, et al. Timing and distribution of protein ingestion during prolonged recovery from resistance exercise alters myofibrillar protein synthesis. J Physiol 2013; Drummond MJ, Fry CS, Glynn EL, Timmerman KL, Dickinson JM, Walker DK, Gundermann DM, Volpi E, Rasmussen BB. Skeletal muscle amino acid transporter expression is increased in young and older adults following resistance exercise. J Appl Physiol 2011;111(1): 135-42; Drummond MJ, Glynn EL, Fry CS, Timmerman KL, Volpi E, Rasmussen BB. An increase in essential amino acid availability upregulates amino acid transporter expression in human skeletal muscle. Am J Physiol 2010;298(5):E1011-E8). Applicant's results, as summarized below, the first in examination of the transport proteins in ED, show either little effect or, indeed, a down regulation of SNAT2 and LAT1 mRNA, respectively, indicative of a suppression of global amino acid transporter expression following exercise and protein ingestion when in ED. Given that exercise and protein intake increased MPS compared to resting ED there does not appear to be any acute relationship between the transcriptional activities of amino acid transporters such that it would prevent any anabolic response. The physiological significance of changes in amino acid transporter mRNA expression are beyond the scope of Applicant's present study, however one could speculate that the down regulation of transporter expression could potentially result in depressing the capacity of amino acid uptake in to skeletal muscle when in chronic energy deficit and represents an area for future study. This phenomenon may be consequence of a physiological adjustment to lower energy availability. Given that turnover is a high energy demanding process, shifting the system towards a state of reduced protein turnover would increase energy availability for processes of higher priority for survival. Alternatively, exercise has been shown to enhance amino acid sensitivity of skeletal muscle to circulating amino acids, which could suggest that the down regulation of transporter mRNA expression with
exercise (relative to a fasting control) is a reflection of a reduced transporter requirement to facilitate amino acid uptake. Therefore, the physiological significance of changes in amino acid transporter mRNA and, ultimately, protein expression with exercise and dietary manipulations is further warranted.
[00104] In conclusion, Applicant's studies provide novel data on the effect of a short-term energy restricted diet on skeletal muscle metabolism in vivo humans (Mettler S, Mitchell N, Tipton KD. Increased protein intake reduces lean body mass loss during weight loss in athletes. Med Sci Sports Exerc 2010;42(2): 326-37; Campbell WW, Haub MD, Wolfe RR, Ferrando AA, Sullivan DH, Apolzan JW, Iglay HB. Resistance Training Preserves Fat-free Mass Without Impacting Changes in Protein Metabolism After Weight Loss in Older Women. Obesity 2009; 17(7): 1332-9; Pikosky MA, Smith TJ, Grediagin A, Castaneda-Sceppa C, Byerley L, Glickman EL, Young AJ. Increased protein maintains nitrogen balance during exercise-induced energy deficit. Med Sci Sports Exerc 2008;40(3): 505-12; Layman DK, Evans E, Baum JI, Seyler J, Erickson DJ, Boileau RA. Dietary Protein and Exercise Have Additive Effects on Body Composition during Weight Loss in Adult Women. J Nutr 2005; 135(8): 1903- 10; Walberg JL, Leidy MK, Sturgill DJ, Hinkle DE, Ritchey SJ, Sebolt DR. Macronutrient Content of a Hypoenergy Diet Affects Nitrogen Retention and Muscle Function in Weight Lifters. Int J Sports Med 1988;09(04):261-6). Collectively, Applicant's data shows that 5 days of moderate energy deficit, at an energy availability equivalent to 30 kcal-kg"1 FFM-day"1 is sufficient to inhibit rates of muscle protein synthesis. Without being bound to any theories, Applicant believes that if such an energy deficit was sustained for prolonged (i.e., several months) periods, it would lead to substantial reductions in muscle mass. Applicant's results also show that targeted use of a bolus of high quality protein ingestion (15-30g) may have the capacity to off-set the muscle catabolic state. Moreover, our data suggest that the dose required to maximally stimulate muscle protein synthesis under energy balance (-20-25 g of protein; see, Moore DR, Robinson MJ, Fry JL, Tang JE, Glover EI, Wilkinson SB, Prior T, Tarnopolsky MA, Phillips SM. Ingested protein dose response of muscle and albumin protein synthesis after resistance exercise in young men. Am J Clin Nutr 2009;89(1): 161-8; Cuthbertson D, Smith K, Babraj J, Leese G, Waddell T, Atherton P, Wackerhage H, Taylor
PM, Rennie MJ. Anabolic signaling deficits underlie amino acid resistance of wasting, aging muscle. FASEB J 2005;19(3):422-4) may well be higher in individuals in energy deficit. Regardless, the current investigation provides important new information on the effect of energy deficit on skeletal muscle metabolism and shows the attenuation of muscle protein synthesis at rest in energy deficit can be rescued/augmented by the combined anabolic effects of resistance exercise and protein ingestion.
[00105] By way of example and not limitation, the following examples are illustrative of various embodiments of the present disclosure. The formulations and processes below are provided for exemplification only, and they can be modified by the skilled artisan to the necessary extent, depending on the special features that are desired.
[00106] EXAMPLE 1
[00107] Subjects and Methods
[00108] Ethical Approval.
[00109] Subjects were informed of any potential risks involved in the study before providing their written informed consent. The study was approved by the Australian Institute of Sport Ethics Committee and conformed to the standards set by the latest revision of the Declaration of Helsinki.
[00110] Subjects.
[00111] Sixteen young, healthy, resistance trained subjects (8 females, 8 males) were recruited, one failed to finish. Therefore, the data represents that from the remaining 15 participants (see, Table 1 above). Body composition was measured 1-2 weeks before the first experimental trial using a whole body scan narrowed fan-beam dual energy X-ray analysis (DXA Lunar Prodigy, GE Healthcare, Madison, WI) with GE Encore 13.60 software (GE, Madison, WI).
[00112] Experimental Design.
[00113] The study employed a within subject design, with subjects completing four experimental interventions: energy balance (EB) at rest; energy deficit (ED) at rest;
and then ED with exercise both with and without protein feeding. All trials were performed in a randomized order with the exception of the EB trial, which was undertaken first (see, FIG. 1).
[00114] Dietary Intervention.
[00115] Subjects were each provided with individualized pre-packaged meals for 5 days before each experimental trial. Before the resting EB trial, subjects were provided with meals equivalent to an energy availability (EA) of 45 kcal-kg"1 FFM · day"1, where EA is defined as energy intake minus the energy cost of exercise. For all ED trials, diets consisted of an energy availability of 30 kcal-kg"1 FFM -day"1. Between days 1-3 of the dietary control period subjects were permitted to exercise and the diet adjusted to account for the energy expenditure of the exercise sessions and thus restore EA to the set level. The total protein content was 1.4 g-kg"1 BM- day"1 for both dietary treatments. No alcohol was consumed by the subjects during the 5-day dietary control period, and they refrained from caffeine intake 24 hours before each trial day. Between experimental trials, there was a 9 day 'washout' period during which subjects were encouraged to continue their normal exercise and dietary habits.
[00116] Experimental Trials.
[00117] After 5 days of dietary control, subjects reported to the laboratory between 0700 and 0800 hours after a 10-12 hour overnight fast and a catheter was inserted in the antecubital vein of each arm for blood sampling and tracer infusion. A first (baseline) blood sample was drawn for the resting EB trial (or muscle biopsy from the vastus lateralis was obtained for the ED trials) immediately before a primed, continuous (0.05 pmol-kg^-min"1; 2 junol-kg"1 prime) infusion of -[ring-13 C6] phenylalanine commenced.
[00118] After a resting period of 3 hours, a muscle biopsy was obtained. For the three non-tracer naive subjects the first muscle biopsy was taken before the infusion started for their EB trial.
[00119] The ED trials were undertaken after the resting EB trial with the protein/placebo ingestion randomized and counterbalanced. Drinks contained 15 g or 30 g of protein (IS08 WPI; 86.8 g protein, 1.5 g fat, 3.1 g carbohydrates per 100 g) or no protein in form of a flavour and volume matched placebo drink. Each protein drink was enriched with 5% L-[n'«g-13C6]phenylalanine and mixed with water to a total volume of 500 mL. The first ED trial for each subject was divided in two periods. The first (pre- exercise) period of the trial determined resting ED and was identical to the EB trial with the exception of an initial muscle biopsy. In the second period, subjects undertook a bout of resistance exercise (REX; described subsequently) with muscle biopsies obtained after 1 hour and 4 hours post-exercise recovery. Drinks were ingested immediately following cessation of the exercise bout. The remaining ED trials were identical but primed constant infusion of tracer commenced prior to exercise.
[00120] Exercise.
[00121] One repetition maximum (1 RM) inclined (45°) leg press (GLPH1100, Body-Solid, Forest Park IL) test was completed by each subject a minimum of one week prior to the experimental trials. After a warm up of 2 sets of 5 moderate intensity repetitions the 1 RM was determined as the highest successfully lifted weight during a maximum of 6 attempts. On the day of an ED experimental trial subjects completed 2 warm up sets of 5 repetitions at -50 and -60% 1 RM with 2 minutes rest between sets. The resistance exercise training bout incorporated 6 sets of 8 repetitions at -80% 1 RM with 3 minutes rest between sets. Exercise range of motion was -85° for the knee joint, with leg extension endpoint set at -5° from full extension.
[00122] Biological Samples.
[00123] Blood samples (4 mL) were taken at rest, before the exercise bout and at repeated time-points throughout recovery (see, FIG. 1). Muscle biopsy samples were taken from different incisions, separated by -1 cm using 5 mm Bergstrom needles adapted for manual suction. Muscle was cleaned with saline solution to remove excess blood and
immediately frozen in liquid N2. Muscle and plasma samples were stored at -80 °C until subsequent analysis.
[00124] Analytical Procedures
[00125] Insulin and Amino Acid Concentration.
[00126] Plasma insulin concentration was measured using an automated enzyme amplified chemiluminescence Immulite® 1000 system (Siemens diagnostics, Australia) according to manufacturer's guidelines. Plasma amino acids (AA) were analyzed by high performance liquid chromatography to determine amino acid concentrations as described previously (see, West DW, Burd NA, Coffey VG, Baker SK, Burke LM, Hawley JA, Moore DR, Stellingwerff T, Phillips SM. Rapid aminoacidemia enhances myofibrillar protein synthesis and anabolic intramuscular signaling responses after resistance exercise. Am J Clin Nutr 2011;94(3):795-803; Wilkinson SB, Tarnopolsky MA, MacDonald MJ, MacDonald JR, Armstrong D, Phillips SM. Consumption of fluid skim milk promotes greater muscle protein accretion after resistance exercise than does consumption of an isonitrogenous and isoenergetic soy-protein beverage. Am J Clin Nutr 2007;85(4): 1031- 40).
[00127] Western Blot.
[00128] Intracellular signalling proteins were extracted, isolated and quantified as previously described (see, Coffey V, Moore D, Burd N, Rerecich T, Stellingwerff T, Garnham A, Phillips S, Hawley J. Nutrient provision increases signalling and protein synthesis in human skeletal muscle after repeated sprints. Eur J Appl Physiol 2011 ;111(7): 1473-83). Amount of protein loaded in each well was 40 μg. Polyclonal anti- phospho mammalian target of rapamycin (mTOR) Ser2448 (#2971), monoclonal anti- phospho-Akt Ser473 (#9271), nbosomal protein S6 Ser 235/6 (#4856), 4E-BP1 Thr37/46 (# 2855), eEF2 Thr56 (# 2331), AMPK Thrl72 (#2535) and anti-a-tubulin control protein (#3873) were purchased from Cell Signaling Technology (Danvers, MA). Polyclonal anti- phospho- p70S6K Thr 389 (#PK1015) was from Millipore (Temecula, CA).
[00129] Fractional Synthetic Rate.
[00130] Pre-infusion plasma sample proteins, extracted by acetonitrile, were utilized as the baseline enrichment in tracer naive subjects (see, Burd NA, Groen BB, Beelen M, Senden JM, Gijsen AP, van Loon LJ. The reliability of using the single-biopsy approach to assess basal muscle protein synthesis rates in vivo in humans. Metabolism 2012;61(7):931-6). For non-tracer naive subjects (n=3, males) a pre-infusion muscle biopsy was used for baseline enrichment. Muscle tissue was processed as previously described (see, Moore DR, Tang JE, Burd NA, Rerecich T, Tarnopolsky MA, Phillips SM. Differential stimulation of myofibrillar and sarcoplasmic protein synthesis with protein ingestion at rest and after resistance exercise. J Physiol 2009;587(4): 897-904).
[00131] Calculations.
[00132] The fractional synthetic rate of myofibrillar proteins was calculated using the standard precursor-product method:
[00133] FSR (%-h-1) = [Ep2 - Epi]/Eic x 1/t x 100
[00134] Where Ep2 - Epi represents the change in bound protein enrichment between two biopsy samples; EiC is the average enrichment of intracellular phenylalanine between the two biopsy samples; and t is the time between biopsies. The utilization of 'tracer-naive' subjects (n=12) allowed us to use the pre-infusion blood sample (i.e. mixed plasma protein fraction) as the baseline enrichment (Epl) for the calculation of resting muscle protein synthesis (Burd NA, Holwerda AM, Selby KC, West DWD, Staples AW, Cain NE, Cashaback JGA, Potvin JR, Baker SK, Phillips SM. Resistance exercise volume affects myofibrillar protein synthesis and anabolic signalling molecule phosphorylation in young men. J Physiol 2010;588(16):3119-30).
[00135] RNA Extraction, Reverse Transcription and RT-PCR.
[00136] Skeletal muscle tissue (-20 mg) was used to isolate RNA using a modification of the acid guanidinium thiocyanate-phenol-chloroform extraction, as
previously described (see, Coffey VG, Reeder DW, Lancaster GI, Yeo WK, Febbraio MA, Yaspelkis BB, 3rd, Hawley JA. Effect of high-frequency resistance exercise on adaptive responses in skeletal muscle. Med Sci Sports Exerc 2007;39(12):2135-44). Reverse transcription and real-time Polymerase Chain Reaction (RT-PCR) was performed as previously described (see, Camera DM, West DWD, Burd NA, Phillips SM, Garnham AP, Hawley JA, Coffey VG. Low Muscle Glycogen Concentration Does Not Suppress the Anabolic Response to Resistance Exercise. J Appl Physiol 2012; West DWD, Burd NA, Churchward- Venne TA, Camera DM, Mitchell CJ, Baker SK, Hawley JA, Coffey VG, Phillips SM. Sex-based comparisons of myofibrillar protein synthesis after resistance exercise in the fed state. J Appl Physiol 2012;112(11): 1805-13). Taqman-FAM-labelled primer/probes for Atrogin-1 (Hs01041408_ml*), MuRF-1 (Hs00822397_ml *), SLC38A2 (Hs00255854_ml*), and SLC7A5 (Hs00185826_ml) primers (Applied Biosystems, Carlsbad, CA) were used. Glyceraldehyde-3 -phosphate dehydrogenase (GAPDH, HS99999905_ml*) was used as the housekeeping gene. The relative amounts of mRNAs were calculated using the relative quantification (AACT) method (see, Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001 ;25(4):402-8).
[00137] Statistical Analysis.
[00138] Data were analyzed using two way repeated measures analysis of variance (ANOVA) with Student-Newman-Keuls post hoc analysis (gender χ time) for cell signaling, RT-PCR and myofibrillar FSR There were no differences between genders and data were subsequently combined for further analysis using one way repeated measures ANOVA with Student-Newman-Keuls post hoc test. Data for plasma insulin and amino acids concentration were analyzed using two way repeated measures ANOVA with Student-Newman-Keuls post hoc test where resting energy balance and energy deficit trials were independently analyzed from the exercise trials. Data for Western blotting were log- transformed prior to analysis. All data are presented as mean ± standard deviation (SD) and the level of statistical significance was set at P < 0.05.
[00139] Results
[00140] Plasma Insulin Concentration.
[00141] There were no differences in plasma insulin concentration during the resting EB and ED trials. There was a time x group interaction for plasma insulin concentration (P<0.001) after exercise and protein feeding. Plasma insulin concentration increased above pre-exercise levels only with 15 and 30 g protein ingestion reaching peak values 20-40 minutes post-exercise (see, FIG. 2). Plasma insulin concentration for the 30 g treatment was above resting values from 20 minutes until 2 hours post-exercise (2-4.5 fold P < 0.05), whereas for the 15 g group, plasma insulin concentration was elevated above rest from 20 minutes until 1 hour post-exercise (2-3.5 fold; P < 0.05). Plasma insulin was higher in the 15 and 30 g treatments compared to placebo 20-40 minutes post-exercise (2.3-3.8 fold; P < 0.001), however only 30 g was different compared with PL later at 1 and 2 hours post-exercise (1.7-2 fold; P < 0.05) and was also higher than 15 g at 2 hours post- exercise (1.9 fold ; P < 0.02).
[00142] Amino Acids Concentration.
[00143] There were no differences in essential amino acids (EAA), branched chain amino acids (BCAA) or leucine plasma concentrations during the resting EB and ED trials. Plasma concentrations of EAA, BCAA and leucine increased above pre-exercise values between 20-120 minutes post exercise (see, FIGS. 3A-C) for both the 15 and 30 g treatments. The 30 g protein protocol resulted in higher aminoacidemia at 20 minutes post exercise (1.4 fold; P < 0.004) compared with 40 minutes post exercise following 15 g protein ingestion (1.7 fold; P < 0.001). Plasma concentration peaked 40-60 minutes post exercise (1.8-1.9 fold; P < 0.001) and remained above pre exercise values until 2 hours post exercise (1.6-1.9 fold; P < 0.02) in both the 15 g and 30 g treatments. Plasma EAA concentration increased in 30 g compared to 15 g between 20 minutes and 1 hour post exercise (1.2-1.3 fold; P < 0.03) (see, FIG. 3A). Plasma BCAA and leucine concentration followed a similar pattern but differences between 15 and 30 g remained until 2 hours post- exercise (1.2-1.8 fold P < 0.02) (see, FIGS. 3B and 3C).
[00144] Muscle Myofibrillar Fractional Synthetic Rate.
[00145] Resting ED myofibrillar FSR was lower compared to resting EB (0.019 vs 0.026 %-h, 27%, P < 0.001) (see, FIG. 4). Resistance exercise in ED with placebo returned myofibrillar FSR to values comparable to resting EB in the acute post exercise recovery period. Resistance exercise followed by 15 g and 30 g protein ingestion increased post-exercise myofibrillar FSR -16% and -34% above resting EB, respectively (0.030 and 0.038 %-h respectively; P < 0.02). The 30 g protein treatment also increased myofibrillar FSR above 15 g by -14% (P < 0.003). There were no differences between genders in any of the treatments. Linear regression analysis showed a positive correlation between the quantity of protein ingested per kg of BM or FFM and myofibrillar FSR (r =0.43 and 0.42 respectively, P< 0.001) (see, FIGS. 5A-B).
[00146] Cell Signaling.
[00147] There were no differences in phosphorylation status between resting EB and ED for any of the proteins quantified. AktSer473 phosphorylation was higher than resting ED in all treatments 1 hour post exercise (1.8 -3.2 fold; P < 0.05 (see, FIG. 6A). Protein intake increased Akt phosphorylation above resting EB to a similar extent 1 hour post exercise regardless of protein quantity (15 g -2.1 fold, 30 g -2.4 fold; P < 0.02). There were similar effects on mTORSer244B and S6KThr 389 phosphorylation. Protein intake increased mTORSer244B phosphorylation above resting EB levels and placebo at the 1 hour post exercise time point (-2.5 fold from resting EB, -2 fold from PLl h; P < 0.006) (see, FIG. 6B). However, only the 30 g treatment prolonged the elevation in mTOR phosphorylation to 4 hours post-exercise (-2.1 fold; P < 0.05). The p70 S6KThr 389 phosphorylation increased above resting levels 1 hour and 4 hours following resistance exercise and protein ingestion (2.6-7 fold; P < 0.05) (see, FIG. 6C). Peak phosphorylation above rest was observed with 30 g protein at 1 hour post-exercise (7 fold; P < 0.001) and was higher than 15 g protein at the equivalent time point (1.8 fold, P=0.051). Phosphorylation of rpS6 Ser 236/237 above resting EB was highest 1 hour after exercise with post exercise protein ingestion (12.5-19.2 fold; P < 0.001) (see, FIG. 6D). There were no
differences in AMPK1 , 4EBPl ltirjb/4/ or eEF2 lfir5b phosphorylation at any time (data not shown).
[00148] mRNA Expression.
[00149] There were only minor changes in MuRF-1 mRNA content from resting EB but MuRF-1 was different from rest and select post exercise time points after 4 hours post-exercise recovery in the 15 g protein treatment (1.85 fold; P < 0.003) (see, FIG. 7A). Atrogin-1 mRNA content was higher than resting EB and ED, and when compared with 1 hour post exercise following 4 hours recovery (1.98-2.27 fold; P < 0.006) (see, FIG. 7B). There were no differences in system A amino acid transporter (SNAT2) mRNA content but in all treatments there was a decrease in system L amino acid transporter (LATl) mRNA content at 1 and 4 hours post-exercise compared to resting EB (-0.49-0.6; P < 0.03). In addition, LATl mRNA content following resistance exercise with PL (4 h) and 15 g protein ingestion (1 hour) was lower compared with resting ED (0.55-0.64; P < 0.04) (see, FIG. 7D).
[00150] In conclusion, Applicant has surprisingly found that during an energy deficit (ED) the loss of fat free mass (FFM) can be mitigated by exercise and consumption of higher dietary protein both of which are potent stimuli for MPS. The nature of the relationship between MPS, exercise, and protein during ED is unknown. Applicant has determined the effect of 5 days ED (30 kcal-kg"1 Fat Free Mass (FFM)-day energy availability (EA)) on basal MPS and cell signaling during ED and energy balance (EB; 45 kcal-kg"1 LBM- day EA) as well as after REX in the fasted state and with the ingestion of whey protein (15 and 30 g) in ED in young, healthy male (n=8) and female subjects (n=7). There were no sex-based differences (P = 0.3) for MPS. Basal rates of MPS were 27% lower in ED than EB (PO.001). REX in the fasted state restored rates of MPS to those measured in EB. However, ingestion of 15 and 30 g of protein after REX in ED increased MPS -16 and -34% above resting EB, (PO.02). Basal phosphorylation of mTOR- mediated signalling was similar in ED and EB. p70 S6Kthr389 phosphorylation increased above EB with exercise and protein intake together (-2-7 fold; P<0.05) but not with REX alone. Applicant surprisingly concluded that short-term (e.g., 5 day) energy deficit down
regulates basal MPS. However, a single bout of resistance exercise in ED rescues rates of MPS to values measured at rest in EB. The ingestion of protein after exercise further increases MPS above resting EB in a dose-dependent manner. The results of the present study highlight the effect of combining resistance exercise with increased post-exercise protein availability for enhancing rates of skeletal muscle protein synthesis during periods of energy restriction.
[00151] It should be understood that various changes and modifications to the presently preferred embodiments described herein will be apparent to those skilled in the art. Such changes and modifications can be made without departing from the spirit and scope of the present subject matter and without diminishing its intended advantages. It is therefore intended that such changes and modifications be covered by the appended claims.
Claims
1. A method for enhancing muscle protein synthesis in an individual suffering from energy deficit, the method comprising:
administering to the individual a composition comprising protein in an amount from about 15 g to about 30 g during a time period selected from the group consisting of during exercise, post-exercise, and combinations thereof;
wherein the exercise is a resistance exercise.
2. The method according to Claim 1, wherein the composition is administered immediately following a resistance exercise.
3. The method according to Claim 1, wherein the protein is whey protein.
4. The method according to Claim 1, wherein the protein is a high-quality protein having a Protein Digestibility Corrected Amino Acid Score (PDCAAS) greater than 0.7.
5. The method according to Claim 1, wherein the individual is suffering from a short-term energy deficit, wherein short-term energy deficit ranges from about 1 day to about 10 days.
6. The method according to Claim 1, wherein the composition is formulated for administration to an individual selected from one of an infant, a child, a young adult, an elderly adult, an athlete, an individual undergoing rehabilitation, an individual in need of weight management, an individual suffering from malnutrition, a febrile individual, a sick individual, and combinations thereof.
7. The method according to Claim 1, wherein the composition further comprises at
least one source of ω-3 fatty acids.
8. The method according to Claim 7, wherein the ω-3 fatty acids are selected from the group consisting of a-linolenic acid ("ALA"), docosahexaenoic acid
("DHA"), eicosapentaenoic acid ("EPA"), and combinations thereof.
9. The method according to Claim 1, wherein the composition further comprises at least one antioxidant selected from the group consisting of astaxanthin, carotenoids, coenzyme Q10 ("CoQlO"), flavonoids, glutathione, Goji (wolfberry), hesperidin, lactowolfberry, lignan, lutein, lycopene, polyphenols, selenium, vitamin A, vitamin C, vitamin E, zeaxanthin, and combinations thereof.
10. The method according to Claim 1, wherein the composition further comprises at least one vitamin; at least one mineral; or at least one vitamin and at least one mineral,
wherein the vitamin is selected from the group consisting of vitamin A, Vitamin Bl (thiamine), Vitamin B2 (riboflavin), Vitamin B3 (niacin or niacinamide), Vitamin B5 (pantothenic acid), Vitamin B6 (pyridoxine, pyridoxal, or
pyridoxamine, or pyridoxine hydrochloride), Vitamin B7 (biotin), Vitamin B9 (folic acid), and Vitamin B12 (various cobalamins; commonly cyanocobalamin in vitamin supplements), vitamin C, vitamin D, vitamin E, vitamin K, Kl and K2 (i.e., MK-4, MK-7), folic acid, biotin, and combinations thereof; and
wherein the mineral is selected from the group consisting of boron, calcium, chromium, copper, iodine, iron, magnesium, manganese, molybdenum, nickel, phosphorus, potassium, selenium, silicon, tin, vanadium, zinc, and combinations thereof.
11. The method according to Claim 1, wherein the composition further comprises at least one phytonutrient is selected from the group consisting of carotenoids, plant sterols, quercetin, curcumin, limonin, and combinations thereof.
12. The method according to Claim 1, wherein the composition further comprises a prebiotic selected from the group consisting of acacia gum, alpha glucan, arabinogalactans, beta glucan, dextrans, fructooligosaccharides, fucosyllactose, galactooligosaccharides, galactomannans, gentiooligosaccharides,
glucooligosaccharides, guar gum, inulin, isomaltooligosaccharides,
lactoneotetraose, lactosucrose, lactulose, levan, maltodextrins, milk
oligosaccharides, partially hydrolyzed guar gum, pecticoligosaccharides, resistant starches, retrograded starch, sialooligosaccharides, sialyllactose,
soyoligosaccharides, sugar alcohols, xylooligosaccharides, their hydrolysates, and combinations thereof.
13. The method according to Claim 1, wherein the composition further comprises a probiotic selected from the group consisting of Aerococcus, Aspergillus, Bacteroides, Bifidobacterium, Candida, Clostridium, Debaromyces,
Enterococcus, Fusobacterium, Lactobacillus, Lactococcus, Leuconostoc, Melissococcus, Micrococcus, Mucor, Oenococcus, Pediococcus, Penicillium, Peptostrepococcus, Pichia, Propionibacterium, Pseudocatenulatum, Rhizopus, Saccharomyces, Staphylococcus, Streptococcus, Torulopsis, Weissella, non- replicating microorganisms, and combinations thereof.
14. The method according to Claim 1, wherein the protein is administered in a dose that is higher than a dose typically recommended for individuals experiencing energy balance.
15. The method according to Claim 1, wherein the composition is a source of
complete nutrition.
16. The method according to Claim 1, wherein the composition is a source of
incomplete nutrition.
17. The method according to Claim 1, wherein the enhancing muscle protein synthesis is enhancing skeletal muscle translation initiation signaling.
18. The method according to Claim 1, wherein the enhancing muscle protein synthesis is enhancing messenger ribonucleic acid (mRNA) expression.
19. The method according to Claim 1, wherein the enhancing muscle protein synthesis is enhancing myofibrillar protein synthesis.
20. The method according to Claim 1, wherein the enhancing muscle protein synthesis is reducing a loss of fat free mass.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361880007P | 2013-09-19 | 2013-09-19 | |
US61/880,007 | 2013-09-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2015040533A1 true WO2015040533A1 (en) | 2015-03-26 |
Family
ID=51626568
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2014/064478 WO2015040533A1 (en) | 2013-09-19 | 2014-09-12 | Methods for enhancing muscle protein synthesis during energy deficit |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2015040533A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3500112A4 (en) * | 2016-07-15 | 2020-02-12 | Zea10, LLC | Brewer's spent-grain based protein powder |
CN111529715A (en) * | 2020-04-22 | 2020-08-14 | 山东大学 | Dextran-docosahexaenoic acid coupling polymer and synthesis method and application thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2327315A1 (en) * | 2009-11-29 | 2011-06-01 | Nestec S.A. | Dosing protocols for increasing protein synthesis in an active individual |
WO2011064373A1 (en) * | 2009-11-29 | 2011-06-03 | Nestec S.A. | Method of enhancing muscle protein synthesis |
EP2583566A1 (en) * | 2011-10-21 | 2013-04-24 | Nestec S.A. | Whey protein micelles to enhance muscle mass and performance |
-
2014
- 2014-09-12 WO PCT/IB2014/064478 patent/WO2015040533A1/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2327315A1 (en) * | 2009-11-29 | 2011-06-01 | Nestec S.A. | Dosing protocols for increasing protein synthesis in an active individual |
WO2011064373A1 (en) * | 2009-11-29 | 2011-06-03 | Nestec S.A. | Method of enhancing muscle protein synthesis |
EP2583566A1 (en) * | 2011-10-21 | 2013-04-24 | Nestec S.A. | Whey protein micelles to enhance muscle mass and performance |
Non-Patent Citations (56)
Title |
---|
ARETA JL; BURKE LM; ROSS ML; CAMERA DM; WEST DWD; BROAD EM; JEACOCKE NA; MOORE DR; STELLINGWERFF T; PHILLIPS SM ET AL.: "Timing and distribution of protein ingestion during prolonged recovery from resistance exercise alters myofibrillar protein synthesis", J PHYSIOL, 2013 |
BIOLO G; MAGGI SP; WILLIAMS BD; TIPTON KD; WOLFE RR: "Increased rates of muscle protein turnover and amino acid transport after resistance exercise in humans", AM J PHYSIOL, vol. 268, no. 3, 1995, pages E514 - E20 |
BIOLO G; TIPTON KD; KLEIN S; WOLFE RR: "An abundant supply of amino acids enhances the metabolic effect of exercise on muscle protein", AM J PHYSIOL, vol. 273, 1997, pages E122 - 9 |
BORGENVIK M; APRO W; BLOMSTRAND E: "Intake of branched-chain amino acids influences the levels of MAFbx mRNA and MuRF-1 total protein in resting and exercising human muscle", AM J PHYSIOL, vol. 302, no. 5, 2012, pages E510 - E21 |
BREEN L; PHILLIPS SM: "Nutrient interaction for optimal protein anabolism in resistance exercise", CURR OPIN CLIN NUTR METAB CARE, vol. 15, no. 3, 2012, pages 226 - 32 |
BURD NA; GROEN BB; BEELEN M; SENDEN JM; GIJSEN AP; VAN LOON LJ: "The reliability of using the single-biopsy approach to assess basal muscle protein synthesis rates in vivo in humans", METABOLISM, vol. 61, no. 7, 2012, pages 931 - 6 |
BURD NA; HOLWERDA AM; SELBY KC; WEST DWD; STAPLES AW; CAIN NE; CASHABACK JGA; POTVIN JR; BAKER SK; PHILLIPS SM: "Resistance exercise volume affects myofibrillar protein synthesis and anabolic signalling molecule phosphorylation in young men", J PHYSIOL, vol. 588, no. 16, 2010, pages 3119 - 30 |
CAMERA DM; EDGE J; SHORT MJ; HAWLEY JA; COFFEY VG: "Early time course of Akt phosphorylation after endurance and resistance exercise", MED SCI SPORTS EXERC, vol. 42, no. 10, 2010, pages 1843 - 52 |
CAMERA DM; WEST DWD; BURD NA; PHILLIPS SM; GARNHAM AP; HAWLEY JA; COFFEY VG: "Low Muscle Glycogen Concentration Does Not Suppress the Anabolic Response to Resistance Exercise", J APPL PHYSIOL, 2012 |
CAMPBELL WW; HAUB MD; WOLFE RR; FERRANDO AA; SULLIVAN DH; APOLZAN JW; IGLAY HB: "Resistance Training Preserves Fat-free Mass Without Impacting Changes in Protein Metabolism After Weight Loss in Older Women", OBESITY, vol. 17, no. 7, 2009, pages 1332 - 9 |
CERMAK NAOMI M ET AL: "Protein supplementation augments the adaptive response of skeletal muscle to resistance-type exercise training: a meta-analysis", THE AMERICAN JOURNAL OF CLINICAL NUTRITION,, vol. 96, no. 6, 1 December 2012 (2012-12-01), pages 1454 - 1464, XP009169317, ISSN: 1938-3207 * |
CERMAK NM; RES PT; DE GROOT LC; SARIS WH; VAN LOON LJ: "Protein supplementation augments the adaptive response of skeletal muscle to resistance-type exercise training: a meta-analysis", AMERICAN JOURNAL OF CLINICAL NUTRITION, 2012 |
COFFEY V; MOORE D; BURD N; RERECICH T; STELLINGWERFF T; GARNHAM A; PHILLIPS S; HAWLEY J: "Nutrient provision increases signalling and protein synthesis in human skeletal muscle after repeated sprints", EUR J APPL PHYSIOL, vol. 111, no. 7, 2011, pages 1473 - 83, XP019915590, DOI: doi:10.1007/s00421-010-1768-0 |
COFFEY VG; REEDER DW; LANCASTER GI; YEO WK; FEBBRAIO MA; YASPELKIS BB; 3RD, HAWLEY JA: "Effect of high-frequency resistance exercise on adaptive responses in skeletal muscle", MED SCI SPORTS EXERC, vol. 39, no. 12, 2007, pages 2135 - 44 |
CREER A; GALLAGHER P; SLIVKA D; JEMIOLO B; FINK W; TRAPPE S: "Influence of muscle glycogen availability on ERK1/2 and Akt signaling after resistance exercise in human skeletal muscle", J APPL PHYSIOL, vol. 99, no. 3, 2005, pages 950 - 6 |
CUTHBERTSON D; SMITH K; BABRAJ J; LEESE G; WADDELL T; ATHERTON P; WACKERHAGE H; TAYLOR PM; RENNIE MJ: "Anabolic signaling deficits underlie amino acid resistance of wasting, aging muscle", FASEB J, vol. 19, no. 3, 2005, pages 422 - 4 |
DREYER HC; FUJITA S; CADENAS JG; CHINKES DL; VOLPI E; RASMUSSEN BB: "Resistance exercise increases AMPK activity and reduces 4E-BP1 phosphorylation and protein synthesis in human skeletal muscle", J PHYSIOL, vol. 576, no. 2, 2006, pages 613 - 24 |
DRUMMOND MJ; FRY CS; GLYNN EL; TIMMERMAN KL; DICKINSON JM; WALKER DK; GUNDERMANN DM; VOLPI E; RASMUSSEN BB: "Skeletal muscle amino acid transporter expression is increased in young and older adults following resistance exercise", J APPL PHYSIOL, vol. 111, no. 1, 2011, pages 135 - 42 |
DRUMMOND MJ; GLYNN EL; FRY CS; TIMMERMAN KL; VOLPI E; RASMUSSEN BB: "An increase in essential amino acid availability upregulates amino acid transporter expression in human skeletal muscle", AM J PHYSIOL, vol. 298, no. 5, 2010, pages E1011 - E8 |
FRY CS; DRUMMOND MJ; GLYNN EL; DICKINSON JM; GUNDERMANN DM; TIMMERMAN KL; WALKER DK; DHANANI S; VOLPI E; RASMUSSEN BB: "Aging impairs contraction-induced human skeletal muscle mTORCl signaling and protein synthesis", SKELET MUSCLE, vol. 1, no. 1, 2011, pages 11, XP021099267, DOI: doi:10.1186/2044-5040-1-11 |
GARTHE I; RAASTAD T; EGIL REFSNES P; KOIVISTO A; SUNDGOT-BORGEN J.: "Effect of two different weight-loss rates on body composition and strength and power-related performance in elite athletes", INTERNATIONAL JOURNAL OF SPORT NUTRITION ANDEXERCISE METABOLISM, vol. 21, no. 2, 2011, pages 97 |
GLENN R. GIBSON; MARCEL B. ROBERFROID: "Dietary Modulation of the Human Colonic Microbiota: Introducing the Concept of Prebiotics", J. NUTR., vol. 125, 1995, pages 1401 - 1412, XP002153893 |
HAAKONSSEN EC; MARTIN DT; BURKE LM; JENKINS DG: "Increased Lean Mass with Reduced Fat Mass in an Elite Female Cyclist Returning to Competition: Case Study", INT J SPORTS PHYSIOL PERFORM, 2013 |
HANSEN D.; DENDALE P; BERGER J; VAN LOON LJ; MEEUSEN R: "The effects of exercise training on fat-mass loss in obese patients during energy intake restriction", SPORTS MED, vol. 37, 2007, pages 31 - 46 |
HANSEN D; DENDALE P; BERGER J; VAN LOON LJ; MEEUSEN R: "The effects of exercise training on fat-mass loss in obese patients during energy intake restriction", SPORTS MED, vol. 37, no. 1, 2007, pages 31 - 46 |
JAMES MONROE JAY ET AL.: "Modern food microbiology", 2005, SPRINGER SCIENCE, pages: 790 |
KARAGOUNIS LG; HAWLEY JA: "Skeletal muscle: increasing the size of the locomotor cell", INT J BIOCHEM CELL BIOL, vol. 42, no. 9, 2010, pages 1376 - 9 |
KUMAR V; ATHERTON P; SMITH K; RENNIE MJ: "Human muscle protein synthesis and breakdown during and after exercise", J APPL PHYSIOL, vol. 106, no. 6, 2009, pages 2026 - 39 |
LAYMAN DK; EVANS E; BAUM JI; SEYLER J; ERICKSON DJ; BOILEAU RA: "Dietary Protein and Exercise Have Additive Effects on Body Composition during Weight Loss in Adult Women", J NUTR, vol. 135, no. 8, 2005, pages 1903 - 10 |
LIVAK KJ; SCHMITTGEN TD: "Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method", METHODS, vol. 25, no. 4, 2001, pages 402 - 8 |
LOUCKS AB; KIENS B; WRIGHT HH: "Energy availability in athletes", J SPORTS SCI, vol. 29, no. 1, 2011, pages 7 - 15 |
LOUIS E; RAUE U; YANG Y; JEMIOLO B; TRAPPE S: "Time course of proteolytic, cytokine, and myostatin gene expression after acute exercise in human skeletal muscle", J APPL PHYSIOL, vol. 103, no. 5, 2007, pages 1744 - 51 |
METTLER S; MITCHELL N; TIPTON KD: "Increased protein intake reduces lean body mass loss during weight loss in athletes", MED SCI SPORTS EXERC, vol. 42, no. 2, 2010, pages 326 - 37 |
METTLER S; MITCHELL N; TIPTON KD: "Increased protein intake reduces lean body mass loss during weight loss in athletes", MEDICINE AND SCIENCE IN SPORTS AND EXERCISE, vol. 42, 2007, pages 326 - 337 |
MOORE DR; ROBINSON MJ; FRY JL; TANG JE; GLOVER EI; WILKINSON SB; PRIOR T; TARNOPOLSKY MA; PHILLIPS SM: "Ingested protein dose response of muscle and albumin protein synthesis after resistance exercise in young men", AM J CLIN NUTR, vol. 89, no. 1, 2009, pages 161 - 8 |
MOORE DR; ROBINSON MJ; FRY JL; TANG JE; GLOVER EI; WILKINSON SB; PRIOR T; TARNOPOLSKY MA; PHILLIPS SM: "Ingested protein dose response of muscle and albumin protein synthesis after resistance exercise in young men", AMERICAN JOURNAL OF CLINICAL NUTRITION, vol. 89, 2009, pages 161 - 168 |
MOORE DR; TANG JE; BURD NA; RERECICH T; TARNOPOLSKY MA; PHILLIPS SM: "Differential stimulation of myofibrillar and sarcoplasmic protein synthesis with protein ingestion at rest and after resistance exercise", J PHYSIOL, vol. 587, no. 4, 2009, pages 897 - 904 |
PARR EB; COFFEY VG; HAWLEY JA.: "Sarcobesity': a metabolic conundrum", MATURITAS, vol. 74, no. 2, 2013, pages 109 - 13 |
PARR EB; COFFEY VG; HAWLEY JA: "Sarcobesity': a metabolic conundrum", MATURITAS, vol. 74, 2013, pages 109 - 113 |
PASIAKOS SM; CAO JJ; MARGOLIS LM; SAUTER ER; WHIGHAM LD; MCCLUNG JP; ROOD JC; CARBONE JW; COMBS GF; YOUNG AJ: "Effects of high-protein diets on fat-free mass and muscle protein synthesis following weight loss: a randomized controlled trial", THE FASEB JOURNAL, 2013 |
PASIAKOS SM; VISLOCKY LM; CARBONE JW; ALTIERI N; KONOPELSKI K; FREAKE HC; ANDERSON JM; FERRANDO AA; WOLFE RR; RODRIGUEZ NR: "Acute Energy Deprivation Affects Skeletal Muscle Protein Synthesis and Associated Intracellular Signaling Proteins in Physically Active Adults", J NUTR, vol. 140, no. 4, 2010, pages 745 - 51 |
PASKIAKOS SM; CAO JJ; MARGOLIS LM; SAUTER ER; WHIGHAM LD; MCCLUNG JP; ROOD JC; CARBONE JW; COMBS GF, JR; YOUNG AJ: "Effects of high-protein diets on fat-free mass and muscle protein synthesis following weight loss: a randomized controlled trial", FASEB JOURNAL, 2013 |
PHILLIPS BE; WILLIAMS JP; GUSTAFSSON T; BOUCHARD C; RANKINEN T; KNUDSEN S; SMITH K; TIMMONS JA; ATHERTON PJ: "Molecular networks of human muscle adaptation to exercise and age", PLOS GENET, vol. 9, no. 3, 2013 |
PHILLIPS BE; WILLIAMS JP; GUSTAFSSON T; BOUCHARD C; RANKINEN T; KNUDSEN S; SMITH K; TIMMONS JA; ATHERTON PJ: "Molecular networks of human muscle adaptation to exercise and age", PLOS GENET, vol. 9, no. 3, 2013, pages EL 0033 89 |
PHILLIPS SM; TIPTON KD; AARSLAND A; WOLF SE; WOLFE RR: "Mixed muscle protein synthesis and breakdown after resistance exercise in humans", AM J PHYSIOL, vol. 273, 1997, pages E99 - 107 |
PIKOSKY MA; SMITH TJ; GREDIAGIN A; CASTANEDA-SCEPPA C; BYERLEY L; GLICKMAN EL; YOUNG AJ: "Increased protein maintains nitrogen balance during exercise-induced energy deficit", MED SCI SPORTS EXERC, vol. 40, no. 3, 2008, pages 505 - 12 |
RAUE U; SLIVKA D; JEMIOLO B; HOLLON C; TRAPPE S: "Proteolytic gene expression differs at rest and after resistance exercise between young and old women", J GERONTOL A BIOL SCI MED SCI, vol. 62, no. 12, 2007, pages 1407 - 12 |
SALMINEN S; OUWEHAND A; BENNO Y. ET AL.: "Probiotics: how should they be defined?", TRENDS FOOD SCI. TECHNOL., vol. 10, 1999, pages 107 - 10, XP055150446 |
SMITH G; REEDS D; HALL A; CHAMBERS K; FINCK B; MITTENDORFER B.: "Sexually dimorphic effect of aging on skeletal muscle protein synthesis", BIOLOGY OF SEX DIFFERENCES, vol. 3, no. 1, 2012, pages 11, XP021108416, DOI: doi:10.1186/2042-6410-3-11 |
SMITH GI; MITTENDORFER B: "Similar muscle protein synthesis rates in young men and women: men aren't from Mars and women aren't from Venus", J APPL PHYSIOL, vol. 112, no. 11, 2012 |
STIEGLER P; CUNLIFFE A: "The role of diet and exercise for the maintenance of fat-free mass and resting metabolic rate during weight loss", SPORTS MED, vol. 36, no. 3, 2006, pages 239 - 62 |
STIEGLER P; CUNLIFFE A: "The role of diet and exercise for the maintenance of fat-free mass and resting metabolic rate during weight loss", SPORTS MEDICINE, vol. 36, 2006, pages 239 - 262 |
WALBERG JL; LEIDY MK; STURGILL DJ; HINKLE DE; RITCHEY SJ; SEBOLT DR: "Macronutrient Content of a Hypoenergy Diet Affects Nitrogen Retention and Muscle Function in Weight Lifters", INT J SPORTS MED, vol. 09, no. 04, 1988, pages 261 - 6 |
WEST DW; BURD NA; COFFEY VG; BAKER SK; BURKE LM; HAWLEY JA; MOORE DR; STELLINGWERFF T; PHILLIPS SM: "Rapid aminoacidemia enhances myofibrillar protein synthesis and anabolic intramuscular signaling responses after resistance exercise", AM J CLIN NUTR, vol. 94, no. 3, 2011, pages 795 - 803 |
WEST DWD; BURD NA; CHURCHWARD-VENNE TA; CAMERA DM; MITCHELL CJ; BAKER SK; HAWLEY JA; COFFEY VG; PHILLIPS SM: "Sex-based comparisons of myofibrillar protein synthesis after resistance exercise in the fed state", J APPL PHYSIOL, vol. 112, no. 11, 2012, pages 1805 - 13 |
WILKINSON SB; TARNOPOLSKY MA; MACDONALD MJ; MACDONALD JR; ARMSTRONG D; PHILLIPS SM: "Consumption of fluid skim milk promotes greater muscle protein accretion after resistance exercise than does consumption of an isonitrogenous and isoenergetic soy-protein beverage", AM J CLIN NUTR, vol. 85, no. 4, 2007, pages 1031 - 40 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3500112A4 (en) * | 2016-07-15 | 2020-02-12 | Zea10, LLC | Brewer's spent-grain based protein powder |
CN111529715A (en) * | 2020-04-22 | 2020-08-14 | 山东大学 | Dextran-docosahexaenoic acid coupling polymer and synthesis method and application thereof |
CN111529715B (en) * | 2020-04-22 | 2021-10-01 | 山东大学 | Dextran-docosahexaenoic acid coupling polymer and synthesis method and application thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2012244748B2 (en) | Nutritional compositions comprising alpha-hydroxyisocaproic acid | |
AU2015202897B2 (en) | Hypocaloric, high protein nutritional compositions and methods of using same | |
US20140294788A1 (en) | Methods for enhancing muscle protein synthesis following concurrent training | |
EP2503906B1 (en) | Nutritional compositions including a high protein component and exogenous nucleotides | |
WO2011056487A2 (en) | Stable thickener formulations | |
AU2012237345A1 (en) | Nutritional compositions for increasing arginine levels and methods of using same | |
EP2563168A1 (en) | Nutritional compositions and methods for weaning from parenteral nutrition to enteral nutrition | |
WO2015040533A1 (en) | Methods for enhancing muscle protein synthesis during energy deficit |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14776910 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 14776910 Country of ref document: EP Kind code of ref document: A1 |